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Abstract 
Attention Deficit Hyperactivity Disorder (ADHD) is a common neurobehavioural 
disorder in children and often persists into adulthood. Current treatments lack 
efficacy in a large number of patients, and the aetiology of ADHD needs to be 
further elucidated in order to develop alternative treatments. The neurokinin-1 
receptor knockout (NK1R-/-) mouse has recently been proposed as an animal 
model of ADHD; it is hyperactive and this is reduced by psychostimulants, 
polymorphisms in the TACR1 gene (the human NK1R gene) have been found in 
patients with ADHD, and NK1R-/- mice have deficits in monoamine transmission, 
consistent with the pathophysiology of ADHD. Finally, the NK1R-/- mouse exhibits 
inattentiveness, impulsivity and perseveration in the 5-Choice Serial Reaction-
Time Task (5-CSRTT).  
The aim of this thesis was to further validate the NK1R-/- mouse model of ADHD 
by studying the effects of d-amphetamine on its performance in the 5-CSRTT, and 
subsequently to test alternative drugs that could be therapeutically beneficial. 
However, over the course of this work, the hyperactivity of NK1R-/- mice was not 
stable when tested acutely. Therefore, telemetry was used to monitor the activity 
of mice in their homecage over many days. Also, the breeding method was 
expanded to include heterozygous matings in order to minimise genetic drift. 
Whilst hyperactivity in this test was robust in both colonies, the impulsivity seen in 
NK1R-/- mice bred from homozygous matings was not present in NK1R-/- mice 
bred from heterozygotes. Furthermore, there was a reduction in choline 
acetyltransferase-positive cells in the striatum of homozygously-bred but not 
heterozygously-bred NK1R-/- mice. 
These findings highlight important interactions between early environment, NK1R 
function and the central cholinergic system. They also support evidence suggesting 
that abnormal cholinergic transmission is involved in ADHD, and could underlie 
impulsivity. Finally, these findings could have important implications for future 
research on impulse control disorders. 
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1 Introduction 
Attention Deficit Hyperactivity Disorder (ADHD) is a common neurobehavioural 
disorder in children and persists into adulthood in many cases (Wender et al., 
2001). Although abnormal catecholamine transmission is thought to be central to 
the disorder, its aetiology remains unclear. Furthermore, there is concern over the 
efficacy and long-term effects of the most commonly prescribed treatments, the 
psychostimulants d-amphetamine and methylphenidate. Animal models play an 
important role in furthering our understanding of human disorders. In this thesis, 
the validation of a new animal model of ADHD, the neurokinin-1 receptor knockout 
mouse (NK1R-/-) is discussed. 
1.1 Attention Deficit Hyperactivity Disorder 
1.1.1 Clinical diagnosis  
The worldwide prevalence of ADHD in children is estimated to be between 5.9% 
and 7.1%, and the disorder is more frequent in males than females (Willcutt, 
2012). ADHD persists into adulthood in one to two-thirds of patients (Wender et 
al., 2001). As defined in the fourth edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV), three core symptoms define ADHD: hyperactivity, 
impulsivity and inattention and they have to be present for at least 6 months prior 
to diagnosis. Within this, three subtypes have been defined: Predominantly 
Hyperactive/Impulsive Type (for patients presenting with 6 or more hyperactive 
and/or impulsive symptoms), Predominantly Inattentive Type (for patients 
presenting with 6 or more inattentive symptoms) and Combined Type (for patients 
presenting with 6 or more symptoms from each of the other two subtypes). More 
female patients than male patients are diagnosed with the Predominantly 
Inattentive Type, while male patients are more likely to have the Combined Type 
(Willcutt, 2012). 
Currently, the most widely prescribed treatments are psychostimulants such as 
methylphenidate (e.g. Ritalin) and d-amphetamine (e.g. Adderall®). However, in 
many patients these treatments are not effective, and there is also concern over the 
Chapter 1 
 
20 
 
safety of long-term stimulant use. In order to identify new treatments the 
pathophysiology of the disease needs to be understood. 
1.1.2 Pathophysiology 
Imaging studies indicate that a disruption of normal fronto-striatal circuits is 
linked to ADHD. Executive function, such as the effective manipulation of working 
memory and response inhibition, is mediated by this network, and deficits in these 
processes are seen in patients with ADHD. In line with this, a hypoactive fronto-
striatal circuit has been found in these patients (Dickstein et al., 2006). Abnormal 
activation of mesolimbic circuitry, which mediates the response to reward, is also 
found in patients with ADHD (Ströhle et al., 2008). 
Dopaminergic, noradrenergic and serotonergic neurons innervate fronto-striatal 
circuits, and abnormal transmission of these monoamines is thought to underlie 
the pathophysiology of ADHD. The long-standing theory of ADHD is the dopamine 
(DA) hypothesis, stating that a deficit in DA within fronto-striatal circuits causes 
ADHD (Levy, 1991). This is supported by the fact that psychostimulants are the 
most widely prescribed treatments for the disorder. However, these stimulants 
block the reuptake, and increase the release of not just DA, but also noradrenaline 
(NA) and serotonin (5-hydroxytryptamine, 5-HT) (Kuczenski and Segal, 1989; 
Wilens, 2006). Furthermore, the selective NA reuptake inhibitor atomoxetine is 
prescribed for the treatment of ADHD (Michelson et al., 2003, 2001), suggesting 
that ADHD is not caused exclusively by a deficit in DA transmission. As seen in 
section 1.1.3.1, the hypothesis that abnormal monoamine transmission is involved 
in ADHD has been supported by genetic studies. 
There is increasing evidence to suggest that cholinergic dysregulation may be 
involved in the pathophysiology of ADHD. Maternal smoking is a risk factor for 
ADHD (Linnet et al., 2003), yet there is also evidence that symptoms of ADHD are 
improved by nicotine (Levin et al., 1996), which could explain why smoking is 
highly comorbid with ADHD (McClernon and Kollins, 2008). Also, within the 
striatum, acetylcholine and DA have a reciprocal relationship: DA receptors 
modulate the firing of striatal cholinergic interneurons, nicotinic acetylcholine 
receptors located on DA axons modulate DA release (Rice and Cragg, 2004) and 
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muscarinic acetylcholine receptors modulate DA receptor activation on striatal 
medium spiny neurons (Zhou et al., 2003). These mechanisms are further 
discussed in chapter 6 and suggest that acetylcholine may play a role in the 
pathophysiology of ADHD. 
1.1.3 Cause 
The underlying cause of ADHD is still widely debated, and understanding it is 
important for the development of new effective treatments (Biederman and 
Faraone, 2005). Various aetiologies have been proposed and are outlined below. 
1.1.3.1 Genetics 
The heritability of ADHD is around 75%, suggesting a genetic basis for the disorder 
(Faraone et al., 2005). Due to the disruption of monoamine transmission in 
patients with ADHD, studies have focussed on genes relating to DA, 5-HT and NA 
transmission. Polymorphisms in genes relating to DA have been found in patients 
with ADHD, including the DA transporter gene DAT1 (Cook et al., 1995) and 
dopamine D4 and D5 receptors (Daly et al., 1999; LaHoste et al., 1996). In addition, 
polymorphisms in the 5-HT transporter gene and the 5-HT1B receptor gene have 
been identified (Hawi et al., 2002; Seeger et al., 2001). Polymorphisms in NA 
transporter and receptor genes have also been associated with ADHD (Comings et 
al., 2003, 2000), although these were found in Tourette’s syndrome patients with  
comorbid ADHD; in other studies looking only at ADHD, no polymorphisms were 
found (Faraone et al., 2005). Animal models have also guided the search for the 
genetic basis of ADHD. For example, the coloboma mouse is hyperactive and this is 
reduced by d-amphetamine. It also has a deletion of the SNAP25 gene, which is 
involved in exocytotic neurotransmitter release (Hess et al., 1996). Subsequently, 
an association between polymorphisms of the SNAP25 gene and ADHD has been 
described (Barr et al., 2000). Animal models of ADHD are further discussed in 
section 1.1.4. 
1.1.3.2 Environmental factors 
Hypoxia during childbirth, caused by a range of complications including pre-
eclampsia (hypertension during pregnancy) or foetal distress, has been linked to 
ADHD (Biederman and Faraone, 2005). Hypoxia disrupts normal DA function in 
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the brain (Boksa and El-Khodor, 2003) which fits with the dopaminergic 
hypothesis of ADHD. Maternal smoking during pregnancy also increases the risk of 
ADHD (Linnet et al., 2003). Animal studies suggest this could be caused by changes 
in the number of DA receptor binding sites as compensation for a loss of nicotinic 
receptors following  pre-natal nicotine exposure (Fung and Lau, 1989; Slotkin et 
al., 1987). 
1.1.4 Animal models of ADHD 
Investigations into the aetiology of ADHD have been aided by the development of 
animal models of the disorder. As well as providing insight into the causes of a 
disease, animal models can also help develop new treatments. A good animal 
model will fulfil three criteria: face, construct and predictive validity. In the context 
of ADHD, face validity means that the animal has the symptoms of the disorder, 
such as deficits in attention, impulsivity and hyperactivity. Construct validity 
means that the symptoms must relate to the pathophysiology of the disorder, such 
as a disruption of fronto-striatal circuits. Finally, the model needs good predictive 
validity, meaning that it can predict new treatments and identify previously 
unknown causes of the disorder. The first step in verifying the predictive validity 
of a model is often to test the effects of currently available treatments. In ADHD, 
this could mean, for example, testing whether psychostimulants reduce the 
animals’ deficits. 
Various animal models of ADHD have been developed, and can be broadly divided 
into two categories: genetic models and pharmacological models. These are 
discussed below. 
1.1.4.1 Genetic models 
The spontaneously hypertensive rat 
The spontaneously hypertensive rat (SHR) was initially developed to study 
hypertension by inbreeding hypertensive Wistar-Kyoto rats (Okamoto and Aoki, 
1963). However, following the finding that the SHR is hyperactive (Moser et al., 
1988), it has become the most widely studied model of ADHD. The SHR has deficits 
in sustained attention and motor impulsivity, thus satisfying the criteria of face 
validity (Sagvolden, 2000). It also has a deficit in DA and NA in fronto-striatal 
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circuits (Russell et al., 2000, 1995). However, while d-amphetamine has been 
shown to alleviate hyperactivity (Myers et al., 1982), methylphenidate did not 
improve hyperactivity, attention or impulsivity (Van den Bergh et al., 2006). 
Another issue with the SHR is that the control animals used are Wistar-Kyoto rats. 
These rats show cognitive deficits when compared to Wistar rats, such as 
hypoactivity (Paré, 1989). Therefore, studies comparing SHRs and Wistar-Kyoto 
rats should be interpreted with caution. 
Table 1.1 Summary of genetic and pharmacological animal models of ADHD. Hyp: 
hyperactivity; Imp: impulsivity; Att: attention. Adapted from Sontag et al. (2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
24 
 
The dopamine-transporter knock-out mouse 
The DA transporter (DAT) clears extracellular DA and is the main target for 
d-amphetamine and methylphenidate. Alterations in the DAT gene have been 
found in patients with ADHD (Cook et al., 1995), and for these reasons the DAT 
knock-out mouse was investigated as a model of ADHD. This mouse is hyperactive 
and this hyperactivity is reduced by d-amphetamine and methylphenidate 
(Gainetdinov et al., 1999). It also shows deficits in spatial memory (Gainetdinov et 
al., 1999) and a decrease in intracellular DA storage and release, presumably  to 
compensate for the loss of DAT (Jones et al., 1998). However, because these mice 
are lacking DAT, the effects of psychostimulants are presumably mediated by other 
monoamine transporters (see: Van der Kooij and Glennon, 2007). In patients with 
ADHD, DAT will still be present even if its function is abnormal. This brings into 
question the predictive validity of this model. 
The thyroid hormone receptor 1 transgenic mouse 
Around 70% of patients with resistance to thyroid syndrome (RTH) meet the 
diagnostic criterion for ADHD. RTH results in elevated thyroid hormone, and the 
thyroid hormone receptor 1 mutant mouse (TR-1) has been investigated in 
relation to ADHD (Siesser et al., 2006). While mice lacking the thyroid hormone 
receptor gene have normal behaviour (Forrest et al., 1996), the TR-1 mouse has a 
mutation in the ligand-binding domain of this gene and is hyperactive, impulsive 
and inattentive, and has deficits in DA turnover. Furthermore, it shows increased 
activity which is reduced by methylphenidate (Siesser et al., 2006). However, the 
main issue with this model of ADHD is that while patients with RTH can exhibit 
symptoms of ADHD, there is no evidence linking thyroid abnormalities to patients 
with ADHD. 
Other genetic models 
The models discussed above are those that currently satisfy to the greatest extent 
the face, construct and predictive validity. Other models have also been studied, 
but they fail to meet all three criteria. These include the coloboma mutant mouse, 
which has a mutation in the SNAP25 gene. As mentioned in section 1.1.3.1, 
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polymorphisms in SNAP25 have been found in patients with ADHD (Barr et al., 
2000). The coloboma mouse is hyperactive and has abnormal DA and NA function 
(Jones et al., 2001). However, while the hyperactivity is reduced by 
d-amphetamine, it is increased by methylphenidate, questioning its predictive 
validity (Hess et al., 1996). Other models, such as the Naples high-excitability rat 
and mice lacking alpha-synuclein proteins have also been studied. The face, 
construct and predictive validity of all of these genetic models of ADHD are 
summarised in Table 1.1.    
1.1.4.2 Pharmacological models 
Due to the involvement of DA in ADHD, rats with neonatal lesions to DA-containing 
neurons have been studied in relation to ADHD. These rats are hyperactive and 
this is reduced by d-amphetamine and methylphenidate (Luthman et al., 1989). As 
well as changes in the DA system, these lesions also increase 5-HT in the striatum 
(Towle et al., 1989). Another pharmacological model that has been studied is 
neonatal hypoxia in rats. As mentioned in section 1.1.3.2, hypoxia during childbirth 
is a risk factor for ADHD. Rats that have experienced hypoxia are hyperactive and 
this is reduced by d-amphetamine (Speiser et al., 1988). DA, NA and 5-HT 
transmission is also altered in these rats (Dell’Anna et al., 1993). These two models 
therefore have some face, construct and predictive validity. Further studies need to 
establish whether there are also deficits in impulsivity or attention in these rats. 
Other models have also been suggested, and are summarised in Table 1.1. 
Although there are many animal models of ADHD, none completely satisfy the 
criteria for face, construct and predictive validity. Recently, a new animal model of 
ADHD has been proposed: the NK1R-/- mouse. In the next section, the neurokinin-
1 receptor (NK1R) and its preferred ligand, substance P, are described. 
1.2 Substance P and the neurokinin-1 receptor 
1.2.1 Substance P 
Substance P is a neuropeptide neurotransmitter expressed by subsets of neurons 
found throughout the central nervous system (CNS) and the peripheral nervous 
system. It was first discovered in 1931 in equine brain and intestine tissue by Von 
Euler and Gaddum (1931) but was not named until 1934 (Gaddum and Schild, 
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1934). The ‘P’ is thought to derive either from ‘preparation’ or ‘power’(Otsuka and 
Yoshioka, 1993). Despite many attempts to purify and characterise substance P, it 
was not until forty years later that its amino acid structure was determined as an 
undecapeptide (11 amino acid sequence): H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-
Gly-Leu-Met-NH2 (Chang et al., 1971).  
The role of substance P as a sensory transmitter was confirmed with the 
demonstration that substance P is present in concentrations around 10-20 times 
higher in dorsal than ventral roots of bovine spinal cord (Takahashi et al., 1974) 
and that substance P exerts an excitatory effect on frog (Konishi and Otsuka, 
1974a) and rat (Konishi and Otsuka, 1974b) neurons in the spinal cord. 
Subsequently, research into substance P focused on its localisation within the 
spinal cord, specifically within the primary afferent terminals of the dorsal horn. 
However, as well as its role in sensory transmission, substance P has been 
implicated in a range of functions, due to its wide distribution in the CNS (for 
review see: Otsuka and Yoshioka, 1993). 
Substance P belongs to a family of tachykinins, which derives from the word 
‘tachy’, meaning rapid, and ‘kinin’, which is the name given to various polypeptides 
involved in vasodilation and smooth muscle contraction. Two other mammalian 
tachykinins have also been discovered: neurokinin A (or substance K) and 
neurokinin B (or neuromedin K). Substance P and neurokinin A are encoded by 
alternative splice variants of the preprotachykinin A gene, and neurokinin B is 
encoded by the preprotachykinin B gene (Kotani et al., 1986; Nawa et al., 1984, 
1983) (Figure 1.1). 
 
Figure 1.1 Illustration of the synthesis of mammalian tachykinins. Numbered boxes represent gene exons. 
PPT: preprotachykinin; SP: substance P; NKA: neurokinin A; NKB: neurokinin B. Adapted from Otsuka and 
Yoshioka (1993). 
1.2.2 Tachykinin receptors 
Each mammalian tachykinin preferentially binds to a different receptor subtype. 
These receptors were first discovered in the 1980s (Buck et al., 1984; Iversen et al., 
1982; Laufer et al., 1986; Lee et al., 1982), and have since been renamed 
neurokinin-1 (NK1), neurokinin-2 (NK2) and neurokinin-3 (NK3). They are the 
Chapter 1 
 
27 
 
preferential binding sites for substance P, neurokinin A and neurokinin B, 
respectively (Mantyh et al., 1989; Regoli et al., 1987). However, all three 
tachykinins have some degree of binding affinity for each receptor (Maggi and 
Schwartz, 1997). 
The cloning of NK1Rs from the rat revealed that they are guanine nucleotide 
binding protein (G-protein) coupled receptors (Hershey and Krause, 1990; Yokota 
et al., 1989). The human receptor is 94.5% homologous to the rat receptor (Gerard 
et al., 1991; Takeda et al., 1991). Substance P binding to NK1Rs activates three G-
protein subunits: Gq/11, Gαs and Gαo, which are predicted to activate three second 
messenger pathways (Garcia et al., 1994; Khawaja and Rogers, 1996; Merritt and 
Rink, 1987; Nakajima et al., 1992; Quartara and Maggi, 1997; Roush and Kwatra, 
1998; Takeda et al., 1992). Gq/11 activates phospholipase Cβ, which in turn induces 
the formation of inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 
increases intracellular calcium concentration, while DAG activates protein kinase 
C. Gαs activates adenylyl cyclase, which synthesises cyclic adenosine 
monophosphate (cAMP). cAMP is involved in various processes including 
intracellular signal transduction, the activation of protein kinases and the 
regulation of ion channels. Finally, Gαo activates phospholipase A2, which causes the 
release of arachidonic acid by the hydrolysis of membrane phospholipids. 
Arachidonic acid regulates signalling enzymes, including phospholipase C and 
protein kinase C (Figure 1.2).  
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Figure 1.2 Illustration of NK1R signaling. Substance P binding to NK1R activates 3 G-protein subunits and 
subsequently 3 second messenger pathways. PLC: phospholipase Cβ; AC: adenylyl cyclase; PLA2: phospholipase 
A2; IP3: inositol 1,4,5-trisphosphate; DAG: diacyl glycerol; cAMP: cyclic adenosine monophosphate; AA: 
arachidonic acid; PKC: protein kinase C. 
1.2.3 Distribution of substance P and NK1R 
Substance P and NK1Rs are located throughout the peripheral and central nervous 
systems (for review see: Otsuka and Yoshioka, 1993; Quartara and Maggi, 1997). In 
this thesis, the focus will be on their distribution within the mouse brain. Levels of 
substance P and NK1R are particularly low within the cortex or hippocampus, 
being located mainly within subcortical areas in rats (Nakaya et al., 1994) and mice 
(Weir, 2012). 
Telencephalon 
NK1Rs are densely expressed in the striatum, within both the caudate-putamen 
and the nucleus accumbens (Nakaya et al., 1994). Substance P expression is also 
high in the striatum, where it is found in the dynorphin-positive, gamma-amino 
butyric acid (GABA)-ergic medium spiny neurons that project to the globus 
pallidus, the substantia nigra and the ventral pallidum (Anderson and Reiner, 
1990), as well as onto striatal cholinergic interneurons (Bolam et al., 1986), which 
all express NK1R (Aubry et al., 1994; Gerfen, 1991). The striatum is involved in 
habit formation, reward and action selection and suppression (Gage et al., 2010; 
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Pennartz et al., 2009). The strong presence of substance P and NK1R in the 
striatum suggests they may play an important role in these processes. 
Substance P fibres are also located in the medial and central nuclei of the amygdala 
(Emson et al., 1978), as are NK1R (Nakaya et al., 1994). The amygdala is involved 
in affective disorders (Phelps and LeDoux, 2005) and, as discussed later in this 
chapter, the anti-depressant effects of NK1R antagonists are thought to be 
mediated, in part, by this structure (Kramer et al., 1998). 
Within the brain, the highest levels of substance P are found within the substantia 
nigra (Davies and Dray, 1976). The substantia nigra forms part of the direct and 
indirect basal ganglia loops, where it plays a key role in modulating motor actions 
(Bolam et al., 2000). However, there is almost no NK1R expression in this region 
(Nakaya et al., 1994). It has been suggested that this mismatch between substance 
P and NK1R expression is caused by striatal substance P-positive neurons that 
project to the substantia nigra (Gerfen, 1991). These projection neurons have a 
local axon collateral that project onto other striatal neurons expressing NK1R. 
Other neurotransmitters, such as GABA, are found in these projection neurons and 
have binding sites in the substantia nigra. This allows neurotransmitters to act in 
different regions depending on the type of receptor expressed. Alternatively, 
substance P could be binding to other tachykinin receptors in the substantia nigra, 
such as NK3 (Dam et al., 1990; Keegan et al., 1992). 
Diencephalon 
The habenula nucleus has one of the highest expression levels of NK1R in the 
brain. This structure is thought to be involved in affective processes such as 
reward and stress, and it has recently been suggested that it is involved in 
suppressing motor responses to aversive or non-rewarding stimuli (Hikosaka, 
2010). Substance P-containing fibres that project to the ventral tegmental area also 
originate in the habenula nucleus (Emson et al., 1977). This projection is involved 
in a range of processes, including stress responses and locomotor activity (Elliott 
et al., 1992; Stinus et al., 1978).  
There is an abundance of substance P within the hypothalamus (Iversen et al., 
1976) and NK1Rs are also expressed throughout the hypothalamus (Nakaya et al., 
Chapter 1 
 
30 
 
1994). Substance P release within this structure is thought to control hormone 
release from the pituitary gland (Aronin et al., 1986; Lasaga and Debeljuk, 2011) 
and is also involved in aggressive behaviour (Haller, 2012). 
Mesencephalon and Metencephalon 
Substance P and NK1R are expressed in the locus coeruleus (Guyenet and 
Aghajanian, 1977; Nakaya et al., 1994). NA is synthesised within the locus 
coeruleus, and NK1R are found on noradrenergic neurons in this structure (Chen 
et al., 2000; Santarelli et al., 2001). This suggests that substance P and NK1R in this 
region may play a modulatory role on the major noradrenergic projections to the 
CNS. 
Substance P and NK1Rs are also expressed in the dorsal raphe nucleus. The major 
serotonergic projections originate in this nucleus, and while NK1R are not located 
on serotonergic neurons, they can modulate serotonergic activity in the dorsal 
raphe nucleus due to their presence on glutamatergic neurons (Liu et al., 2002).  
1.2.4 The role of substance P and NK1R in clinical disorders 
Due to the presence of substance P and NK1Rs in subcortical areas related to 
emotion, stress and reward, their role in affective disorders and addiction has been 
widely studied. This section will review substance P and NK1R agonist and 
antagonist studies in relation to these disorders. 
1.2.4.1 Stress and anxiety 
The link between the substance P/NK1R system and stress has been extensively 
studied. For example, using microdialysis, an increase in substance P release has 
been found in the medial amygdala following immobilisation stress and exposure 
to an elevated platform (Ebner et al., 2004). Radioimmunoassays have also found 
an increase in substance P in limbic areas after foot shock (Siegel et al., 1984) and 
after restraint stress or a saline injection (Rosén et al., 1992). However, a decrease 
in substance P and NK1R binding has also been found following restraint stress 
(Takayama et al., 1986). In order to help clarify the role of substance P and NK1R 
in stress and anxiety responses, the effects of agonists and antagonists have been 
widely studied. Substance P and NK1R agonists tend to induce an anxiogenic 
phenotype in a variety of tests, such as the elevated-plus maze (Baretta et al., 2001; 
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Bassi et al., 2007; Gavioli et al., 1999) and conditioned place avoidance (Elliott, 
1988). In contrast, NK1R antagonists induce an anxiolytic phenotype in paradigms 
including the elevated-plus maze (Santarelli et al., 2001; Teixeira et al., 1996) and 
stress-induced vocalisations (Kramer et al., 1998; Rupniak et al., 2000).  
However, other studies have found an opposite role for substance P and NK1R in 
stress. For example, substance P injections into the nucleus basalis magnocellularis 
induced an anxiolytic phenotype in rats tested in the elevated-plus maze 
(Hasenöhrl et al., 1998b; Nikolaus et al., 1999). Also, ablation of NK1R-expressing 
neurons in the amygdala of mice increased anxiety behaviour in the elevated-plus 
maze (Gadd et al., 2003). These discrepancies could be due to the method of 
agonism or antagonism, the behavioural paradigm used, or the dose. For a full 
review of the role of substance P and NK1R in stress and anxiety, see Ebner & 
Singewald (2006). 
1.2.4.2 Depression 
Stress is a risk factor for depression, and stress responses are often studied in 
animal models of depression (Nestler and Hyman, 2010). Therefore, the potential 
efficacy of NK1R antidepressants in depression has also been widely studied. 
Elevated levels of substance P have been found in the cerebrospinal fluid of 
depressed patients (Rimón et al., 1984) although this was not replicated in another 
study (Berrettini et al., 1985). An antidepressant role for NK1R antagonists was 
first proposed following the finding that stressed-induced vocalisations and 
vocalisations induced by a substance P agonist are virtually abolished by the 
antidepressants fluoxetine and imipramine, the anxiolytics diazepam and 
buspirone as well as by the NK1R antagonists L733 060 and L760 735 (Kramer et 
al., 1998). Furthermore, the NK1R antagonist MK 869 (Aprepitant) reduced 
symptoms of depression in patients to the same extent as the anti-depressant 
paroxetine, but with fewer side-effects (Kramer et al., 1998). This anti-depressant 
effect of NK1R antagonism was later replicated with another compound, L759 274 
(Kramer et al., 2004). 
Antidepressants enhance 5-HT, NA and DA transmission. The antidepressant 
effects of NK1R antagonism were originally thought to be independent from 
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monoamine systems (Kramer et al., 1998). However, it was later shown that these 
effects may rely on an interaction between NK1Rs and monoamines (Adell, 2004; 
Gobbi and Blier, 2005). Treatment with the NK1R antagonist L760 735 increases 
burst firing of NA neurons in the locus coeruleus of guinea pigs (Maubach et al., 
2002). The NK1R antagonists CP 96345 and RP 67580 increase firing of 5-HT 
neurons in the dorsal raphe nucleus (Gobbi et al., 2007; Haddjeri and Blier, 2001), 
but this was not seen after NA depletion, highlighting an interaction between NA, 
5-HT and NK1R (Gobbi et al., 2007; Haddjeri and Blier, 2008). NK1R antagonists 
also have an effect on DA: the NK1R antagonist GR205 171 increases the firing rate 
of DA neurons in the ventrotegmental area that project to the frontal cortex, thus 
increasing DA. It was suggested that the increase in firing rate was caused by 
blockade of NK1R located on inhibitory GABAergic neurons (Lejeune et al., 2002).  
Despite NK1R antagonists showing promise as a new class of antidepressants, a 
subsequent phase III clinical trial found no effect of Aprepitant on the symptoms of 
major depressive disorder (Keller et al., 2006). This failure may be due to species-
dependent binding affinities of NK1R antagonists. Although the rat, mouse and 
human NK1R are 94.5% homologous (Takeda et al., 1991), and the guinea pig NK1 
receptor is 96.6% homologous to the human receptor (Gorbulev et al., 1992), 
minor variations in the receptor sequence can produce large pharmacological 
differences (Fong et al., 1992). Alternatively, initial trials may have recruited a 
subgroup of patients that preferentially respond to substance P blockade (Keller et 
al., 2006). Indeed, depression is a multifaceted disorder and may be underlain by 
different biological mechanisms. 
1.2.4.3 Reward and addiction 
As well as being involved in stress and depression, substance P and NK1R have 
been investigated in relation to reward. This is due to their location in brain areas 
associated with reward, such as the mesolimbic pathway projecting from the 
ventral tegmental area to the nucleus accumbens. Many studies have looked at the 
effect of substance P and NK1R in a conditioned place preference (CPP) paradigm, 
in which animals learn to associate a chamber with a rewarding drug. Control 
animals will spend significantly more time in the chamber that was previously 
associated with reward. Following microinjections of substance P into the nucleus 
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basalis magnocellularis, the globus pallidus, the amygdala or the caudate-putamen, 
mice spend more time in the substance P-associated chamber compared to the 
saline-associated chamber (Hasenöhrl et al., 1998a; Kertes et al., 2010, 2009; 
Krappmann et al., 1994). In line with this, ablation of NK1R neurons in the 
amygdala abolishes CPP to morphine (Gadd, 2003), and the NK1R antagonists 
L733 060 and L703 606 abolish brain self-stimulation of morphine (Robinson et 
al., 2012). The rewarding effects of substance P may be mediated in part by the 
endogenous opioid system, because the opioid antagonist naloxone abolishes CPP 
to substance P (Hasenöhrl et al., 1991). They also may be partially mediated by the 
DA system, because substance P injections increase DA release within the 
neostriatum and nucleus accumbens (Boix et al., 1992). 
Due to the involvement of substance P in reward, the effects of NK1R antagonists 
in addiction have also been studied. NK1R antagonism with L703 606 reduces free-
choice alcohol consumption (Thorsell et al., 2010) and the NK1R antagonist 
L822 429 abolishes stress-induced alcohol seeking (Schank et al., 2011). In 
addition, a clinical trial has shown that the NK1R antagonist LY686 017 reduces 
alcohol craving in patients (George et al., 2008). Recently, the NK1R antagonist 
Aprepitant has also been suggested as a potential treatment for opioid addiction 
(Walsh et al., 2012). 
1.2.4.4 Other clinical disorders 
One of the most widely studied roles of substance P is in relation to pain. As 
mentioned in section 1.2.1, substance P is concentrated in the primary afferent 
nociceptors which terminate in the dorsal horn (Todd, 2002). Intrathecal 
injections of substance P increases thermal pain sensitivity (Moochhala and 
Sawynok, 1984; Yasphal et al., 1982), while NK1R antagonists reduce mechanical 
hypersensitivity induced by nerve ligation in rats (Cumberbatch et al., 1998). 
Furthermore ablation of NK1R-expressing neurons in the spinal cord results in 
reduced mechanical pain sensitivity (Mantyh et al., 1997; Nichols et al., 1999), 
although this effect may not be NK1R-mediated, since ablation of these neurons 
would also cause other receptor subtypes to be lost. However, NK1R antagonists 
failed to reduce pain in human patients (Rupniak and Kramer, 1999), perhaps 
because in animals they are reducing stress, rather than the pain response (Hill, 
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2000). It is also possible that NK1R antagonists would be effective at treating a 
different subset of patients that have visceral pain, rather than neuropathic pain, 
since NK1R antagonists have also been shown to alleviate visceral pain in rats 
(Gaudreau and Plourde, 2003). 
A clinical success for NK1R antagonists has been in the treatment of emesis. NK1R 
antagonists reduce vomiting in ferrets (Bountra et al., 1993; Gardner et al., 1995), 
and the NK1R antagonist Aprepitant is now licenced to treat emesis in patients 
undergoing chemotherapy for cancer (Martin et al., 2003). Aprepitant has also 
shown promise as an anti-tumor drug for the treatment of cancer (Muñoz and 
Rosso, 2010). Finally, the NK1R antagonist CJ12 255 can prevent post-operative 
tissue adhesion in patients (Reed et al., 2008).  
Overall, this highlights the role of substance P and NK1R in a variety of central and 
peripheral mechanisms. In order to further establish their precise role in these 
disorders, mice lacking functional NK1R have also been widely studied. 
1.3 NK1R knockout mice 
Genetically modified mice are an invaluable tool in science for understanding the 
function of individual genes. A knock-out mouse is created by rendering the 
protein coding for a specific gene non-functional. Comparison of knockout mice to 
wildtype mice whose genetic background differs only for the gene of interest 
enables the function of that gene to be further understood. In this section, the 
methodology behind creating a knockout mouse will be explained, following which 
the creation and phenotype of the NK1R-/- mouse will be described. 
1.3.1 Creation of a single-gene knock-out mouse 
The first step in creating a knockout mouse is to insert an engineered 
deoxyribonucleic acid (DNA) cassette into the gene of interest that prevents the 
gene from coding for the usual protein (e.g. NK1R). The cassette contains flanking 
DNA and a selection marker, such as an antibiotic resistance gene. This cassette is 
then inserted into embryonic stem cells through electroporation. Through 
naturally occurring homologous recombination, some stem cells will contain the 
new DNA. Following injection of an antibiotic into the growth medium, the 
selection marker contained within the cassette means that only the embryonic 
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stem cells that have incorporated the new DNA survive. These cells are 
subsequently injected into a blastocyst and implanted into a mother, who gives 
birth to chimeric mice. These chimeric mice are mated with wildtype mice and, if 
the new DNA sequence has been taken up by the germ cells of the chimeric mouse, 
mice that are heterozygous for the gene of interest are born. Heterozygous mice 
can then be mated to create wildtype, heterozygous and knockout mice. 
1.3.2 Issues with knockout mice 
1.3.2.1 Breeding methods 
In order to minimise animal wastage and cost, homozygous mice are often bred 
separately, in order to generate litters that contain all wildtype or all knockout 
mice. However, an issue with this is that de novo genetic mutations can occur that 
are passed down to future generations, thus causing the wildtype and NK1R-/- 
mouse colonies to drift (Crusio et al., 2009). If colonies are maintained 
homozygously, these issues can be minimised by occasionally backcrossing the 
mice onto an identical background strain. Another issue with maintaining 
homozygous colonies is that early environment can affect mouse phenotype 
(Crusio, 2004). Indeed, it is possible that wildtype and knockout mice provide 
different maternal care, which can cause changes in the genotype and phenotype of 
their offspring (e.g. Meaney, 2001). This can be prevented by breeding mice from 
heterozygous parents. These issues are further discussed in chapter 5. 
1.3.2.2 Background strain 
The phenotype of a knockout mouse is not necessarily solely due to loss of the 
gene of interest. Indeed, different mouse strains vary genetically, and depending 
on the background strain on which the mutation is created, the phenotype can be 
very different (Crawley et al., 1997). Differences between mouse strains have been 
found for a variety of behaviours including locomotor activity, learning and 
memory, and parental behaviour (for review see: Crawley et al., 1997). An 
interaction between background strain and NK1R has previously been shown 
(McCutcheon et al., 2008): NK1R-/- mice bred on a mixed C57BL/6 X 129/Sv 
background are more sensitive to morphine and show increased neurogenesis in 
the hippocampus compared to wildtype mice. However, NK1R-/- mice bred on a 
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pure C57BL/6 background do not show these differences. This highlights the 
importance of choosing the right strain when creating a knockout, and also 
suggests that the effects of gene deletion should be studied on more than one 
background. 
1.3.2.3 Flanking genes 
During the creation of a knockout mouse, the embryonic cells are often generated 
from a different background to that in which they are subsequently implanted (for 
example, 129/Sv blastocysts are often implanted into a C57Bl/6 foster mother). 
There is an inverse relationship between genetic recombination and distance 
between the loci of genes. This makes it highly probable that mice containing the 
mutation from the 129/Sv blastocysts will share the 129/Sv alleles that are close 
to the gene of interest. Equally, C57BL/6 mice will tend to share C57BL/6 alleles. 
Therefore, differences between wildtype and knockout mice may be caused by the 
alleles close to the gene of interest, and not by the gene itself (Gerlai, 1996). One of 
the ways of overcoming this issue is to ‘backcross’ the offspring onto a single 
background strain, although even this will not completely eliminate the problem 
(Crusio, 2004). For this reason, it is important to compliment knockout mouse 
studies with other techniques, such as pharmacological antagonism of the gene of 
interest. 
1.3.3 Creation of the NK1R-/- mouse 
Initial investigations into the effects of genetic manipulation of NK1R on the 
nervous system used an NK1R-/- mouse on a C57BL/6 X 129/Sv background. This 
was achieved by implanting the vector cassette into 129/Sv blastocysts, and 
subsequently implanting the blastocysts into a C57BL/6 foster mother (De Felipe 
et al., 1998). The offspring were later crossed onto an MF1 strain, in order to 
minimise the influence of the 129/Sv component. 129/Sv mice perform poorly in 
various behavioural tests, for example showing increased anxiety in the elevated-
plus maze (EPM) compared to C57BL/6 mice (Hagenbuch et al., 2006; Homanics et 
al., 1999). Another group created NK1R-/- mice on a pure 129/SvEv background 
(Santarelli et al., 2001). NK1R-/- mice have also been bred by taking the original 
129/Sv X C57BL/6 mice and backcrossing them onto a C57BL/6 strain for 10 
generations (McCutcheon et al., 2008). In this thesis, NK1R-/- mice on a 129/Sv X 
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C57BL/6 background crossed with an MF1 strain were used. A full description of 
their creation is given in section 2.1.1.  
1.3.4 Behavioural studies with NK1R-/- mice 
As discussed throughout section 1.2.4, substance P and NK1R have been studied in 
relation to pain, affective disorders and reward. In this section, the behaviour of 
NK1R-/- mice in paradigms modelling symptoms of these disorders is described. 
1.3.4.1 Affective disorders 
Investigations with NK1R-/- mice suggest that they have blunted stress responses: 
they do not develop stress-induced analgesia and are less aggressive in the 
resident intruder test (De Felipe et al., 1998). Also, in wildtype pups, the stress of 
maternal separation causes an increase in vocalisations. This is reduced by 
anxiolytic and antidepressant drugs, as well as NK1R antagonists, and NK1R-/- 
mice show a reduction in vocalisations compared to wildtype mice (Rupniak et al., 
2000; Santarelli et al., 2001). NK1R-/- mice also show a reduction in risk 
assessment behaviours in the Light/Dark Exploration Box (Fisher et al., 2007; 
Herpfer et al., 2005). In the forced swim and tail-suspension tests, wildtype mice 
treated with the antidepressant fluoxetine show an increase in struggle duration, 
and this is also seen in NK1R-/- mice (Rupniak et al., 2001). However, there have 
also been discrepancies in the anxiolytic profile of NK1R-/- mice. Santarelli et al. 
(2001) found that NK1R-/- mice spent more time in the open arms of the EPM, but 
this increase was not seen in other studies (De Felipe et al., 1998; Murtra et al., 
2000a; Rupniak et al., 2001). As mentioned in section 1.3.3, this difference is likely 
to be due to the background strain used, since the 129/Sv wildtype mice used by 
Santarelli et al. (2001) have an anxiogenic profile in the EPM that is not seen in 
C57BL/6 wildtype mice (Hagenbuch et al., 2006). 
1.3.4.2 Pain 
The role of NK1R in pain is complex. NK1R-/- mice do not show stress-induced 
analgesia, but show normal responses to acute pain (De Felipe et al., 1998). 
However, other studies have shown that NK1R-/- mice do not develop 
hyperalgesia to capsaicin administered viscerally or into the paw (Laird et al., 
2001, 2000). These different findings may relate to a dissociation between pain 
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and stress responses, and as discussed in section 1.2.4.4, this may be the reason for 
the failure of NK1R antagonists in the clinic (Hill, 2000). 
1.3.4.3 Reward and addiction 
The response to morphine is blunted in NK1R-/- mice. They fail to show increased 
locomotion in response to acute or chronic morphine, they do not self-administer 
or develop CPP to morphine, and they also have a blunted response to naloxone-
induced opiate withdrawal (Murtra et al., 2000a; Ripley et al., 2002). The 
rewarding effects of alcohol are also absent in NK1R-/- mice: they consume less 
alcohol than wildtype mice in a free-choice drinking paradigm, and do not develop 
CPP to alcohol (George et al., 2008). These effects are not due to a global disruption 
of reward pathways, since the behavioural responses to food and cocaine are 
normal. 
1.3.4.4 Locomotor hyperactivity 
NK1R-/- mice show increased locomotor activity in the open field and in the 
Light/Dark Exploration Box (LDEB) after a vehicle injection (Fisher et al., 2007; 
Herpfer et al., 2005) and this is blunted by d-amphetamine (Yan et al., 2010). As 
discussed in section 1.3.6.1, this is the initial finding that led to the NK1R-/- mouse 
being proposed as a model of ADHD. However, initial studies with NK1R-/- mice 
found no differences in activity in the open field (De Felipe et al., 1998). The 
hyperactive phenotype of the NK1R-/- mouse, and the discrepancies in activity 
found between studies are fully discussed in chapter 5. 
1.3.5 Neurochemical phenotype of NK1R-/- mice 
As discussed in section 1.2.4, the substance P/NK1R system interacts with brain 
monoamines. In this section, abnormalities in monoamine transmission found in 
NK1R-/- mice are discussed. 
1.3.5.1 Serotonin 
Similar to the effects seen after administration of NK1R antagonists in wildtype 
mice, NK1R-/- mice have an increase in the firing rate of serotonergic neurons in 
the dorsal raphe nucleus (Santarelli et al., 2001). Surprisingly, the authors found 
very little overlap between NK1R and serotonergic neurons. However, in the locus 
coeruleus, NK1R are co-localised with NA neurons (Santarelli et al., 2001), and the 
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locus coeruleus modulates firing of 5-HT neurons in the dorsal raphe nucleus 
(Peyron et al., 1996).  Radioligand binding of an agonist and antagonist for 5-HT1A 
autoreceptors in the dorsal raphe nucleus was reduced in NK1R-/- mice. This, 
combined with a decrease in 5-HT1A autoreceptor mRNA, suggests that 5-HT1A 
autoreceptors are downregulated in NK1R-/- mice (Froger et al., 2001). This was 
further supported by the finding that in the frontal cortex,  although baseline 5-HT 
efflux does not differ between genotypes, the selective 5-HT reuptake inhibitor 
(SSRI) paroxetine induces a 4-fold increase in 5-HT efflux in NK1R-/- mice 
compared to wildtype mice (Froger et al., 2001). Finally, administration of 
substance P into the dorsal raphe nucleus decreases 5-HT efflux in the frontal 
cortex of wildtype mice, but this decrease is not seen in NK1R-/- mice. This 
indicates that an increase in 5-HT is normally reduced by substance P binding to 
NK1R (Guiard et al., 2007).  
1.3.5.2 Noradrenaline 
Anaesthetised NK1R-/- mice have increased basal NA in the prefrontal cortex 
compared to wildtype mice (Herpfer et al., 2005). This is not due to a difference in 
NA reuptake, since the NA reuptake inhibitor desiprimine increases NA to the 
same extent in both genotypes. Furthermore, Western blots revealed no difference 
in the amount of NA transporter protein (Fisher et al., 2007; Herpfer et al., 2005). 
This suggests that the increase was due to an increase in NA release. However, 
whereas the local infusion of an α2-autoreceptor antagonist into the prefrontal 
cortex did not reveal any genotype differences in NA efflux, when administered 
systemically, NA efflux was increased in wildtype but not NK1R-/- mice. There was 
a reduction in radioligand binding to α2-autoreceptors in the locus coeruleus of 
NK1R-/- mice, suggesting that this difference is caused by the desensitisation of α2-
autoreceptors (Fisher et al., 2007). Since NA neurons project from the locus 
coeruleus to the prefrontal cortex, this desensitisation could also explain the 
increased basal NA seen in NK1R-/- mice. However, a further study found that a 
depolarising pulse of potassium infused via the dialysis probe increased NA efflux 
to the same extent in wildtype and NK1R-/- mice, but a second pulse increased NA 
efflux only in NK1R-/- mice. This effect was calcium-dependent, indicating that it 
was caused by exocytosis. This suggests that differences in NA efflux are caused by 
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both abnormal autoreceptor regulation and increased release of NA in the 
prefrontal cortex of NK1R-/- mice (Yan et al., 2009).  
1.3.5.3  Dopamine 
NK1R-/- mice have abnormal DA transmission. In the prefrontal cortex of freely-
moving NK1R-/- mice, there is a 50% decrease in DA efflux compared to wildtype 
mice. While there is no difference in basal DA efflux within the dorsal striatum, 
d-amphetamine increases DA efflux in wildtype mice but does not affect efflux in 
NK1R-/- mice (Yan et al., 2010). These abnormalities are also seen in wildtype 
mice treated with the NK1R antagonist RP 67580, suggesting that DA transmission 
in the prefrontal cortex, as well as the striatal DA response to d-amphetamine, is 
mediated by NK1R (Yan et al., 2010). 
The neurochemical and hyperactive phenotype of NK1R-/- mice described in this 
section has led to the proposal that the NK1R-/- mouse could be a new animal 
model of ADHD. Below, the face, construct and predictive validity of the NK1R-/- 
mouse are summarised. 
1.3.6 NK1R-/- mice and ADHD 
1.3.6.1 Face and predictive validity  
NK1R-/- mice and wildtype mice injected with the NK1R antagonist RP 67580 are 
hyperactive (Herpfer et al., 2005; Yan et al., 2010), and this hyperactivity is 
reduced by  d-amphetamine and methylphenidate (Yan et al., 2010). Recently, 
these mice have also been shown to exhibit impulsivity and inattention in the 
5-Choice Serial Reaction-Time Task (5-CSRTT) (Yan et al., 2011). This behavioural 
test was developed in order to simultaneously test motoric impulsivity and visual 
attention in rodents (Carli et al., 1983; Humby et al., 2005). These findings are 
further discussed in chapter 3. 
1.3.6.2 Construct validity 
NK1R-/- mice have abnormalities in DA, NA and 5-HT transmission, which fits with 
the theory that abnormal monoamine transmission is central to ADHD. The human 
equivalent of the NK1R gene is the tachykinin-1 receptor (TACR1). Genetic 
association studies in patients with ADHD have identified four single nucleotide 
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polymorphisms in the TACR1 gene that are positively associated with ADHD (Yan 
et al., 2010). This suggests that the NK1R-/- mouse has good construct validity. 
1.4 Aims 
In this thesis, the NK1R-/- mouse is further investigated as a model of ADHD by 
testing the effects of d-amphetamine on impulsivity and attention in the 5-CSRTT. 
The L-type calcium channel blocker nifedipine is also tested in NK1R-/- mice in the 
5-CSRTT as an alternative treatment for ADHD. Next, work establishing conditions 
under which hyperactivity is robust in NK1R-/- mice is presented. Finally, due to 
potential issues with breeding mice from homozygotes, the behavioural deficits 
and molecular phenotype of mice bred from heterozygotes are also investigated.  
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2 Materials and methods 
2.1 Animals 
All experiments in this thesis were licensed under the Animals (Scientific 
Procedures) Act 1986. 
2.1.1 Creation of the NK1R-/- mouse 
NK1R-/- mice were created based on the method outlined in section 1.3.1, in De 
Felipe et al. (1998) and in Figure 2.1. A vector cassette containing an internal 
ribosome entry site, the coding sequence lacZ and a neomycin-resistance gene for 
positive selection were inserted into the StuI site in exon1 of the NK1R gene. Two 
copies of the HSV-tk gene were also inserted at the 5’ end for negative selection. 
The vector cassette was electroporated into embryonic stem cells from 129/Sv 
mice and following homologous recombination, the stem cells that did not contain 
the new DNA (and therefore did not have the neomycin-resistence gene) were 
killed by injecting the antibiotic geneticin (G418). Gancyclovir (GANC) was injected 
to remove cells containing the HSV-tk gene due to random integration of the 
vector, rather than at the specific locus. Cells containing the targeted vector were 
injected into blastocysts from C57BL/6 mice and implanted into a C57BL/6 
mother. Chimeric male offspring were mated with C57BL/6 female wildtype mice, 
and subsequently mice heterozygous for the mutation were mated leading to the 
birth of wildtype, heterozygous and NK1R-/- mice on a 129/Sv X C57BL/6 
background. Later, these mice were crossed once with mice from an MF1 
background, in order to dilute the 129/Sv component. All mice used in this thesis 
are on a 129/Sv X C57BL/6 background crossed with an MF1 strain. It is important 
to note that the C57BL/6 mice are from Harlan (Bicester, UK), and that these mice 
lack the gene coding for α-synuclein (Specht and Schoepfer, 2001). This has been 
linked to a decrease in impulsivity in the 5-CSRTT (Peña-Oliver et al., 2012). 
However, because the background is identical in wildtype and NK1R-/- mice, this 
should not affect any genotype differences. 
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2.1.2 Breeding method 
During initial work in this thesis, wildtype and NK1R-/- mice were obtained by 
homozygous breeding, meaning that NK1R-/- and wildtype mice were bred 
separately. Due to concerns about genetic drift and early environment, discussed 
in section 1.3.2 (Crusio, 2004; Crusio et al., 2009), mice were later bred from 
heterozygous matings, so that each litter could in theory contain wildtype, NK1R-/- 
and heterozygous mice. Male and female mice were mated between the age of 2 
and 8 months, after which they were replaced with new breeding pairs. Offspring 
were weaned at 3 weeks. 
2.1.3 Housing 
Mice were housed in a central facility at University College London. Due to the 
location of the equipment, mice used in the telemetry experiment in chapter 5 
were housed in a different central facility at University College London, but the 
housing conditions were identical in both facilities. Mice were kept in cages 
containing bedding and environmental enrichment in groups of 2-5. Cages were 
cleaned twice weekly. Water and food were available ad libitum apart from during 
the 5-CSRTT experiment (2.4.1.2). The rooms were kept at 21±2°C and 45±5% 
humidity. Lights were on between 08.00 and 20.00, apart from during some of the 
later telemetry experiments (see chapter 5 for details), when lights were on 
between 07.00 and 19.00. The light/dark cycle was consistent for all mice from 
birth and throughout the experiment.  Mice that were a minimum of 6 weeks old 
were used for each experiment. Only male mice were used because in humans 
ADHD is more prevalent in males than females (Willcutt, 2012). Also, sex 
differences in 5-CSRTT performance have been found in rats (Bayless et al., 2012) . 
Future investigations into the NK1R-/- mouse should look at whether any deficits 
present in males are also present in females. 
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Figure 2.1 Illustration of the method used to create the NK1R-/- mouse. 
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2.2 Genotyping 
2.2.1 Verification with polymerase chain reaction 
2.2.1.1 Ear punching 
Ear clippings were taken with a 2mm ear punch from mice aged at least 2 weeks, 
placed into a 0.5mL eppendorf tube, and kept on ice until digestion. 
2.2.1.2 Digestion 
75L of alkaline lysis reagent (25mM NaOH, 0.2mM disodium EDTA, dissolved in 
ultra-pure water) were added to the sample-containing tubes and they were 
heated at 95C for 30mins before being cooled at 4C. 75L of neutralising reagent 
(40mM Tris-HCl dissolved in ultra-pure water) was then added to each tube and 
they were kept at -20C until amplification. 
2.2.1.3 Polymerase chain reaction  
While samples were defrosting, the polymerase chain reaction (PCR) master mix 
was made, containing primers for the NK1R gene (NK1-F and NK1-R), as well as a 
primer for the neomycin-resistance gene inserted into the vector cassette (Neo-F). 
19L of master mix was added to 0.5mL eppendorfs containing 6L of each 
sample. The master mix for each tube contained: 
 43.86L Thermophilic DNA Polymerase 10X Reaction Buffer, Mg-Free 
(Promega) 
 9.418L dNTP mix (Promega) 
 28.322L 25 mM magnesium chloride 
 23.375L NeoF: 5’-GCAGCGATCGCCTTCTATC-3’ 
 23.375L NK1-F: 5’-CTGTGGACTCTAATCTCTTCC-3’ 
 23.375L NK1-R: 5’-ACAGCTGTCATGGAGTAGATAC-3’ 
 169.388L nuclease-free water 
 1.887L Taq DNA polymerase (Promega) 
The master mix was also added to three control tubes containing a sample from a 
wildtype mouse, an NK1R-/- mouse, and nuclease-free water. The tubes were then 
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placed in a thermocycler (PTC-100 Programmable Thermal Controller, MJ 
Research, Boston, USA) for DNA amplification (Table 2.1). 
Table 2.1 DNA amplification steps. 
Step Temperature Duration   
 
 
Cycle  
35 times 
1 95C 5mins 
2 60 C 30s 
3 72 C 30s 
4 94 C 30s 
5 60 C 30s 
6 72 C 5min 
 
2.2.1.4 Electrophoresis 
Following DNA amplification and cooling at 4C, 4L of loading buffer was added 
to each tube. Loading buffer contained 0.25% bromophenol blue, 0.25% xylene 
cyanol FF and 30% glycerol. 14L from each tube was loaded into wells on a 2% 
agarose gel (2g agarose dissolved in 100ml 0.5M Tris-borate-EDTA (TBE) buffer 
(National Diagnostics, Hull, UK)) with 8L ethidium bromide. 5L of ladder was 
loaded into the first well (Bioline, London, UK) and samples were run in duplicate. 
The gel was electrophoresed by adding 500mL of TBE buffer and 2L of ethidium 
bromide to the tank and running the gel at 115V for approximately 1h with a 
FEC105 Voltage Power Pack. The gel was visualised and photographed on an 
ultraviolet transilluminator plate (UVP Ltd, Cambridge, UK). For wildtype mice, a 
band was seen at 350 bases and for NK1R-/- mice a band was seen at 260 bases. 
Heterozygous mice had a band at both of these bases (Figure 2.2). 
 
Figure 2.2 Genotyping using Polymerase Chain Reaction. Example of a gel showing bands for wildtype 
(+/+), NK1R-/- (-/-) and heterozygous (+/-) mice. One well was loaded with H2O instead of a DNA sample to 
control for contamination. 
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2.2.2 Verification with immunohistochemistry 
Following PCR, genotypes can be further verified with immunohistochemistry (see 
section 2.5). This was done in chapter 6 with an antibody against NK1R. Because 
wildtype and heterozygous mice both show strong staining for NK1R, this method 
must be used in conjunction with PCR.  
2.3 Culling 
2.3.1 Transcardial perfusion 
Mice were terminally anaesthetised with an i.p. injection of 0.3mL sodium 
pentobarbital (Euthatal; Merial, Harlow, UK). Once breathing had stopped and 
reflexes were absent, mice were intracardially injected with 20 mL of heparinised 
0.9% saline followed by 20mL of 4% paraformaldehyde (PFA) in 0.1M phosphate 
buffer (PB). The brain was removed and put into 4% PFA overnight and then 
transferred into 30% sucrose (in 0.1M PB containing 0.02% sodium azide) for at 
least 24h to cryoprotect the brains. 
2.3.2 CO2 asphyxiation 
Mice were placed into a chamber into which carbon dioxide (CO2) was infused until 
mice were unconscious. Cervical dislocation was subsequently performed to 
ensure death.  
2.4 Behavioural paradigms 
2.4.1 5-CSRTT 
2.4.1.1 Apparatus 
Four operant chambers (21.6 x 17.8 x 12.7 cm) placed within ventilated sound-
attenuating boxes (55.9 x 38.1 x 35.6 cm) were used to train and test the mice 
(Med Associates, St.Albans, VT, USA). On one wall there were five equally spaced 
apertures (1cm diameter) containing an infrared laser beam to detect nose pokes 
and a stimulus light. On the opposite wall there was an aperture for the magazine 
(2.2cm diameter) containing an infrared laser beam to detect nose pokes, a light 
and a milk dipper (Figure 2.3). A milk tray placed under the dipper enabled the 
delivery of 0.01 mL of 30% condensed milk (diluted in H2O). Delivery was 
signalled by illumination of the magazine. A house light was mounted above the 
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magazine and the floor was a metal grid under which a tray of sawdust was placed 
in order to facilitate cleaning. Stimulus presentation and nose poke recording was 
recorded by a Smart Control Package 8IN/16OUT with an interface for Windows 
by MED-PC (Med Associates, St.Albans, VT, USA). 
 
Figure 2.3 Illustration of the 5-CSRTT apparatus. 
2.4.1.2 Procedure 
Wildtype and NK1R-/- mice were housed in cages of four. Wildtype and NK1R-/- 
mice from homozygous matings were housed separately, while those from 
heterozygous matings were housed together. At 6-8 weeks of age they were put on 
a restricted food diet in order to reduce their weight to 90% of their free-feeding 
weight. Water was available ad libitum. All mice were brought to the lab at 09.00, 
weighed and habituated to the experimental room for 30mins. 6 wildtype and 6 
NK1R-/- mice were tested between 10.00 and 12.00 and 6 wildtype and 6 NK1R-/- 
mice were tested between 13.00 and 15.00, Monday to Friday.  
Habituation 
For the first three days, mice were placed in the boxes with all the lights 
illuminated. A nose poke into the magazine hole led to delivery of the reward for 
10s. Condensed milk was placed into the stimulus holes on the first two days to 
encourage the animals to nose poke.  
Following this, the mice had to perform a non-spatial version of the task. When 
placed into the box, the house light and magazine light were illuminated. A trial 
was initiated by a nose poke into the magazine hole, following which the magazine 
light was extinguished and all five stimulus lights were illuminated. A nose poke 
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into any of the stimulus light apertures led to delivery of the reward. Eating the 
reward triggered the beginning of the next trial. Mice had to receive a total of 50 
reinforcers in 30mins on 2 consecutive days to pass to the first training stage. If 
this did not happen after 10 sessions, mice passed to the first training stage 
anyway. 
Training stages 
 All training sessions lasted 30mins or 100 trials (after subtracting premature 
trials), whichever came first. Mice were trained on six stages of increasing 
difficulty and were required to meet certain response criteria for 2 consecutive 
days before passing to the next stage (apart from at stage 6 where the criteria had 
to be met for 3 consecutive days, and mice were kept on stage 6 for at least 7 days 
before passing to the testing stages). The parameters and passing criteria of each 
stage are presented in Table 2.2. 
Table 2.2 Stimulus parameters and progression criteria for the 5-CSRTT training stages. SD: Stimulus 
duration; LH: limited hold; ITI: inter-trial interval. Adapted from Yan et al. (2011). 
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At the beginning of each session, mice were placed in the box with the house light 
and magazine light illuminated. A nose poke into the magazine would initiate a 
trial. One of the five stimulus lights would be illuminated after a fixed amount of 
time (inter-trial interval, ITI), and would remain illuminated for a certain amount 
of time (stimulus duration, SD). Finally, mice had a fixed amount of time in which 
to respond to the stimulus light (limited hold, LH). If they made a correct response, 
the reward would be delivered. Consumption of the reward initiated the next trial. 
If the mice poked into the wrong stimulus hole (incorrect response), failed to 
respond within the limited hold (omission), or responded before the stimulus 
appeared (premature response), the house light was extinguished for 5s (time 
out). Any responses made during the time out reset the 5s. Following the time out, 
the house light and magazine were re-illuminated and mice had to poke into the 
magazine hole without receiving a reward in order to start the next trial. If mice 
made a correct response and continued to poke in the stimulus holes, this was not 
punished but each poke was recorded as a perseverative response. 
Testing 
Once the mice passed stage 6, they were challenged once weekly with tests to 
promote inattention and impulsivity: the long inter-trial interval (LITI) and the 
variable inter-trial interval (VITI). In the LITI, mice had to wait 7s before stimulus 
onset. In the VITI, they had to wait 2, 5, 10 or 15s before stimulus onset, delivered 
on a random schedule. The duration of the session was increased to 45mins in 
these tests. Details of the testing schedule and drug administration are given in the 
corresponding chapters. 
2.4.1.3 Scoring 
The following behaviours were recorded and analysed: 
 Total number of trials: Total number of trials completed during the testing 
period, minus any premature responses 
 %Accuracy: Total number of correct responses / (total number of correct 
responses + total number of incorrect responses) 
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 %Omissions: Total number of omissions / (total number of correct 
responses + total number of incorrect responses + total number of 
omissions) 
 %Premature responses: Total number of premature responses / (total 
number of correct responses + total number of incorrect responses + total 
number of omissions + total number of premature responses) 
 Latency to correct response: Time to make a correct response (s) 
 Latency to collect the reward: Time to collect the reward after a correct 
response (s) 
 Perseverative responses: Total number of responses into the correct 
stimulus hole after a correct response 
2.4.2 LDEB 
2.4.2.1 Apparatus 
Two boxes were used for testing. They measured 45 x 20 x 25 cm and were divided 
into two zones: a light zone with white walls and floor (30 cm long, 20 lux) and a 
dark zone with black walls and floor (15 cm long, 4 lux). Line markings on the floor 
divided both zones into 5 x 5 cm squares and in between the two zones there was a 
guillotine-style door (Figure 2.4). 
 
Figure 2.4 Illustration of the LDEB apparatus. 
2.4.2.2 Procedure 
Animals were brought to the experimental room at 10.00 and left to habituate until 
13.00. One wildtype and one NK1R-/- mouse were tested during each session. 
They were placed individually into the dark zone to habituate for 90mins. When 
injections were given, they were administered after 60mins before replacing the 
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mice into the dark zone for a further 30mins. After this, the mice were transferred 
with minimal handling to the centre of the light zone, the guillotine door was 
removed and behaviour was recorded on camera for 30mins. 
2.4.2.3 Scoring 
The following behaviours were scored blind in 5min time bins and analysed: 
 Total number of line crosses 
 Activity in the light/unit of time 
 Total time spent in the light zone (s) 
 Number of transitions to the light zone 
2.4.3 Activity chamber 
2.4.3.1 Apparatus 
A transparent Perspex box (30 x 19 x 18 cm) was covered in white paper and 
placed in an activity meter (41 x 41 cm, Columbia Instruments, USA). The activity 
meter emitted parallel infrared laser beams spaced 27mm apart and 28mm from 
the floor. Light in the chamber measured 100 lux. 
2.4.3.2 Procedure 
Mice were habituated to the experimental room for 3 days prior to testing, and for 
30mins on the testing day. They were then placed in the centre of the activity 
chamber. Their behaviour was recorded for 10mins. 
2.4.3.3 Scoring 
An ambulatory activity count was recorded by the activity meter every time the 
mice made two consecutive beam breaks. The total ambulatory activity was 
recorded at the end of each 5min time bin. 
2.4.4 Telemetry 
2.4.4.1 Apparatus 
A radiotelemetry probe weighing 1.6g and measuring 1.1cm³ (TAF-10, Data 
Sciences International, USA) was implanted into a mouse and output an activity 
parameter. This is calculated based on the strength of the probe signal relative to 
an antenna implanted in the centre of the telemetry mat. The activity count 
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therefore depends on the distance moved, the orientation of the animal, and how 
much it moves during the testing period. Each mouse cage is placed on a telemetry 
mat and as the mouse moves about the cage, the signal received by the antenna 
varies in strength based on the distance and orientation of the mouse. A Data 
Exchange Matrix (Data Sciences International, USA) monitors the changes in signal 
(16 samples/s) and transfers these data as digital pulses to the computer. This is 
translated into an activity count by the Dataquest A.R.T.™ software (Data Sciences 
International, USA). 
2.4.4.2 Surgery 
Mice were placed in a chamber and anaesthesia was induced with 5% isoflurane. 
Once the animals were unconscious they were placed on a heated pad and 
maintained with 2% isoflurane and oxygen at 0.5L/minute administered through a 
nose cone. The mice were placed on their back and the limbs were loosely taped 
down. Hair was shaved from the ventral area and the incision site was scrubbed 
with disinfectant and alcohol. A 2cm incision was made through the skin on the 
ventral abdomen. A subcutaneous pocket was made along the lateral flank with 
blunt dissection and the transmitter probe was inserted. The skin was closed with 
6-0 non-absorbable sutures and an analgesic was administered. Following removal 
of the anaesthetic, mice were kept on heated pads until they were moving 
normally. They were left to recover for 7 days before measuring their activity.  
2.4.4.3 Procedure 
Mice were housed individually post-surgery. After recovery, each cage was placed 
on a telemetry mat and the probes were turned on with a magnet. During the light 
phase the cages were lit at 100 lux. Activity was recorded by the computer every 
15mins for 2mins throughout the experiment. In all experiments, baseline activity 
was monitored for 48h. In experiments where mice were injected, they 
subsequently received an injection 30mins before the dark phase every other day. 
On completion of the experiment, mice were culled by CO2 asphyxiation (see 
section 2.3.2), the probe was cut out of the pocket and the probe was turned off 
with a magnet. Activity counts for each 2min time bin were transferred into 
Microsoft Excel for analysis. 
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2.5 Immunohistochemistry 
2.5.1 Sectioning 
Following transcardial perfusion and brain removal (see section 2.3.1), brains 
were placed on a frozen platform and cut coronally at 40m and placed in 5% 
sucrose with 0.02% sodium azide in 0.1M PB in sets of six (every sixth section was 
placed in the same well). All staining was performed on free-floating sections. 0.1M 
PB contained 190 mM monosodium phosphate and 810 mM Disodium hydrogen 
phosphate (BDH Laboratory Supplies, Poole, UK). 
2.5.2 Blocking 
In order to reduce non-specific binding, sections are blocked for 1h in 0.03% 
Triton X-100 (BDH Laboratory Supplies, Poole, UK) and 3% normal serum in 0.1M 
PB. Where possible, the host serum was from the same species as the secondary 
antibody. For 3,3'-Diaminobenzidine (DAB) immunohistochemistry, hydrogen 
peroxide was added to the blocking solution to eliminate any endogenous 
peroxidase activity. 
2.5.3 Antibodies 
After being blocked, sections are placed in the primary antibody prepared in Tris-
Triton Buffered Saline (TTBS, containing 0.05 M Tris base, 0.3% Triton X-100 and 
0.9% sodium chloride) and left on a rocking platform at room temperature 
overnight, or at 4ºC for three nights. They were then washed three times in 0.1M 
PB for 10mins and incubated in the secondary antibody for either 1h30 
(fluorescent staining) or 2h (DAB staining). Full details of the antibodies and 
concentrations used are given in chapter 6. 
2.5.4 Amplification 
2.5.4.1 Avidin-Biotin 
Avidin is a glucoprotein that has high affinity for the vitamin biotin, which is 
present in all living cells. When biotin is conjugated to the secondary antibody, the 
avidin complexes will bind to it. For fluorescent staining, a marker such as 
fluorescein isothiocyanate (FITC) is conjugated to avidin. For DAB staining, horse 
radish peroxidase (HRP) is conjugated to avidin (ABC complex, Vectastain kit, 
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Vector Labs). As explained in section 2.5.5, this allows the antigen of interest to be 
visualised.  
2.5.4.2 Tyramide signal amplification 
Tyramide is activated by HRP, and binds to electron-rich regions adjacent to the 
HRP-binding sites. Used in conjunction with the ABC complex, this amplifies the 
signal by increasing the number of binding sites that can be visualised. 
Details of the amplification methods used in each immunohistochemistry 
experiment are given in chapter 6. 
2.5.5 Visualisation 
2.5.5.1 DAB 
DAB staining was visualised with the DAB substrate kit (Vector Labs). The 
substrate solution contains peroxide. DAB reacts with HRP in the presence of 
peroxide to form an insoluble brown polymer. During the amplification step, HRP 
is conjugated to avidin (ABC complex, Vectastain kit, Vector Labs), which binds to 
the biotinylated secondary antibody. This allows the antigen of interest to be 
visualised. 
2.5.5.2 Fluorescence 
Fluorescent dyes emit light at a certain wavelength. These can bind directly to the 
secondary antibody, or can bind to avidin, which will then bind to the biotinylated 
secondary antibody. In this thesis, two different dyes were used: Alexa Fluor 594, 
which fluoresces red (617 nm) when excited at 590 nm and FITC, which fluoresces 
green (515 nm) when excited at 495 nm. Because different dyes emit light at 
different wavelengths, this method is commonly used to simultaneously detect 
more than one antigen. 
2.5.6 Mounting 
Sections were placed in 0.01M PB and mounted onto gelatinised slides. For DAB 
staining, the slides were dehydrated by placing them in gradually increasing 
concentrations of alcohol. DPX mounting medium (BDH Laboratory Supplies, 
Poole, UK) was then used for cover-slipping. For fluorescent staining, the slides are 
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cover-slipped with Fluoromount aqueous mounting medium (Sigma-Aldrich, 
Poole, UK). 
2.5.7 Imaging 
DAB sections were visualised and images were captured with a Nikon E4500 
camera attached to a Nikon Eclipse E800 microscope. Fluorescent sections were 
visualised and images were captured with a CCD camera (C-4742-95; Hamamatsu 
Photonics, Hamamatsu, Japan) attached to a Leica DMR microscope (Leica Imaging 
Systems Ltd., Cambridge, UK). Details of cell quantification are given in chapter 6. 
2.6 Western blots 
The following solutions were used for western blotting: 
Radioimmunoprecipitation assay (RIPA) buffer 
100 mM sodium chloride 
100 mM sodium fluoride 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
5 mM ethylenediaminetetraacetic acid (EDTA) 
1 mM sodium orthovanadate 
1% NP-40 
Loading buffer 
50% glycerol 
10% sodium dodecyl sulphate (SDS, Sigma-Aldrich) 
0.5% bromophenol blue (Sigma-Aldrich) 
MOPS running buffer  
0.05 M 3-(N-morpholino) propane sulphonic acid (MOPS) (Invitrogen, Oregon) 
0.05 M Tris base 
3.5 mM SDS 
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1 mM EDTA 
Transfer buffer 
48 mM Tris base 
39 mM glycine 
0.037% SDS 
10% methanol 
2.6.1 Tissue preparation 
2.6.1.1 Dissection 
Mice were killed by CO2 asphyxiation (see section 2.3.2) and their brains were 
removed and frozen on dry ice. Brains were stored at -80°C until dissection. Frozen 
brains were cut into 1mm coronal sections with an acrylic mouse brain matrix 
(Zivic Instruments, PA, USA). Using a 1.5mm diameter tissue punch, sections were 
taken from the dorsal striatum and frozen at -80°C. 
2.6.1.2 Homogenisation 
Tissue was kept on ice throughout the procedure to avoid protein denaturation. 
Protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktails 1 & 
2 (Sigma-Aldrich) were added to RIPA buffer and this was added to each tissue 
sample. Samples were homogenised in a FastPrep Biopulveriser (MP Biomedicals 
Europe, France) for 10s, and then kept on ice for 1-2h. Samples were then 
centrifuged at 12 000 RPM for 15mins and the supernatant was transferred into a 
new Eppendorf tube. 
2.6.1.3 Protein determination 
Protein was measured with a biocinchoninic (BCA) kit. Protein standards of known 
concentration were loaded in duplicate to the first row of a 96 well plate. Tissue 
samples were added in duplicate to subsequent rows. Bicinchoninic acid and 4% 
copper sulphate was added to all wells. The plate was incubated at 37ºC for 
30mins and protein concentration was determined with a colorimeter. 
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2.6.2 Protein transfer 
Loading buffer was added to samples containing 15μg of protein to make a volume 
of 19μL. They were boiled for 5mins to denature the proteins then cooled on ice. A 
10% gel was covered with running buffer (see section 2.6) and 15 μL of each 
sample was loaded to the wells. Proteins were separated using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE, 50mins, 180V). Meanwhile, a 
polyvinylidine difluoride membrane (Bio-Rad, UK) was prepared by briefly 
soaking it in 100% methanol and then in transfer buffer. The gel and membrane 
were then placed in the transfer tank between filter paper and sponges. An ice 
block was added to the tank to prevent the gel from sticking to the membrane and 
the gel was electroblotted onto the membrane (1h, 100V). 
2.6.3 Immunoblotting 
Details of antibodies and concentrations are given in chapter 6. The membrane 
was blocked for 1h in 4% milk diluted in 0.1 M phosphate-buffered saline and 
0.1% Tween 20 (PBS-Tween). It was then incubated overnight at 4ºC on a roller in 
the antibody diluted in the same milk solution. The next day, the membrane was 
washed 3 times for 10mins in PBS-Tween and then placed in the secondary 
antibody on a roller for 45mins. Following 3 more washes, it was placed in 0.1 M 
PBS before being developed with enhanced chemiluminescence western blotting 
detection reagents (GE Healthcare) and visualised with a ChemiDoc-XRS molecular 
imaging system (Bio-Rad, UK). 
2.6.4 Normalising 
In order to normalise each sample, the membrane was incubated for 90mins in 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH is an enzyme 
involved in glycosis and is found in high levels in almost all tissues and cells. It is 
therefore useful for protein normalisation. The membrane was washed again and 
placed in the secondary antibody for 45mins, washed and rinsed in PBS without 
Tween before being developed, as above. 
2.6.5 Analysis 
Photographed membranes were analysed using Image J software (NIH, USA). The 
ratios for the band densities of the antibody of interest/GAPDH were calculated. 
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The mean ratio for the wildtype control samples was calculated and all samples 
were expressed as a percentage of this mean ratio. Further details are given in 
chapter 6. 
2.7 Statistical analysis 
All statistics were performed in IBM SPSS PC+ (SPSS Inc, Chicago, Illinois, USA). 
When experiments had only two experimental groups, they were analysed with 
independent or paired-samples t-tests. When experiments had three or more 
experimental groups, they were analysed with Analysis of Variance (ANOVA). 
Details of independent and dependent variables are provided in the relevant 
chapters. All data were checked for homogeneity of variance with Levene’s test and 
if this was violated they were square-root, log10 or arc-sine transformed. If data 
continued to violate Levene’s test, they were analysed with non-parametric tests 
(Kruskal-Wallis or Friedman tests followed by Mann-Whitney U or Wilcoxon tests). 
Data were also checked for sphericity with Mauchley’s test of sphericity. If this was 
violated, the Greenhouse-Geisser correction was applied. In all experiments, 
statistical significance was set at P<0.05. 
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3 Effects of d-amphetamine on the performance of 
NK1R-/- mice in the 5-Choice Serial Reaction-Time 
Task 
3.1 Introduction 
In order to validate the NK1R-/- mouse as a model of ADHD, it was tested in the 
5-CSRTT. This test measures impulsivity and attention (two diagnostic features of 
ADHD). NK1R-/- mice were shown to be more inattentive and impulsive, and to 
make more perseverative responses than wildtype mice (Yan et al., 2011). In this 
chapter, the same mice were tested in the 5-CSRTT in order to evaluate the effects 
of d-amphetamine, one of the current treatments for ADHD, on performance in this 
task. 
3.1.1 5-Choice Serial Reaction-Time Task 
3.1.1.1 Development 
In humans, sustained attention and impulsivity can be assessed with the 
Continuous Performance Task (CPT; Beck et al., 1956). In this test, participants are 
asked to respond to certain stimuli and inhibit responses to others. A version of the 
CPT with an added spatial component was also created, in which patients have to 
continuously monitor the location of a light stimulus in one of five apertures (see: 
Wilkinson, 1963). Based on these tasks, the rodent 5-CSRTT was developed (Carli 
et al., 1983) in order to test attention and impulsivity in rats, and was later adapted 
for mice (Humby et al., 2005). By creating a rodent 5-CSRTT analogous to the tasks 
used to test humans, the neurochemical basis of sustained attention and 
impulsivity could be further understood. Attention is assessed by the animals’ 
accuracy (percentage of correct responses) and also the percentage of omissions 
(no response during a trial). Impulsivity is measured by the number of premature 
responses (responses made before stimulus onset). This test also measures 
perseveration, or ‘compulsivity’, when more than one response into a stimulus hole 
is made within the same trial. Although not a diagnostic feature, perseverative 
responding is commonly seen in patients with ADHD (Lawrence et al., 2004).  
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3.1.1.2 Neurobiology 
Brain structures 
Despite the complex nature of the 5-CSRTT, lesions to specific brain areas do not 
prevent task acquisition, and in this way the neurobiology of 5-CSRTT 
performance can be studied. Various brain structures in the cortico-striatal 
network are involved in optimal performance, and this network is often implicated 
in the pathophysiology of ADHD (Dalley et al., 2008). Attention, impulsivity and 
compulsivity are thought to be underlain by different cortico-striato loops (Figure 
3.1). Specifically, the dorsal part of the frontal cortex is involved in attention, with 
lesions to the anterior cingulate cortex reducing accuracy (Chudasama et al., 2003). 
On the other hand, the ventral part of the frontal cortex is involved in response 
inhibition, with lesions to the orbitofrontal cortex increasing perseverative 
responses, and lesions to the infralimbic cortex increasing impulsivity (Chudasama 
et al., 2003). Within the striatum there is also a dissociation between ventral and 
dorsal areas. Lesions to the core of the nucleus accumbens, which is part of the 
ventral striatum, decrease response inhibition (Christakou et al., 2004) as 
evidenced by an increase in impulsivity and perseverative responses. This mimics 
the effects of lesions to the ventral part of the frontal cortex. In contrast, lesions to 
the medial dorsal striatum cause deficits in accuracy, impulsivity and perseveration, 
while lesions to the lateral dorsal striatum prevent task performance (Rogers et al., 
2001). Interestingly, despite the spatial aspect of the task, hippocampal lesions 
have little effect on task performance (Kirkby and Higgins, 1998). 
Neurotransmitters 
Dopamine 
DA has long been linked to the pathophysiology of ADHD due to the fact that a 
deficit in DA within fronto-striatal circuits is thought to underlie the symptoms of 
ADHD (Levy, 1991), and also due to the ability of psychostimulants to alleviate the 
symptoms. For this reason, the effects of DA depletion within fronto-striatal 
circuits have been studied. In the 5-CSRTT, striatal DA depletion induces omissions 
and slows response latencies (Baunez and Robbins, 1999; Cole and Robbins, 1989). 
DA depletion within the dorsal striatum also induces perseverative responding 
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(Baunez and Robbins, 1999). On the other hand, DA depletion in the prefrontal 
cortex selectively impairs accuracy (Granon et al. 2000). Premature responses in 
the 5-CSRTT have also been linked to DA. Dopaminergic lesions to the nucleus 
accumbens reduce premature responses (Cole and Robbins, 1989), although more 
recent studies with DA agonists and antagonists suggest opposing effects whether 
DA is depleted in the core or the shell (Besson et al., 2010).  
 
Figure 3.1. Fronto-striatal loops involved in optimal 5-CSRTT performance. ACC: anterior cingulate 
cortex; dStr: dorsal striatum; IL: infralimbic cortex; Nacc: nucleus accumbens; OFC: orbitofrontal cortex; 
dmStr: dorsal medial striatum. Adapted from Bari and Robbins (2011). 
 
Noradrenaline 
NA is also implicated in ADHD, and drugs that act predominantly on the 
noradrenergic system have shown good efficacy in the treatment of this disorder. 
These include guanfacine (Sallee et al., 2009), a selective alpha2-adrenoceptor 
agonist and atomoxetine (Kratochvil et al., 2003), a noradrenaline reuptake 
inhibitor. In the 5-CSRTT, NA has been linked to response accuracy. Cortical NA 
depletion decreases accuracy (Carli et al., 1983; Milstein et al., 2007) and NA re-
uptake inhibition improves this measure (Robinson, 2012). An increase in NA 
within cortical areas (Navarra et al., 2008; Robinson, 2012) and the shell of the 
nucleus accumbens (Economidou et al., 2012) also reduce premature responses in 
the 5-CSRTT. 
Serotonin 
The role of 5-HT in the 5-CSRTT is unclear. Some studies report increased 
premature responses following central 5-HT depletion (Harrison et al., 1999, 1997), 
whilst other studies report a positive correlation between increased 5-HT and 
premature responses (Koskinen et al., 2000a, 2000b; Puumala and Sirviö, 1998). 
Also, the 5-HT(2C) receptor knockout mouse shows no differences in premature 
responses compared to wildtype mice (Fletcher et al., 2012). These discrepencies 
are thought to be due to the large number of 5-HT receptor subtypes: currently at 
least 15 have been identified. Apart from 5-HT3 receptors, which are ligand-gated 
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ion channels, all the receptor subtypes are G protein-coupled receptors. Depending 
on the receptor subtype, they can be excitatory or inhibitory, and they perform 
different functions with the peripheral and central nervous system (Barnes and 
Sharp, 1999; Hoyer et al., 2002). Another reason for these discrepancies is the 
different levels of receptor subtype activation in distinct brain regions (Robinson 
et al., 2008). Despite these contradictory findings, studies agree that increased 
5-HT release impairs response accuracy (see Robbins, 2002). 
Acetylcholine 
In line with the current treatments for ADHD, research into the 
neuropharmacology of the 5-CSRTT has largely focussed on monoamine systems. 
However, studies have also suggested a role for the cholinergic system in 
attentional processes. Specifically, cholinergic lesions to the nucleus basalis of 
Meynert, which projects to the frontal cortex, impair accuracy in rats in the 
5-CSRTT (McGaughy et al., 2002; Muir et al., 1994). A reduction in accuracy was 
also found in mice injected systemically with scopolamine, a muscarinic receptor 
antagonist (Humby et al., 1999; Jones and Higgins, 1995). As mentioned above, the 
striatum plays an important role in 5-CSRTT performance, and cholinergic 
interneurons in this region exert strong control over DA (Pisani et al., 2001; Wang 
et al., 2006). As yet though, the effects of striatal cholinergic lesions on 5-CSRTT 
performance have not been studied.  
3.1.2 Amphetamine 
3.1.2.1 Mechanism 
The current most prescribed treatments for ADHD are psychostimulants such as 
d-amphetamine (Adderall) and methylphenidate (Ritalin). Amphetamine acts 
primarily by increasing DA levels. This is achieved by binding to the DAT and 
inhibiting DA reuptake. The DAT/ amphetamine complex can also enter the cell, 
where amphetamine ‘exchanges’ with intracellular DA, causing DA to exit the cell 
through the sodium-mediated mechanism that clears DAT. This causes an increase 
in extracellular DA. At high doses, amphetamine also inhibits monoamine oxidase, 
an enzyme that breaks down DA (Seiden et al., 1993). Although the effects of 
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amphetamine are predominantly dopaminergic, it also increases extracellular 
5-HT (Kuczenski and Segal, 1989) and NA (Kuczenski and Segal, 1992). 
In this chapter, the dextrorotatory stereoisomer of amphetamine, 
dextroamphetamine (d-amphetamine), was used. This drug is prescribed to 
patients with ADHD under the name Adderall®.  
3.1.2.2 Effects in the 5-CSRTT 
One of the aims of the rodent version of the 5-CSRTT was to identify drugs in 
rodents that would have good predictive validity for treating attentional disorders. 
However, initial studies with amphetamine failed to show a therapeutic effect, 
instead showing an increase in premature responses following amphetamine 
administration in rats (Cole and Robbins, 1989, 1987; Harrison et al., 1997) and 
mice (Loos et al., 2010). These studies used a fixed inter-trial interval (ITI), 
meaning that the time between trial initiation and stimulus presentation was the 
same on every trial. An alternative version of the 5-CSRTT using a variable ITI has 
found an improvement in premature responses after amphetamine, although this 
was accompanied by an increase in omissions (Bizarro et al., 2004).  
The effects of amphetamine on 5-CSRTT performance in other animal models of 
ADHD have not been tested. However, the most validated animal model of ADHD, 
the Spontaneously Hypertensive Rat (SHR), shows a reduction in inattention, 
impulsivity and activity following d-amphetamine in another task of visual 
attention (Sagvolden and Xu, 2008). 
3.1.3 Aims 
In order to further validate the NK1R-/- mouse as a model of ADHD, the effects of 
d-amphetamine in the 5-CSRTT were evaluated. The mice used in this experiment 
had previously been trained in the 5-CSRTT, as outlined in section 2.4.1.2. During 
training, NK1R-/- mice made significantly more omissions during stages 2-4 and 
significantly more perseverative responses during stages 1-5 than wildtype mice. 
However, there were no differences by the end of training (stage 6), apart from in 
the latency to collect the reward, which was longer in NK1R-/- mice (Yan et al., 
2011). These mice had also been tested with a long and a variable inter-trial 
interval (LITI and VITI, respectively). The inter-trial interval (ITI) is the time 
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between trial initiation and stimulus onset. In the LITI, the ITI was increased to 7s, 
and in the VITI, the ITI was 2, 5, 10 or 15s. Therefore, these tests promote 
inattention and impulsivity. These tests revealed that NK1R-/- were more 
inattentive, impulsive and compulsive than wildtype mice (Yan et al., 2011, Figure 
3.2). In the present chapter, these mice were again tested with a LITI and a VITI, 
but this time following administration of d-amphetamine. Although the 
hyperactivity of NK1R-/- mice was reduced with 2.5mg/kg d-amphetamine (Yan et 
al., 2010), two lower doses were used here, in line with the doses prescribed to 
patients with ADHD. These doses are within the range used in other studies 
looking at the effects of amphetamine in the 5-CSRTT (e.g. Loos et al., 2010).  
 
Figure 3.2 Behaviour of wildtype (WT) and NK1R-/- mice when they were first tested in the 5-CSRTT 
with a long (LITI) and a variable (VITI) inter-trial interval (n=12). NK1R-/- mice were more inattentive 
(A, C, E), impulsive (F) and made more perseverative responses (B, D) than wildtype mice. *P<0.05; **P<0.01; 
***P<0.001. Adapted from (Yan et al., 2011).  
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3.2 Methods 
3.2.1 Animals 
12 wildtype and 12 NK1R-/- mice (129/Sv x C57BL/6 crossed with an MF1 strain) 
from homozygous matings were used in this experiment. The mice were 6-8 weeks 
old at the start of the experiment, and weighed 25-40g (see section 2.1 for full 
details of breeding and housing). Throughout the experiment, food was restricted 
to maintain each mouse at 90% of its free-feeding weight. Water was available ad 
libitum and all animals were weighed daily. 
The two genotypes were housed separately in cages of four, so that each cage 
contained four wildtype or four NK1R-/- mice. One mouse from each genotype 
died before the end of the experiment. 
3.2.2 5-Choice Serial Reaction-Time Task 
The apparatus and protocol are discussed in detail in section 2.4.1. Briefly, mice 
were habituated to the boxes then trained over six stages of increasing difficulty 
(see table Table 2.2). Once their performance at stage six was stable (total trials 
minus premature responses = 100; %accuracy > 75%; %omissions < 25%), 
treatment-naive mice were challenged with a Long Inter-Trial Interval (LITI), 
which increased the time between trial initiation and stimulus appearance to 7s 
(no injection 1, NI-1). They were then tested in the LITI 30 minutes after an 
intraperitoneal (i.p.) injection of d-amphetamine (0.3 mg/kg, A(0.3) and 1 mg/kg, 
A(1)), vehicle (0.9% saline) or they experienced a second un-injected test (NI-2). 
All mice underwent each test condition once only at weekly intervals, on a pseudo-
latin square randomisation schedule. Between each weekly test, mice were trained 
once-daily on stage six, and were only tested if their performance was stable for 3 
consecutive days prior to testing. 
To further highlight deficits in attention and impulsivity, mice were then tested 
with a Variable Inter-Trial Interval (VITI), which set the time between trial 
initiation and stimulus appearance to 2, 5, 10 or 15s, on a random schedule (NI-1). 
Following this they received the same series of treatments, substituting the LITI 
for the VITI (see Figure 3.3). All tests lasted until the mice had completed 100 trials 
(minus premature responses), or after 45 minutes. 
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Figure 3.3 Testing sequence for wildtype and NK1R-/- in the 5-CSRTT. NI-1: no injection 1; NI-2: no 
injection 2; Veh: vehicle; A(0.3): d-amphetamine 0.3mg/kg; A(1): d-amphetamine 1mg/kg. LITI: long inter-trial 
interval. VITI: variable inter-trial interval. 
3.2.3 Statisical analysis 
The behaviours scored in the 5-CSRTT are described in section 2.4.1.3. They are 
summarised below: 
 Total number of trials 
 %Accuracy 
 %Omissions 
 %Premature responses 
 Latency to correct response 
 Latency to collect the reward 
 Perseverative reponses 
In addition, the total number of trials to reach baseline was calculated. Full details 
of the statistical analysis are given in section 2.7. The training data and first LITI 
and VITI tests (NI-1) have been analysed and discussed elsewhere (Yan et al., 
2011, Figure 3.2). The data for the treatments and NI-2 were analysed with a 2-
way repeated measures ANOVA, with ‘genotype’ as the between-subjects factor and 
‘treatment’ as the within-subjects factor. In order to look at the effects of vehicle 
injection, NI-2 was first compared to vehicle, and then vehicle was compared to the 
treatment groups. A significant main effect of either independent variable or a 
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significant interaction between them led to post-hoc 1-way ANOVAs or paired 
sample t-tests. Data for the LITI and VITI were analysed separately. In the VITI, as 
well as analysing the overall data, data for each ITI (2s, 5s, 10s and 15s) was 
analysed separately. 
  
Chapter 3 
 
69 
 
3.3 Results 
3.3.1 Number of trials to reach baseline 
There was no genotype difference in the number of trials (t(22) = 0.279, P=0.783). 
Wildtype mice took an average of 32.5 trials and NK1R-/- mice took an average of 
33.9 trials to complete training (Figure 3.4). As training was carried out 5 days a 
week, the mice were between 3-4 months when they were first tested in the 5-
CSRTT. 
 
Figure 3.4 Total number of trials to reach baseline in the 5-CSRTT in wildtype (WT) and NK1R-/- mice. 
3.3.2 LITI 
3.3.2.1 Effects of vehicle injection 
%Omissions 
There was a main effect of genotype (F(1,22) = 5.09, P<0.05). At NI-2, NK1R-/- 
mice had significantly higher %omissions than wildtype mice (F(1,22) = 7.61, 
P<0.05). There was also a significant interaction (F(1,22) = 4.83, P<0.05). Whereas 
vehicle injection increased %omissions in wildtype mice (t(11) = 2.84, P<0.05), 
they remained unchanged in NK1R-/- mice (Figure 3.5A). 
Perseverative responses 
There was a significant interaction (F(1,22) = 9.73, P<0.01). Whereas the vehicle 
injection significantly increased perseverative responding in NK1R-/- mice (t(11) = 
2.36, P<0.05), it significantly decreased this measure in wildtype mice (t(11) = 2.62, 
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P<0.05). This caused a genotype difference in the vehicle-injected group (F(1,22) = 
6.58, P<0.05) (Figure 3.5C). 
Latency to collect the reward 
There was a significant interaction (F(1,22) = 7.15, P<0.05). The vehicle injection 
increased the latency to collect the reward in NK1R-/- mice only (t(11) = 3.48, 
P<0.01). This increase led to a genotype difference in vehicle-injected mice, with 
NK1R-/- mice being significantly slower to collect the reward (F(1,22) = 9.51, 
P<0.01) (Figure 3.5G). 
%Premature responses, %accuracy, total number of trials and latency to 
correct response 
These measures did not differ in un-injected and vehicle treated mice (Figure 3.5 
and Table 3.1). 
Table 3.1 Statistical values for the behaviours that did not differ in the un-injected or vehicle-injected 
mice tested in the 5-CSRTT with an LITI. 
 
Main effect of 
genotype 
Main effect of 
treatment 
Main interaction 
%Premature 
responses 
F(1,22) = 0.72, 
P=0.78 
F(1,22) = 2.16, 
P=0.16 
F(1,22) = 0.35, 
P=0.56 
%Accuracy 
F(1,22) = 2.29, 
P=0.14 
F(1,22) = 0.82, 
P=0.38 
F(1,22) = 0.01, 
P=0.94 
Total number of 
trials 
F(1,22) = 0.02, 
P=0.89 
F(1,22) = 0.31, 
P=0.58 
F(1,22) = 0.22, 
P=0.65 
Latency to 
correct response 
F(1,22) = 3.59, 
P=0.71 
F(1,22) = 1.93, 
P=0.18 
F(1.22) = 0.22, 
P=0.64 
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3.3.2.2 Effects of d-amphetamine 
Perseverative responses 
NK1R-/- mice perseverated significantly more in all treatment groups (F(1,22) = 
12.97, P<0.01). There was also a main effect of treatment (F(1.56, 34.13) = 5.45, 
P<0.05). The higher dose of d-amphetamine reduced perseveration in both 
genotypes (wildtype c.f. A(0.3): t(11) = 2.4, P<0.05; NK1R-/- c.f. vehicle: t(11) = 2.4, 
P<0.05; NK1R-/- c.f. A(0.3): t(11) = 2.57, P<0.05) (Figure 3.5C). 
Latency to correct response 
 There was a main effect of treatment (F(1.35, 28.36) = 9.59, P<0.01). Overall, the 
higher dose of d-amphetamine increased the latencies of both genotypes (c.f. 
vehicle: t(22) = 2.67, P<0.05; c.f. A(0.3): t(22) = 3.99, P=0.001) (Figure 3.5F). 
Latency to collect the reward 
NK1R-/- mice were consistently slower to collect the reward (main effect of 
genotype: F(1,21) = 16.03, P=0.001). The higher dose of d-amphetamine increased 
the latencies of both genotypes (c.f. vehicle: t(22) = 2.80, P=0.01; c.f. A(0.3): t(22) = 
2.41, P<0.05) (Figure 3.5G). 
%Premature responses, %accuracy, %omissions or total number of trials 
There was no effect of vehicle or either dose of d-amphetamine on any of these 
measures (Table 3.2 and Figure 3.5). 
Table 3.2 Statistical values for the behaviours that did not differ in the amphetamine-injected mice 
tested in the 5-CSRTT with an LITI. 
 
Main effect of 
genotype 
Main effect of 
treatment 
Main interaction 
%Premature 
responses 
F(1,22) = 2.31, 
P=0.14 
F(1.3,28.59) = 2.93, 
P=0.09 
F(1.3,28.59) = 
2.52, P=0.13 
%Accuracy 
F(1,21) = 0.29, 
P=0.59 
F(2,42) = 0.63, P=0.54 
F(2,42) = 0.26, 
P=0.77 
%Omissions 
F(1,22) = 0.045, 
P=0.83 
F(1.45,31.86) = 3.642, 
P=0.051 
F(1.45,31.86) = 
1.42, P=0.25 
Total number 
of trials 
F(1,22) = 1.31, 
P=0.27 
F(1.02,22.52) = 1.48, 
P=0.24 
F(1.02,22.52) = 
1.23, P=0.28 
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Figure 3.5 Effects of vehicle (Veh), d-amphetamine (0.3 and 1mg/kg; A(0.3) and A(1)) or no injection 
(NI-2) on performance of wildtype (WT) and NK1R-/- mice in the 5-CSRTT tested with a LITI (n=12). 
(A) %Omissions, (B) %Premature responses, (C) Perseverative responses, (D) Total number of trials, (E) 
%Accuracy, (F) Latency to correct response and (G) Latency to collect the reward. *P<0.05; **P<0.01; 
***P<0.001. Black bars linking WT and NK1R-/- indicate a difference at P<0.05 at least. 
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3.3.3 VITI 
Other than the effects of d-amphetamine on %omissions, statistical analysis of 
individual time bins revealed no further effects. Therefore, overall differences are 
presented. 
3.3.3.1 Effects of vehicle injection 
The vehicle injection did not modify the behaviour of either genotype, so that the 
genotype differences present in the un-injected groups were also present in the 
vehicle-injected groups. Compared to wildtype mice, NK1R-/- mice were slightly 
less accurate (3%), made more omissions, more perseverative responses and were 
slower to respond and to collect the reward. There were no genotype differences 
in %premature responses or total number of trials (Table 3.3). 
Table 3.3 Genotype differences between un-injected and vehicle-injected wildtype and NK1R-/- mice 
tested in the 5-CSRTT with a VITI (n=12). Overall F values for the main effect of genotype in the repeated 
measures ANOVA is given, followed by the values for the post-hoc one-way ANOVA if the P value is significant. 
%Accuracy 
NI-2: X2 = 5.83, P<0.05 
Vehicle: X2 = 7.98, P<0.01 
%Omissions 
F(1,20) = 12.25, P<0.01 
NI2: F(1,20) = 6.59, P<0.05 
Vehicle: F(1,21) = 13.12, P<0.01 
Latency to correct response 
F(1,20) = 7.79, P<0.05 
NI-2: F(1,20) = 6.31, P<0.05 
Vehicle: F(1,21) = 7.12, P<0.05 
Latency to collect the reward 
F(1,20) = 8.55, P<0.01 
NI-2: F(1,20) = 7.63, P<0.01 
Vehicle: F(1,21) = 10.39, P<0.01 
Perseverative responses 
F(1,20) = 11.03, P<0.01 
NI-2: F(1,20) = 6.50, P<0.05 
Vehicle: F(1,21) = 7.96, P=0.01 
%Premature responses F(1,20) = 2.60, P=0.122 
Total number of trials F(1,20) = 0.249, P=0.623 
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3.3.3.2 Effects of d-amphetamine 
%Omissions 
Overall there was no genotype difference in %omissions following d-amphetamine 
(Figure 3.6A). Analysis of individual time bins showed that at the 15s ITI, the 
higher dose of d-amphetamine reduced %omissions in NK1R-/- mice (X2 = 6.62, 
P<0.05; c.f. vehicle: Z = 2.04, P<0.05; c.f. A(0.3): Z = 2.04, P<0.05) (Figure 3.7D). 
%Premature responses 
There was a main effect of treatment (F(2,42) = 3.63, P<0.05). The higher dose of 
d-amphetamine increased premature responding in NK1R-/- only (c.f. vehicle: 
t(11) = 2.58, P<0.05; c.f. A(0.3): t(11) = 2.94, P<0.05). This increase led to a 
significant genotype difference (F(1,21) = 5.32, P<0.05) (Figure 3.6B).  
Perseverative responding 
There was no longer a genotype difference in perseverative responding following 
d-amphetamine, but there were no significant increases or decreases in either 
genotype (Figure 3.6C). 
%Accuracy 
Both doses of d-amphetamine slightly reduced accuracy in wildtype mice (X2 = 
8.15, P<0.05, vehicle c.f. A(0.3): Z= 2.60, P<0.01; c.f. A(1): Z = 2.24, P<0.05) but did 
not affect NK1R-/- mice (Figure 3.6E). 
Latency to correct response 
NK1R-/- mice were slower to make a correct response across all treatment groups 
(F(1,21) = 8.08, P=0.01). The low dose of d-amphetamine slightly increased the 
latencies in wildtype mice (F(1.58, 33.25) = 4.11, P<0.05; vehicle c.f. A(0.3): t(10) = 
3.69, P<0.01) (Figure 3.6F). 
Latency to collect the reward 
There was a main effect of treatment (F(1.44, 30.26) = 7.85, P<0.01). Overall, both 
doses of d-amphetamine increased the latencies (vehicle c.f. A(0.3): t(22) = 2.624, 
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P<0.05; c.f. A(1): t(22) = 2.312, P<0.05). This effect was seen at all ITIs (Figure 
3.6G). 
Total number of trials 
The total number of trials was not affected by d-amphetamine (X2 =0.875, P=0.65) 
(Figure 3.6D). 
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Figure 3.6 Effects of vehicle (Veh), d-amphetamine (0.3 and 10 mg/kg; A(0.3) and A(1)) or no injection 
(NI-2) on performance of wildtype (WT) and NK1R-/- mice in the 5-CSRTT tested with a VITI (n=12). 
(A) %Omissions, (B) %Premature responses, (C) Perseverative responses, (D) Total number of trials, (E) 
%Accuracy, (F) Latency to correct response and (G) Latency to collect the reward. *P<0.05; **P<0.01; 
***P<0.001. Black bars linking WT and NK1R-/- indicate a difference at P<0.05 at least. 
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Figure 3.7 Amphetamine (1mg/kg) reduces %Omissions in NK1R-/- mice at the 15sec ITI. 
%Omissions of wildtype (WT) and NK1R-/- mice in the 5-CSRTT tested in the VITI at each ITI 
(n=12). (A) 2sec ITI, (B) 5sec ITI, (C) 10sec and (D) 15sec ITI following vehicle (Veh), 
d-amphetamine (0.3 and 1mg/kg; A(0.3) and A(1)) or no injection (NI-2). *P<0.05;**P<0.01; 
***P<0.001. Black bars linking wildtype (WT) and NK1R-/- indicate a difference at P<0.05 at least. 
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3.4 Discussion 
3.4.1 Attention 
Omissions in the 5-CSRTT are an index of attention. NK1R-/- mice made more 
%omissions than wildtype mice, and this difference was no longer present after 
treatment with d-amphetamine. A significant reduction in %omissions following 
d-amphetamine was only evident in NK1R-/- mice in the VITI at the longest ITI 
(15s). Mice are trained with a 5s ITI, and between each weekly test they are kept 
on a baseline ITI of 5s. %omissions were particularly high when the ITI was 
increased to 15s, presumably because mice had to wait much longer than they 
were used to. Therefore, it was possible to pull out an effect of drug. Another index 
of attention in the 5-CSRTT is %accuracy, and this was reduced in uninjected and 
vehicle-injected NK1R-/- mice in the VITI. This difference was abolished following 
d-amphetamine treatment, due to a reduction in %accuracy in wildtype mice. 
Omissions and impaired accuracy in the 5-CSRTT have been linked to a decrease in 
NA transmission (Milstein et al., 2007). Furthermore, drugs that increase NA 
transmission have been prescribed to patients as alternative treatments to 
psychostimulants. Due to the therapeutic effect of increased NA, it seems 
surprising that the NK1R-/- mouse, which has elevated NA in the pre-frontal cortex 
(Yan et al., 2009), has higher omissions and lower accuracy than wildtype mice. 
However, other reports have suggested that attention depends on optimal NA 
release (Aston-Jones and Cohen, 2005). D-amphetamine increases NA release, and 
it therefore seems surprising that it reduces omissions in NK1R-/- mice if they 
already have elevated levels of NA. However, d-amphetamine has a biphasic effect 
on NA, and at low doses can reduce its release (Ryan et al., 1985). 
3.4.2 Perseveration 
In the LITI, the vehicle injection increased perseverative responding in NK1R-/- 
mice, but reduced it in wildtype mice. In both genotypes, perseverative responding 
was reduced by the higher dose of d-amphetamine. The vehicle-induced increase 
in NK1R-/- mice was not apparent in the VITI, although this could be due to the 
fact that perseverative responses at NI-2 were already higher than in the LITI. In the 
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VITI, both doses of d-amphetamine abolished the genotype difference in 
perseverative responding.  
Perseverative responding in the 5-CSRTT has been linked to a deficit in DA 
transmission (Baunez and Robbins, 1999), which fits with the reduction in 
extracellular DA found in the NK1R-/- mouse (Yan et al., 2010). Stress has 
previously been reported to increase DA release, which could explain why 
perseveration was reduced in wildtype mice following vehicle injection (Finlay and 
Zigmond, 1997). However, NK1R are required for the DA response to stress 
(Renoldi and Invernizzi, 2006). It follows that perseveration was only reduced in 
NK1R-/- mice following d-amphetamine, which mimics the dopaminergic stress 
response by increasing DA release. D-amphetamine has similarly been shown to 
reduce perseveration in rats with striatal 6-hydroxydopamine lesions (Baunez and 
Robbins, 1999). 
3.4.3 Premature responding 
%Premature responses were increased in NK1R-/- mice when they were first tested 
in the VITI (Yan et al., 2011, Figure 3.2). In the present chapter, when being tested 
for a second time without injection, this difference no longer reached statistical 
significance. A previous study has shown that %premature responses are reduced 
in mice tested repeatedly in the VITI (Walker et al., 2011) which could explain why 
this deficit is reduced on repetition of the test in NK1R-/- mice. However, it is also 
interesting to note that adults with ADHD are predominantly inattentive, and tend 
not to present with impulsive symptoms (Willcutt, 2012). Therefore, the decrease 
in %premature responses may be due to the fact that the mice are older, and the 
NK1R-/- mouse may be a good model for identifying more effective treatments for 
patients with the Predominantly Inattentive subtype of ADHD. 
D-amphetamine did not reduce %premature responses, and even exacerbated them 
in NK1R-/- mice at the higher dose, as seen previously in mice treated with the 
same dose of amphetamine (Loos et al., 2010). Although impulsivity in the 
5-CSRTT is thought to be due to disrupted 5-HT transmission, reports disagree on 
whether an increase (Dalley et al., 2002; Puumala and Sirviö, 1998) or decrease 
(Harrison et al., 1997) in 5-HT underlies impulsivity. There are at least 14 types of 
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5-HT receptors (Barnes and Sharp, 1999), and they have different effects on 
impulsivity. For example, blockade of 5-HT2A receptors decreases impulsivity, 
while blockade of 5-HT2C receptors causes an increase in this measure (Robinson 
et al., 2008).  Therefore, the effects of 5-HT agonism or antagonism in certain brain 
areas could depend on the different levels of receptor subtypes. Either way, basal 
5-HT in NK1R-/-  mice is elevated (Yan et al., 2010) and d-amphetamine increases 
5-HT release (Kuczenski and Segal, 1989). It follows that d-amphetamine would 
exacerbate the deficit in impulsive responding by further increasing 5-HT release. 
Impulsivity in the 5-CSRTT has been described as motoric impulsivity, and other 
reports have similarly shown an increase in %premature responses following 
treatment with d-amphetamine. However, impulsivity is not a unitary construct 
(Evenden, 1999; Winstanley et al., 2006) and there are other rodent tests that 
measure different facets of impulsivity. Motoric impulsivity can be further 
investigated with tasks such as the go/no-go test and the stop-signal reaction-time 
task (Eagle and Robbins, 2003; Harrison et al., 1999). These tasks measure the 
ability to rapidly inhibit a pre-programmed motor response. Another test of 
impulsivity is delay discounting, which measures impulsive choice, rather than 
motoric impulsivity. As yet, the NK1R-/- mouse has not been tested in this task, 
although another study found that rats showing high impulsivity in the 5-CSRTT 
also show deficits in delay discounting (Robinson et al., 2009). It would therefore 
be interesting to investigate the effects of d-amphetamine on performance of 
NK1R-/- mice in other tasks of impulsivity. 
3.4.4 Task performance 
NK1R-/- mice were slower to collect the reward than wildtype mice in the LITI and 
VITI. This could indicate that NK1R-/- mice are less motivated by the reward. 
However, an increase in latency to collect the reward occurred in parallel with an 
increase in perseverative responding in NK1R-/- mice. Therefore, NK1R-/- mice 
could be slower because they were continuing to poke into the stimulus hole 
rather than collecting the reward. Furthermore, there were no genotype 
differences in the total number of trials completed, illustrating that NK1R-/- mice 
are as motivated to perform the task. 
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In all treatment groups in the VITI, NK1R-/- mice were slower to make a correct 
response. This difference is not apparent in the LITI, suggesting that NK1R-/- mice 
slow their response times when task demands are high.  
3.4.5 Deficits are dependent on task parameters 
Many previous reports using the 5-CSRTT either test using a long, fixed inter-trial 
interval (LITI) or a variable inter-trial interval (VITI). These tests measure 
separate response strategies (Sanchez-Roige et al., 2012). In the LITI, animals can 
rely on internal timing to know when the stimulus will appear, whereas in the VITI, 
they have to continually monitor the stimulus holes. Running both of these tests in 
the present experiment highlighted the importance of choosing the right task 
parameters. An increase in %premature responses is not evident in NK1R-/- mice 
tested in the LITI. This suggests that NK1R-/- mice have no deficits in internal 
timing and perform well when stimulus onset is predictable. Also, the majority of 
premature responses in the VITI were only apparent at the 10s and 15s ITIs, 
whereas the ITI in the LITI is only 7s. The mice were trained on a 5s ITI and it is 
possible that a 2s increase in ITI was not great enough to disrupt performance. The 
same reasoning could explain why the genotype differences in %omissions and 
perseverative responding are more robust in un-injected and vehicle-injected 
NK1R-/- mice tested in the VITI.  
3.4.6 Conclusions 
D-amphetamine abolished genotype differences in %omissions, %accuracy and 
perseverative responding between wildtype and NK1R-/- mice tested in the 
5-CSRTT. Because there were no longer deficits in impulsivity in NK1R-/- mice on 
repetition of the task, it could be useful as a model of the Predominantly 
Inattentive subtype of ADHD. Having looked at the effects of d-amphetamine, the 
next aim was to identify alternative drugs that alleviate the deficits in NK1R-/- 
mice, and that could potentially be therapeutically beneficial in patients that do not 
currently respond to treatment. 
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4 Nifedipine, an L-type calcium channel blocker, 
reduces impulsivity but increases inattentiveness 
in the 5-CSRTT 
4.1 Introduction 
Animal models of human disorders can help the discovery of new potential 
treatments. This can be achieved by testing whether different compounds alleviate 
the animals’ deficits. A report has suggested that L-type calcium channel blockers, 
which are currently used to treat hypertension, can alleviate ADHD-like symptoms 
(Krause et al., 2009). Therefore, in this chapter, the effects of nifedipine, an L-type 
calcium channel blocker, were evaluated in the 5-CSRTT. The results in this 
chapter are also discussed in Dudley et al. (2013). 
4.1.1 ADHD and hypertension 
One of the most widely studied rodent models of ADHD is the Spontaneously 
Hypertensive Rat (SHR, Okamoto and Aoki, 1963) which exhibits hyperactivity, 
impulsivity and attentional deficits (Russell et al., 2005). This suggests a link 
between ADHD and hypertension. However, hypertension is not evident in SHR 
until they reach adulthood, while the behavioural deficits are present before 
puberty (Russell et al., 2005). In a retrospective study, Krause et al. (2009) found 
that prior to being diagnosed, children with hypertension exhibited behavioural 
deficits akin to those seen in patients with ADHD, including hyperactivity and 
attention deficits. Interestingly, these symptoms were improved following anti-
hypertensive treatment, including the L-type calcium channel blocker nifedipine. 
Therefore, the effects of nifedipine warrant further investigation in relation to 
ADHD. 
4.1.2 L-type calcium channels 
L-type calcium channels are voltage-gated calcium channels. Their activation is 
long-lasting (hence ‘L’-type calcium channels) and allows calcium entry into cells. 
The properties of the channel are determined by four α1 subunit pores: Cav1.1-1.4. 
L-type calcium channels regulate various processes including muscle contraction, 
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synaptic plasticity and gene expression (for review see: Lipscombe et al. 2004). 
They are widely distributed throughout the central and peripheral nervous 
systems. Within the brain, they are prevalent in the striatum (Hirota and Lambert, 
1997). This is of particular interest because the striatum has been implicated in the 
pathophysiology of ADHD, and NK1R are densely expressed in this area (Nakaya et 
al., 1994). 
4.1.3 Nifedipine 
Nifedipine is a dihydropyridine, which is a class of chemicals that block L-type 
calcium channels. Nifedipine has high affinity for the Cav1.2 subunit. This subunit 
represents the majority of L-type calcium channels found within the mouse brain, 
where it is particularly expressed within the striatum and cerebral cortex 
(Sinnegger-Brauns et al., 2009). By blocking calcium entry into smooth muscle 
cells, nifedipine decreases vasoconstriction and subsequently lowers blood 
pressure. For this reason, nifedipine is currently used to treat patients with 
hypertension.  
4.1.4 L-type calcium channels and NK1R 
Pharmacological evaluation of NK1R antagonists have revealed non-specific L-type 
calcium channel blocking properties (Guard et al., 1993; Rupniak et al., 1993, 2003; 
Schmidt et al., 1992), and a  depressant effect of the NK1R antagonist RP 67580 on 
blood pressure has previously been reported (Laird et al., 1993). Furthermore, 
nifedipine and another L-type calcium channel blocker, verapamil, both induce an 
antinociceptive phenotype in rodents similar to that seen in wildtype mice treated 
with an NK1R antagonist (Miranda et al., 1992; Rupniak et al., 1993). This suggests 
an interaction between L-type calcium channels and NK1R. Currently, it is not 
known whether there are abnormalities in the expression or function of L-type 
calcium channels in NK1R-/- mice. However, it is possible that L-type calcium 
channel blockers administered to wildtype mice could mimic the behavioural 
deficits seen in NK1R-/- mice in the 5-CSRTT. 
4.1.5 Aims 
The study by Krause et al. (2009) suggests that the L-type calcium channel blocker 
nifedipine could alleviate the behavioural deficits seen in NK1R-/- mice tested in 
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the 5-CSRTT. However, pharmacological studies with NK1R antagonists suggest 
that L-type calcium channel antagonism could induce these behavioural deficits in 
wildtype mice. Therefore, in this study the effects of nifedipine on performance of 
wildtype and NK1R-/- mice in the 5-CSRTT were studied. In the previous chapter 
more behavioural deficits were evident in NK1R-/- mice under VITI testing 
conditions than in the LITI, presumably due to increased task difficulty. For this 
reason mice were only tested in the VITI in the present chapter. Also, in order to 
confirm that any effects on 5-CSRTT performance were not due to any sedative 
effects of the drug, activity of nifedipine-treated wildtype and NK1R-/- mice was 
measured in the LDEB. 
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4.2 Methods 
4.2.1 Animals 
The mice and housing conditions are described in section 2.4.1 and were identical 
to those used in chapter 3. For the LDEB experiment, mice were tested at 6-8 
weeks of age. 
4.2.2 5-CSRTT 
The apparatus and the food deprivation protocol are decribed in section 2.4.1. 
Wildtype mice weighed 34.5±0.5g and NK1R-/- mice weighed 28.9±0.8g at the 
start of the experiment. Following habituation and training in the 5-CSRTT, 
wildtype and NK1R-/- mice (n=6-10) were challenged with a Variable Inter-Trial 
Interval (VITI) (2, 5, 10 or 15s, delivered on a random schedule). After an initial 
un-injected VITI test (NI-1), the mice were retested in the VITI 30 minutes after an 
intraperitoneal (i.p.) injection of nifedipine (3mg/kg and 10mg/kg), vehicle (20% 
Tween 80 in 0.9% saline), or a second un-injected test (NI-2). All mice experienced 
each test condition once only at weekly intervals (on a Friday), on a pseudo-latin 
square randomisation schedule. Between each weekly test, mice were trained 
once-daily on stage 6, and were only tested if their performance was stable for 3 
consecutive days. 
4.2.3 LDEB 
The protocol is as described in (Herpfer et al., 2005). For a full description of the 
protocol and apparatus, see section 2.4.2. Briefly, mice (n=4-6) were placed in the 
dark zone for 60 minutes before being injected (i.p.) with nifedipine (3mg/kg and 
10mg/kg) or vehicle (20% Tween 80 in 0.9% saline). Following a further 30 
minutes in the dark zone, they were placed in the centre of the light zone and the 
total number of line crosses and line crosses in the light zone over 30 minutes was 
recorded and scored blind. 
4.2.4 Statistical analysis 
Full details of statistical analysis are given in section 2.7. The behaviours scored in 
the 5-CSRTT are identical to those in chapter 3, and described in full in section 
2.4.1.3. In addition, the total number of trials to reach baseline was analysed with 
an independent-samples t-test and the training performance of wildtype and 
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NK1R-/- mice was compared with a 2-way repeated measures ANOVA, with ‘stage’ 
as the within-subjects factor and ‘genotype’ as the between-subjects variable. In the 
test phase, four different analyses were performed. First, uninjected wildtype and 
NK1R-/- mice were compared when they were first tested in the VITI (NI-1). Next, 
the first and second uninjected tests (NI-1 and NI-2) were compared to look at the 
effects of repeated testing on task performance. Then uninjected (NI-2) and 
vehicle-injected mice were compared to look at the effect of injection. Finally, 
vehicle-injected mice were compared with nifedipine-injected mice. Each 
comparison was analysed with a 2-way repeated measures ANOVA, with ‘genotype’ 
as the between-subjects factor, and ‘treatment’ as the within-subjects factor. A 
significant main effect of either independent variable or a significant interaction 
between them led to post-hoc 1-way ANOVA or paired sample t-tests. The LDEB 
data were analysed with a 2-way between subjects ANOVA, with ‘genotype’ and 
‘treatment’ as the between-subjects factors, followed by post-hoc 1-way ANOVA 
and LSD tests.  
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4.3 Results 
4.3.1 5-Choice Serial Reaction-Time Task 
4.3.1.1 Number of trials to reach baseline 
There was no genotype difference in the number of trials (t(14) = 0.047, P=0.963). 
Wildtype mice took an average of 31.5 trials and NK1R-/- mice took an average of 
29 trials to complete training (Figure 4.1). As training was carried out 5 days a 
week, the mice were between 3-4 months when they were first tested in the 5-
CSRTT. 
 
Figure 4.1 Total number of trials to reach baseline in the 5-CSRTT in wildtype (WT) and NK1R-/- mice. 
4.3.1.2 Training differences 
The only genotype difference during training was in %accuracy. There was a main 
interaction between stage and genotype (F(5,70) = 3.98, P<0.01). NK1R-/- mice 
were more accurate than wildtype mice at stages 3 (F(1,21) = 13.06, P<0.01), 5 
(F(1,18) = 16.64, P=0.001) and 6 (F(1,14) = 9.42, P<0.01). 
4.3.1.3 VITI 
%Omissions 
%Omissions did not differ between the two genotypes during either of the 
uninjected tests or following vehicle injection. Nifedipine increased %omissions, 
but the magnitude of this increase depended on genotype (treatment*genotype 
interaction: F(2,28) = 3.98, P<0.05). Whereas both doses of nifedipine increased 
%omissions in wildtype mice (veh c.f. nifed-3: t(5) = 5.03, P<0.01; c.f. nifed-10: 
t(5)= 6.18, P<0.01), only the higher dose increased this measure in NK1R-/- mice 
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(veh c.f. nifed-10: t(9) = 4.56, P=0.001) (Figure 4.2A). Despite this increase, 
wildtype mice had significantly higher %omissions than NK1R-/- mice after both 
doses of nifedipine (nifed-3: F(1,15) = 8.82, P=0.01; nifed-10: F(1,14) = 9.99, 
P<0.01). 
%Premature responses 
%Premature responses were increased in NK1R-/- mice at NI-1 compared to 
wildtype mice (t(14.46) = 2.26, P<0.05). This increase was no longer present at NI-
2. %Premature responses were reduced overall by the vehicle injection (main 
effect of injection: F1,14 = 7.61, P<0.05; c.f. NI-2: t(15) = 2.66, P<0.05). Nifedipine 
further reduced %premature responses, but this depended on genotype 
(treatment*genotype interaction: F(2,28) = 4.53, P<0.05). Both doses of nifedipine 
reduced %premature responses in wildtype mice (veh c.f. nifed-3: t(5) = 2.86, 
P<0.05; c.f. nifed-10: t(5) = 3.64, P<0.05). This reduction was only seen following 
the higher dose of nifedipine in NK1R-/- mice (veh c.f. nifed-10: t(9) = 7.62, 
P<0.001) (Figure 4.2B). 
Perseverative responding 
NK1R-/- mice made more perseverative responses than wildtype mice, especially 
at NI-2 (X2 = 5.70, P<0.05). This measure was not affected by vehicle injection, and 
NK1R-/- mice continued to make more perseverative responses than wildtype 
mice following nifedipine injection (main effect of genotype: F(1,14) = 14.15, 
P<0.01). Nifedipine reduced perseverative responding in wildtype mice but did not 
affect NK1R-/- mice (treatment*genotype interaction: F(2,28) = 4.67, P<0.05; 
wildtype: veh c.f. nifed-3: t(5) = 2.72, P<0.05; c.f. nifed-10: t(5) = 3.94, P<0.05) 
(Figure 4.2C).  
Total number of trials 
Repetition of the test or vehicle injection did not affect the total number of trials. 
There was a reduction in trials completed following the higher dose of nifedipine 
in wildtype mice only (X2 = 6.91, P<0.05; veh c.f. nifed-10: Z = 2.2, P<0.05) (Figure 
4.2D). 
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%Accuracy 
Repetition of the test, vehicle injection or nifedipine did not affect %accuracy in 
either genotype (Figure 4.2E). 
Latency to correct response 
The latency to correct response was slightly decreased in both genotypes on 
repetition of the test (main effect of repetition: F(1,14) = 6.59, P<0.05), and 
increased following vehicle injection (main effect of injection: F(1.14) = 20.19, 
P=0.001). This increase was slightly greater in wildtype mice, so that vehicle-
injected NK1R-/- mice were faster to respond (main effect of genotype: F(1,14) = 
4.66, P<0.05). Both doses of nifedipine increased the latency to correct response 
(main effect of treatment: F(1.23,14.78) = 20.13, P<0.001; veh c.f. nifed-3: t(15) = 
3.59, P<0.01; c.f. nifed-10: t(13) = 5.47, P<0.001) but there were no genotype 
differences (Figure 4.2F). 
Latency to collect the reward 
Latency to collect the reward did not change on repetition of the test, but was 
increased following vehicle injection (main effect of treatment: F(1,14) = 11.19, 
P<0.01; veh c.f. NI-2: t(15) = 3.18, P<0.01). This measure was also increased 
following nifedipine (main effect of treatment: F(1.25,15.02) = 17.36, P<0.001; veh 
c.f. nifed-3: t(15) = 3.59, P<0.01; c.f. nifed-10: t(13) = 5.47, P<0.001), but did not 
differ in the two genotypes (Figure 4.2G). 
4.3.2 Light/Dark exploration box 
Nifedipine did not affect the total number of line crosses or line crosses in the light 
zone of either genotype (Figure 4.3). There were also no genotype differences. The 
statistical values are summarised in (Table 4.1). 
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Table 4.1 Statistical values for the total number of line crosses and line crosses in the light zone in 
wildtype and NK1R-/- mice tested in the LDEB. 
 
Main effect of 
genotype 
Main effect of 
treatment 
Main interaction 
Total number of 
line crosses 
F(1,32) = 0.97, 
P=0.33 
F(2,32) = 1.92, 
P=0.16 
F(2,32) = 0.92, 
P=0.41 
Line crosses in 
the light zone 
F(1,32) = 0.62, 
P=0.44 
F(2,32) = 2.70, 
P=0.08 
F(2,32) = 0.05, 
P=0.95 
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Figure 4.2 Effects of vehicle (Veh), nifedipine (3 and 10mg/kg; Nifed-3 and Nifed-10) or no injection 
(NI-2) on performance of wildtype (WT) and NK1R-/- mice in the 5-CSRTT tested with a VITI (n=6-10). 
(A) %Omissions, (B) %Premature responses, (C) Perseverative responses, (D) Total number of trials, 
(E) %Accuracy, (F) Latency to correct response and (G) Latency to collect the reward. Solid black bars 
linking white and black bars indicate P<0.05, at least. Black bars linking treatment groups indicate P<0.05 at 
least. *P<0.05; **P<0.01; ***P<0.001. 
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Figure 4.3 Nifedipine does not affect the activity of wildtype (WT) or NK1R-/- mice in the LDEB (n=4-6). 
(A) Total number of line crosses and (B) number of line crosses in the light zone made by wildtype (WT) and 
NK1R-/- mice in the LDEB (N=5-8). Mice received an i.p. injection of vehicle (Veh) or nifedipine (3 or 10 
mg/kg; Nifed-3 or Nifed-10). There were no statistically significant differences.  
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4.4 Discussion 
4.4.1 Effects of nifedipine on attention and impulsivity 
In the 5-CSRTT, an increase in %omissions with no simultaneous increase in 
response latencies is an index of inattentiveness (Robbins, 2002). Whereas it was 
shown in chapter 3 that NK1R-/- mice have significantly higher %omissions than 
their wildtype counterparts, this difference was not replicated here. It is not clear 
why a deficit in attention was not present in the current study, although patients 
with ADHD often present with unstable symptoms (Lahey et al., 2005; Todd et al., 
2008). Also, %premature responses (an index of impulsivity) were increased in 
NK1R-/- mice when first tested in the VITI, but were reduced on repetition of the 
test. This was also seen in the previous chapter. As discussed in section 3.4.3, a 
decrease in impulsivity on repetition of the 5-CSRTT has been shown in another 
study (Walker et al., 2011) and suggests that mice can quickly adapt to the task 
demands.  
In order to improve the validity of the NK1R-/- mouse model of ADHD, it is 
important to identify conditions under which the behavioural deficits are stable. 
Indeed, one of the aims of this animal model is to identify novel treatments. If the 
behavioural deficits are not consistent in NK1R-/- mice, then it may not be possible 
to test whether different drugs can improve them. However, %accuracy in 
wildtype and NK1R-/- mice is very high, so perhaps making the task parameters 
more difficult (for example by shortening the stimulus duration) would identify 
more robust deficits.  
The effects of nifedipine on %omissions and %premature responses differed 
between genotypes. While the higher dose of nifedipine (10mg/kg) increased 
%omissions and reduced %premature responses in both genotypes, at the lower 
dose (3mg/kg) only wildtype mice were affected. This highlights a link between 
NK1R function and L-type calcium channels. It also suggests that L-type calcium 
channels contribute to impulsivity and attention in the 5-CSRTT, and that their 
antagonism with nifedipine may be therapeutically beneficial in patients with 
impulse control disorders. 
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Surprisingly, NK1R-/- mice had higher %accuracy than wildtype mice during 
training. %Accuracy is an index of attention in the 5-CSRTT and this suggests that 
NK1R-/- are actually more attentive than wildtype mice. However, this difference 
was no longer present during the testing phase and unlike %omissions, %accuracy 
was not affected by nifedipine. This suggests that when mice missed the stimulus 
light, they chose not to respond, rather than guessing and making an incorrect 
response. This could imply that nifedipine was affecting the animals’ motivation to 
perform the task. At the lower dose of nifedipine this did not appear to be the case 
because despite an increase in %omissions in wildtype mice, there was no 
significant reduction in the total number of trials completed. However, there was a 
reduction in trials completed at the higher dose of nifedipine, and the 
simultaneous decrease in %premature responses, increase in %omissions and 
increases in the latencies to respond and to collect the reward suggest that this dose 
impaired task performance. As seen from the LDEB data, this does not appear to be 
due to a sedentary effect of the drug because nifedipine did not impair the activity 
of wildtype or NK1R-/- mice. However, if the higher dose of nifedipine is causing a 
rapid reduction in blood pressure, the animals may feel sick and be unwilling to 
drink the milk reward. 
4.4.2 Central mechanisms 
The neural mechanisms underlying the decrease in impulsivity and simultaneous 
increase in inattentiveness by nifedipine are unclear. This bidirectional 
relationship between attention and impulsivity is not surprising, because 
redirecting attention to salient stimuli requires inhibition of ongoing actions. 
%Premature responses in the 5-CSRTT represent ‘motoric impulsivity’ (Winstanley 
et al., 2006). The suppression of unwanted motor behaviour relies on the ‘indirect’ 
striatopallidal pathway and subsequent facilitation of the ‘direct’ striatonigral 
pathway is required to initiate new actions and respond to new stimuli. These 
pathways form loops projecting through the cortex, basal ganglia, thalamus and 
striatum. 
A recent study has shown that the thalamic projections in these loops converge on 
cholinergic interneurons in the striatum, and that these interneurons are involved 
in the inhibition of unwanted actions in order to redirect attention to salient 
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stimuli (Ding et al., 2010; Thorn and Graybiel, 2010). Thalamic activation of 
cholinergic interneurons causes postsynaptic activation of muscarinic M1 
receptors, located on medium spiny neurons (MSNs).  This suppresses L-type 
calcium channel currents (Wang et al., 2006), thereby reducing network 
excitability and inhibiting unwanted actions. Blocking L-type calcium channels 
with nifedipine would add to overall network inhibition, thus reducing impulsivity. 
It is possible that too much inhibition of the indirect ‘No-Go’ pathway would 
prevent activation of the direct ‘Go’ pathway, and prevent attention from being 
redirected. This mechanism could explain the opposing effects nifedipine has on 
%omissions and %premature responses. In order to test this hypothesis, it would be 
interesting to test an L-type Cav1.2 calcium channel knockout mouse in the 5-
CSRTT. 
NK1R are predominantly located on cholinergic interneurons in the striatum. 
Substance P binding to these receptors triggers acetylcholine release (Anderson et 
al., 1994; Kemel et al., 2002). In contrast, D2 receptors located on cholinergic 
interneurons inhibit acetylcholine release (Wang et al., 2006; Wilson, 2006). A 
reduction in acetylcholine release would reduce the M1 receptor suppression of 
L-type calcium channels in MSNs. The would lead to greater excitability within the 
network, and reduced behavioural inhibition. This could explain why a higher dose 
of nifedipine is required in NK1R-/- mice to reduce impulsivity and attention.  
4.4.3 NK1R and hypertension 
While the central mechanisms described above could explain the genotype-
dependent responses to nifedipine, they could also be caused by a difference in 
blood pressure. Substance P induces smooth muscle contraction and vasodilation , 
and these effects are thought to be mediated by NK1R (reviewed in: Maggi, 1995; 
Otsuka and Yoshioka, 1993). In humans, administration of the NK1R antagonist 
CP99 994 blocks the vasorelaxation of pulmonary arteries (Corboz et al., 1998). It 
remains to be determined whether NK1R-/- mice are hypertensive. However, if 
this is the case, it could explain why a higher dose of nifedipine is required in 
NK1R-/- mice to modify behaviour in the 5-CSRTT. In order to verify this, it would 
be interesting to test an L-type calcium channel blocker that does not cross the 
blood-brain barrier. 
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4.4.4 Perseverative responding 
Consistent with the results from the previous chapter, perseverative responding 
was greater in NK1R-/- mice than in wildtype controls. Both doses of nifedipine 
reduced perseverative responding in wildtype mice but did not affect NK1R-/- mice. 
In the previous chapter, perseverative responding was reduced following d-
amphetamine, and this was thought to be due to an increase in DA release (see 
section 3.4.2). However, nifedipine does not affect DA release in the brain (El Ayadi 
et al., 2001; Reiriz et al., 1994), nor does it affect extracellular NA (Silverstone et 
al., 1992) or 5-HT (Sharp et al., 1990). 
The decrease in perseverative responding seen in wildtype mice may result directly 
from blockade of L-type calcium channels, rather than through changes in 
monoamines. TS-2 neo mice, that have a mutation in the L-type Cav1.2 calcium 
channel gene, exhibit perseveration and repetitive behaviours (Bader et al., 2011). 
This mutation is thought to cause a failure in channel inactivation (i.e. increased 
channel opening), suggesting that the behavioural deficits seen in TS2-neo mice 
could be improved by L-type calcium channel blockers (Splawski et al., 2004). This 
fits with the current findings that nifedipine reduces perseverative responding in 
wildtype mice. A similar trend was seen in NK1R-/- mice, although as seen for 
other behaviours, this was only present at the higher dose. 
4.4.5 NK1R antagonists and L-type calcium channels 
Recent work in our lab tested the effects of the NK1R antagonist RP 67580 on the 
behaviour of wildtype and NK1R-/- mice in the 5-CSRTT (Weir, 2012). Two doses 
were studied, 5 and 10 mg/kg. While the lower dose increased %premature 
responses in wildtype mice, this effect was not seen at the higher dose. Also, the 
higher dose increased %omissions and the latencies to respond and collect the 
reward in wildtype and NK1R-/- mice. The finding that RP 67580 affects NK1R-/- 
mice suggests that it was acting at a target other than NK1R. Nifedipine induced 
similar deficits to those seen following the higher dose of RP 67580, suggesting 
that this secondary target is L-type calcium channels, as has previously been 
reported (Rupniak et al., 1993, 2003). This means that pharmacological studies 
with NK1R antagonists may not induce the deficits seen in NK1R-/- mice, even if 
they are caused by non-functional NK1R. 
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4.4.6 Activity in the LDEB 
In this study, activity in the LDEB was measured in order to verify that nifedipine 
was not inducing gross motor deficits that could impair 5-CSRTT performance. 
Although there was a tendency for the total activity and the activity in the light 
zone to be increased in NK1R-/- mice, this did not reach statistical significance. 
Previous studies using the same LDEB protocol and number of animals have found 
an increase in activity in NK1R-/- mice (Herpfer et al., 2005; Yan et al., 2010). A 
lack of hyperactivity is an issue for the face validity of the NK1R-/- mouse of ADHD. 
Therefore, the work in chapter 5 focussed on re-establishing hyperactivity in 
NK1R-/- mice.  
4.4.7 Conclusions 
Nifedipine reduces impulsivity and perseverative responding but increases 
inattentiveness in the 5-CSRTT. These effects are greater in wildtype mice, 
highlighting an interaction between NK1R and L-type calcium channels. This 
interaction is could be linked to cholinergic interneurons in the striatum and their 
projections in the indirect striatopallidal pathway. Nifedipine induced a similar 
behavioural profile to that seen in wildtype and NK1R-/- mice given the NK1R 
antagonist RP 67580, indicating that the effects seen following injection of RP 
67580 are related to L-type calcium channel blockade. Overall the results in this 
chapter suggest that L-type calcium channel blockers may be beneficial for impulse 
control disorders. However, the next aim was to identify treatments that would 
simultaneously improve impulsivity, perseverative responding and attention.
Chapter 5 
 
98 
 
5 Establishing hyperactivity in NK1R-/- mice 
5.1 Introduction 
In order to identify drugs that improve the deficits in NK1R-/- mice, it is important 
to have a behavioural screen. Due to the time it takes to train and test mice in the 
5-CSRTT, it is not possible to rapidly test a range of drugs in this task. It has 
previously been shown that NK1R-/- mice are hyperactive and that this is reduced 
by d-amphetamine (Yan et al., 2010). Tests of activity are quick and can therefore 
be efficient drug screens. However, activity can be measured in a variety of tests 
and, depending on the test, can be more or less affected by stress. In the current 
chapter I aim to identify testing conditions that reveal robust hyperactivity in 
NK1R-/- mice. 
5.1.1 Hyperactivity in NK1R-/- mice 
NK1R-/- mice have higher activity than wildtype mice in a locomotor activity 
chamber and show an increase in total line crosses in the LDEB (Herpfer et al., 
2005). Also, in the LDEB, the NK1 antagonists RP 67580 and L733 060 increase 
activity in wildtype mice. This suggests a role for NK1R in hyperactivity. 
Furthermore, both the increased activity of NK1R-/- mice and the increase in 
activity in wildtype mice injected with NK1R antagonists are reduced by 
d-amphetamine in the LDEB (Yan et al., 2010). D-amphetamine is currently used to 
treat patients with ADHD, indicating that the LDEB could help identify drugs that 
are therapeutically effective in ADHD. For this reason, initial work in this chapter 
aimed to use the LDEB to identify novel treatments for ADHD. 
5.1.2 Issues with the LDEB as a test of activity 
The LDEB was initially developed as a test of anxiety, with anxiolytic drugs 
increasing the number of transitions between the light and dark zone, as well as the 
time spent in the light zone (Crawley, 1985, 1981). However, when using this test to 
measure activity, the varying amount of time animals spend in the light and dark 
zones can confound interpretation of the data. In order to overcome this limitation, 
(Yan et al., 2010) divided the activity in the light zone by the time spent in the light 
zone. Another way of controlling for this could be to analyse the overall activity 
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across both zones (as in Herpfer et al., 2005). However, in the protocol used, mice 
are habituated to the dark zone for 90 minutes prior to transferring them to the 
light zone. Because the animals are habituated to the dark zone, they are likely to 
explore it less during the 30 minute testing period. This will affect the total activity 
score. Therefore, if activity is the only measure of interest, it is better to use a 
locomotor activity chamber. As mentioned above, NK1R-/- mice are also 
hyperactive when tested in an activity chamber. However, the effects of drugs in 
this test have not yet been studied. 
5.1.3 Effects of stress on activity 
All rodent behavioural paradigms are susceptible to the effects of stress. When 
comparing the activity of NK1R-/- mice to wildtype controls it is especially 
important to minimise stress because NK1R-/- mice have a blunted response to 
anxiogenic stimuli: they attack less in the resident-intruder test (De Felipe et al., 
1998), they vocalise less following maternal separation (Rupniak et al., 2000; 
Santarelli et al., 2001) and they show decreased anxiety in the elevated-plus maze 
(Santarelli et al., 2001). The stress of an injection can modify behaviour in tests of 
activity but as yet the activity of NK1R-/- and wildtype mice has not been 
measured without injection. As seen in the previous chapters, a vehicle injection in 
the 5-CSRTT can have genotype-dependent effects on behaviour. In this chapter 
the effect of vehicle injection on activity was investigated. 
In order to minimise stress, animals should be well-handled and habituated to the 
experimental room prior to testing. However, one way of avoiding the effects of 
experimenter intervention is to test the activity of animals in their home cage. This 
can be achieved with telemetry, in which a radiotransmitter probe is implanted 
subcutaneously in mice and following full recovery, their activity can be monitored 
by placing their home cages on receiver mats. Another advantage of this technique 
is that activity can be monitored throughout the day and night. Previously, the 
activity of NK1R-/- mice has been measured in 30 minutes tests during the 
animals’ light phase, when mice are least active. 
Chapter 5 
 
100 
 
5.1.4 Influence of breeding method 
Previous studies disagree on whether activity is increased in NK1R-/- mice 
compared to wildtype controls. Initial investigations found no difference in activity 
in the open field or elevated plus-maze (De Felipe et al., 1998; Murtra et al., 
2000a). However, other studies found that NK1R-/- mice showed an increase in 
exploratory behaviour in the open field and elevated plus-maze (Santarelli et al., 
2002, 2001). This discrepancy could be due to the different background strain 
used. Initial investigations used mice bred on a 129/Sv x C57BL/6 background and 
found no differences in activity. In the studies by Santarelli et al. (2002, 2001), 
mice were bred on a 129SvEv line, because the authors were interested in the 
anxiolytic profile of NK1R-/- mice, and wildtype 129Sv mice show high levels of 
anxiety (Homanics et al., 1999). This highlights the influence of genetic background 
on the behavioural phenotype of NK1R-/- mice.  
Throughout this chapter, the same activity testing conditions that identified 
hyperactivity in NK1R-/- mice in the study by (Herpfer et al., 2005) were used. 
Furthermore, the mice used here were taken from the same colony, housed in 
identical conditions. Despite this, hyperactivity was variable in NK1R-/- mice 
tested in the LDEB and could not be identified in a locomotor activity chamber. One 
possible reason for these differences is that the colonies have been maintained 
homozygously, meaning that wildtype mice are bred separately from NK1R-/- 
mice. If this breeding method is used, it is advised to backcross the mice to a 
wildtype inbred strain every few generations to avoid de novo genetic mutations 
occurring that will cause the wildtype and NK1R-/- colonies to drift (Crusio et al., 
2009). An indication this may have been occurring in the colonies used in this 
thesis was that whereas in the study by Herpfer et al. (2005) it was not possible to 
distinguish the genotype based on fur colour, in this thesis younger generations of 
the same colony were used and all wildtype mice were white and NK1R-/- mice 
were brown. If coat colour is segregating with the gene of interest, it is possible 
that other genes are segregating too (Crusio, 2004). 
Another issue with maintaining homozygous colonies is that there can be 
differences in early environment that affect the mouse phenotype (Crusio, 2004). 
Studies have shown that differences in maternal rat grooming behaviour can cause 
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epigenetic changes in stress responses (Meaney, 2001), and that these changes can 
be maintained in future generations (Francis et al., 1999). Epigenetic changes in 
stress responses can also occur in humans with adverse early life experiences 
(McGowan et al., 2009). An interaction between stress response and NK1R has 
previously been reported; there are differences in novelty and morphine-induced 
hyperlocomotion between NK1R-/- mice bred from different strains, and this has 
been linked to different corticosterone responses to stress (McCutcheon et al., 
2008). As mentioned above, stress can affect behaviour in activity paradigms. This 
highlights the importance of minimising differences in early life environment by 
breeding wildtype and NK1R-/- mice from heterozygous parents.  
5.1.5 Aims 
This chapter investigates the hyperactive phenotype of NK1R-/- mice. My first aim 
was to identify whether vehicle-injected NK1R-/- mice in the LDEB show an 
increase in total activity, as in Herpfer et al. (2005), or an increase in activity in the 
light per unit of time, as in (Yan et al., 2010). To check whether any differences in 
activity were due to injection stress, I then tested uninjected activity in the LDEB 
and in locomotor activity chambers. Finally, in order to minimise experimental 
stress, I tested activity in the homecage with telemetry, initially with mice bred 
from homozygotes and then with littermate pairs. In the littermate pair group I 
also looked at whether d-amphetamine would reduce the activity of NK1R-/- mice 
while increasing it in wildtype mice, and also whether the NK1R antagonist 
RP 67580 increased activity in wildtype mice. 
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5.2 Methods 
5.2.1 Mice 
All mice used in this chapter were derived from the same genetic background 
(129/Sv x C57BL/6 crossed with an MF1 strain), but the breeding method changed 
(Figure 5.1). In the LDEB and activity meter experiments, all animals came from 
homozygous breeding pairs. In the telemetry experiment, mice from heterozygous 
breeding pairs were also used. Full details of breeding and housing are described 
in section 2.1.  
5.2.2 Light/dark exploration box 
The protocol was identical to that described in (Herpfer et al., 2005). Full 
description of the apparatus and protocol are described in section 2.4.2. Briefly, 
wildtype and NK1R-/- mice (8-12 weeks old) were habituated to the experimental 
room for 3 hours, and subsequently to the dark zone for 90 minutes. In the first 
experiment (n=8) they received an i.p. injection of saline (0.9%) after 60 minutes, 
before being replaced in the dark zone for a further 30 minutes. In the second 
experiment (n=4) one group received an i.p. injection of saline (0.9%) and the 
other was not injected. Following this, mice were transferred to the centre of the 
light zone and their activity was recorded for 30 minutes. The following 
behaviours were scored blind:  
 Total number of line crosses 
 Time spent in the light zone 
 Activity in the light/unit of time 
 Number of transitions to the light zone 
5.2.3 Locomotor activity chambers 
Again, the protocol was identical to that described in Herpfer et al. (2005) and is 
described in full in section 2.4.3. Ambulatory activity of wildtype and NK1R-/- mice 
(n=4) was scored whenever a mouse made 2 adjacent beam breaks. This was to 
ensure that movement caused by grooming would not count as activity. 
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5.2.4 Telemetry 
Telemetry is a technique in which a radiotransmitter probe is implanted into an 
animal. Mice are placed in their homecage on a mat that contains an antenna and 
activity can be recorded. Full details of surgical implantation of the probe, the 
apparatus and the procedure are given in section 2.4.4. Mice from homozygous 
(n=3) or heterozygous (n=4) breeding pairs (8-12 weeks) were implanted with a 
TA-F10 transmitter (DataSciences, UK) and following recovery, their activity was 
recorded for 48h. In the homozygous breeding experiment, the dark phase was 
from 20.00 – 08.00, and in the heterozygous breeding experiment, the dark phase 
was from 19.00 – 07.00. In the littermate study only, after the initial 48h baseline 
recording mice received an i.p. injection every other day at 18.30h (30 minutes 
before the dark phase). Vehicle (10% Tween 80 in 0.9% saline), d-amphetamine 
(2.5mg/kg) and RP 67580 (5mg/kg) were injected in each mouse once only, in a 
Latin-square design.  Mice were left to settle for 30 minutes, following which the 
lights went off and activity was analysed overnight. Because the effects of the 
injection and treatment were most prominent in the 2h post-injection period 
(19.00-21.00h), activity during this time period was then compared across groups. 
Activity recordings from this 2h time period were also taken from the 48h period 
in which mice were un-injected and averaged over the 2 days. This was then 
compared to the vehicle-injected activity in order to look at the effect of injection 
stress on activity. 
5.2.5 Genotyping 
Mice bred from heterozygous matings were ear-punched at 3 weeks old and 
genotyped as described in section 2.2. The genotypes of some mice from 
homozygous matings were tested in order to check there had been no mix-ups in 
the housing facility. 
5.2.6 Statistical analysis 
Full statistical methods are given in section 2.7. The LDEB data were analysed with 
a 1-way or 2-way between subjects ANOVA, with ‘genotype’ and ‘injection’ as 
between-subjects factors. The locomotor activity chamber data and the total 
activity recorded in the LDEB and with telemetry were analysed with an 
independent t-test, with ‘genotype’ as the between-subjects factor. 48h activity in 
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the light and dark phases and overnight activity post-injection was analysed with a 
2-way repeated-measures ANOVA, with ‘genotype’ as the between-subjects factor 
and ‘time of day’ as the within-subjects factor. Due to the large number of data 
points, data from 2h time bins were analysed separately. Uninjected telemetry data 
were also analysed with a 2-way repeated-measures ANOVA, with ‘genotype’ as the 
between-subjects factor and ‘time of day’ as the within-subjects factor. In order to 
look at the effects of injection and drug, vehicle-injected activity was first 
compared to uninjected activity, and then compared to drug-injected activity. 
Because planned comparisons were made on the effects each drug would have on 
activity, I also compared each treatment with vehicle alone. 
In all experiments using ANOVA, a significant main effect of either independent 
variable or a significant interaction between them led to post-hoc 1-way ANOVA 
followed by LSD tests or paired sample t-tests.  
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Figure 5.1 Illustration of wildtype (WT) and NK1R-/- (KO) breeding methods. Homozygous matings were 
obtained by breeding homozygous wildtype and NK1R-/- mice separately. Heterozygous (Het) matings were 
obtained by breeding homozygous wildtype and NK1R-/- with each other, then breeding the heterozygous 
offspring with each other. 
Chapter 5 
 
106 
 
5.3 Results 
5.3.1 Vehicle-injected LDEB in offspring from homozygous matings 
Activity in the light per unit of time was increased in NK1R-/- mice but this was not 
statistically significant (Figure 5.2A). Total activity was decreased in NK1R-/- mice 
compared to wildtype mice: t(10.23) = 2.84, P<0.05 (Figure 5.2B). The number of 
transitions to the light zone was also reduced in NK1R-/- mice compared to 
wildtype mice (t(14) = 2.41, P<0.05) (Figure 5.2C). NK1R-/- mice tended to spend 
less time in the light zone than wildtype mice, although this did not reach 
significance (P=0.071) (Figure 5.2D).  
5.3.2 Un-injected LDEB in offspring from homozygous matings 
Total activity was reduced in wildtype mice following vehicle injection (F(1,12) = 
6.94, P<0.05; Tukey: P<0.05) (Figure 5.2F). Activity in the light per unit of time was 
not affected by vehicle injection (Figure 5.2E). In the un-injected group, NK1R-/- 
mice had a lower activity count and made fewer transitions to the light zone than 
wildtype mice (Figure 5.2G). However, the overall 2-way ANOVA was not 
significant so further post-hoc analyses were not performed (main effect of 
genotype: P=0.072). There was no difference in the time spent in the light zone 
(Figure 5.2H). 
5.3.3 Activity meter in offspring from homozygous matings 
There was no genotype difference in ambulatory activity in the activity meter 
(t(6) = 0.329, P=0.754) (Figure 5.3). 
5.3.4 Telemetry 
Homozygous colony 
Analysis of circadian rhythms showed that NK1R-/- mice were significantly more 
active than wildtype mice during the first 2h of the dark phase on both days (Day 
1: F(1,4) = 8.45, P<0.05; Day 2: F(1,3) = 10.59, P<0.05) (Figure 5.5). Total activity 
over 48h was significantly increased in NK1R-/- mice bred from homozygous 
matings (t(10) = 2.62, P<0.05). Activity in the dark phase was overall greater than 
in the light phase (Z =2,98, P<0.01). Furthermore, NK1R-/- mice were significantly 
more active in the dark phase (Z=2.40, P<0.05) (Figure 5.4A). 
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Heterozygous colony 
NK1R-/- mice were significantly more active during the first 4h of the dark phase, 
and between 1.00 and 3.00, but only on the second night (19.00-21.00: F(1,6) = 
9.89, P<0.05; 21.00-23.00: F(1,6) = 12.42, P<0.05; 1.00-3.00: F(1,6) = 6.12, P<0.05) 
(Figure 5.5). Total activity over 48h was not significantly different. However, there 
was a main effect of time (F(1,14) = 271.27, P<0.001). Mice were overall 
significantly more active in the dark phase (t(15) = 12.66, P<0.001). Furthermore, 
there was an interaction between time and genotype (F(1,14) = 11.37, P<0.01). 
While there was no genotype difference in the light phase, NK1R-/- mice were 
significantly more active in the dark phase (F(1,14) = 8.05, P<0.05) (Figure 5.4B).  
Vehicle-injected NK1R-/- mice were significantly more active during the first 2h 
after injection (F(1,6) = 11.21, P<0.05) and between 1.00 and 3.00 (F(1,6) = 11.43, 
P<0.05). NK1R-/- mice were also significantly more active than wildtype mice 
between 23.00 and 1.00 after an injection of RP 67580 (F(1,5) = 11.57, P<0.05). 
There were no genotype differences following injection of d-amphetamine (Figure 
5.6). In order to look at the effect of injection on activity, the first two hours of 
post-injection activity were compared to the first two hours of non-injected 
activity. Vehicle injection significantly reduced activity of wildtype mice (F(1,6) = 
17.24, P<0.01; t(3) = 5.54, P<0.05) but not NK1R-/- mice. Furthermore, in the 
vehicle-injected group, NK1R-/- mice were more active than wildtype mice (F(1,6) 
= 17.24, P<0.01; F(1.6) = 11.66, P<0.05) (Figure 5.4C). 
Overall, there was no effect of treatment on activity. However, because one mouse 
died before receiving RP 67580, leaving only 3 NK1R-/- mice in that group, the 
vehicle and d-amphetamine data were also analysed separately. D-amphetamine 
abolished the genotype difference in vehicle-injected wildtype and NK1R-/- mice. 
This was due to an increase in activity in wildtype mice (main interaction: F(1,6) = 
6.9, P<0.05; t(3) = 5.97, P<0.05) (Figure 5.4C).  
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Figure 5.2 NK1R-/- mice from homozygous matings show less exploratory behaviour than wildtype 
(WT) mice in the LDEB. Experiment 1 (n=8): (A) Activity in the light/unit of time, (B) Total Activity, (C) Total 
transitions to the light zone and (D) Time spent in the light zone of wildtype (WT) and NK1R-/- mice following 
vehicle injection. Experiment 2 (n=4): (E) Activity in the light/unit of time, (F) Total Activity, (G) Total 
transitions to the light zone and (H) Time spent in the light zone of wildtype and NK1R-/- mice that were un-
injected or had a vehicle injection. *P<0.05.  
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Figure 5.3 No difference in ambulatory activity measured over 10 minutes in the open field between 
un-injected wildtype (WT) and NK1R-/- mice from homozygous matings (n=4). 
 
 
Figure 5.4 NK1R-/-mice are more active than wildtype (WT) mice in the dark phase when measured 
with a telemetry paradigm. NK1R-/- mice from (A) Homozygous matings (n=3) and (B) Heterozygous 
matings (n=4) were more active during the dark phase. (C) The effect of no injection (NI), vehicle injection, RP 
67580 and d-amphetamine (d-amp) were compared 2h after the dark phase in mice from heterozygous 
matings (n=3-4). Vehicle injection reduced activity in wildtype mice, while d-amphetamine increased it. There 
were no effects on NK1R-/- mice. *P<0.05; **P<0.01.
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Figure 5.5 Activity of wildtype (WT) and NK1R-/- mice from homozygous and heterozygous matings over 48h. NK1R-/- mice from homozygous matings were 
significantly more active at the beginning of each dark phase, while NK1R-/- mice from heterozygous matings only showed an increase in activity on the second night. Black 
arrows indicate the start of the 12h dark phase. Black bars indicate a main effect of genotype over the 2h period (n=3-4). *P<0.05.  
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Figure 5.6 Activity of wildtype (WT) and NK1R-/- mice from heterozygous matings during the dark 
phase following an i.p injection of vehicle (n=4), RP 67580 (n=3) and d-amphetamine (n=4). Black bars 
indicate a main effect of genotype over the 2h period. *P<0.05. 
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5.4 Discussion 
The aim of this chapter was to identify testing conditions that would reveal robust 
hyperactivity in NK1R-/- mice. This was achieved when mice were tested in a 
telemetry paradigm, but the difference in activity was particularly pronounced in 
the dark phase. NK1R-/- mice from homozygous and heterozygous parents were 
hyperactive, suggesting that this behavioural deficit is linked to disrupted NK1R 
function.  
5.4.1 Activity measured in the LDEB and activity meter 
In the LDEB, the activity of NK1R-/- mice tended to increase when activity was 
corrected for the time each mouse spent in the light zone (activity in the light/unit 
of time). This replicates the previous finding by Yan et al. (2010). However, this 
measure was highly variable in NK1R-/- mice and did not reach significance 
despite testing 8 animals in each group. This measure of activity is difficult to 
interpret because while it indicates that mice are moving fast, it does not mean 
that they have covered more distance. For example, mice could run out of the light 
zone within the first few seconds of the test and score highly on this measure. 
Herpfer et al. (2005) found an increase in total activity in NK1R-/- mice in the 
LDEB. However, here the total activity was decreased in NK1R-/- mice compared 
to wildtype mice, whether they received a vehicle injection or not. In fact, the 
vehicle injection only affected wildtype mice, reducing their total activity. This fits 
with previous reports that NK1R-/- mice have a blunted response to stress (De 
Felipe et al., 1998; Rupniak et al., 2000; Santarelli et al., 2002, 2001).  
In contrast, NK1R-/- mice made fewer transitions to the light zone and tended to 
spend less time in the light zone. The LDEB was developed as a test of anxiety 
(Crawley, 1985, 1981). Anxiolytic drugs increase the number of transitions between 
the light and dark zones, and increase the time spent in the light zone. This would 
suggest that NK1R-/- mice have an enhanced, rather than blunted, response to 
stress. In the present experiments, the light zone was dimly light (20 lux) in order 
to make the zone novel but not aversive, as in Herpfer et al. (2005). However, 
anxiolytic drugs have not been tested under these conditions. This is necessary for 
the correct interpretation of NK1R-/- mouse behaviour in this paradigm. 
Furthermore, the use of two zones makes the interpretation of activity data 
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difficult. For this reason, uninjected wildtype and NK1R-/- mice were also tested in 
locomotor activity chambers. However, there was no difference in ambulatory 
activity between the two genotypes. This could suggest that the difference found 
between NK1R-/- and wildtype mice in locomotor activity chambers by Herpfer et 
al. (2005) was induced by vehicle injection. However, as discussed below, both 
uninjected and vehicle-injected NK1R-/- mice were hyperactive when measured 
with telemetry, indicating that an injection is not necessary to induce hyperactivity 
in NK1R-/- mice. 
5.4.2 Telemetry 
The LDEB and activity meter data presented here and in previous studies (Herpfer 
et al., 2005; Yan et al., 2010) was collected in the afternoon, during the animals’ 
light phase. Testing was done at this time because ‘locomotor activity of wildtype 
mice is low and stable’ (Yan et al., 2009). However, mice are much more active in 
their dark phase (overnight), and it is possible that a difference in activity would 
be more evident and robust in this phase. This was confirmed when mice were 
tested with telemetry, where there was a large increase in activity in NK1R-/- mice 
tested in the dark phase. This increase was present in the offspring from 
homozygous and heterozygous breeding pairs. However, hyperactivity seems to be 
more pronounced in NK1R-/- mice bred from homozygous matings, because as 
well as a significant increase in the dark phase, the total activity was increased. 
Furthermore, analysis of activity over 48h showed that NK1R-/- mice from 
littermate pairs were only significantly more active on the second night. This could 
suggest that a lack of NK1R function is related to hyperactivity, but that there is 
something else (genetic, environmental or an interaction between the two) 
exacerbating the activity deficit in mice bred from homozygotes. However, in order 
to confirm that hyperactivity is greater in one colony, they need to be tested 
simultaneously. 
In line with the findings from the LDEB that wildtype mice are more sensitive to 
injection stress, a vehicle injection reduced the activity of wildtype but not 
NK1R-/- mice tested with telemetry. This caused a greater difference in activity 
levels between the genotypes, and provides support to the previous suggestion 
that there was no increase in activity in NK1R-/- mice tested in the locomotor 
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activity chambers because the mice were not injected. Telemetry can measure 
more subtle changes in activity, and differences in activity in locomotor chambers 
may only become apparent following the stress of an injection. 
Based on the finding that NK1R-/- mice are hyperactive, it was predicted that the 
NK1 antagonist RP 67580 would induce hyperactivity in wildtype mice. However, 
here this was not the case. Clearly, acute antagonism cannot replicate the effects of 
a life-long lack of functional NK1R. A previous study in the LDEB has reported an 
increase in activity in the light zone per unit of time in wildtype mice injected with 
RP 67580 from the same colony used here (Yan et al., 2010). However, another 
study with Swiss albino mice showed a decrease in total line crosses in the light 
zone after RP 67580 (Zernig et al., 1993). Another unexpected finding was that 
activity tended to decrease in NK1R-/- following RP 67580. Unfortunately, due to 
the death of one NK1R-/- mouse prior to being injected with RP 67580, this group 
had high variability. Therefore, it is not possible to determine whether this drug 
had any effects on NK1R-/- mice. However, based on the findings from chapter 4, if 
RP 67580 is affecting NK1R-/- mice, it is likely due to its L-type calcium channel 
blocking effects. In order to confirm the effects of RP 67580 on activity, the current 
telemetry study needs to be repeated in more mice.  
D-amphetamine increased activity in wildtype mice but did not affect NK1R-/- 
mice. An increase in activity in wildtype mice following d-amphetamine has 
previously been reported in the LDEB (Yan et al., 2010). However, in the same 
study, activity of NK1R-/- mice was reduced by d-amphetamine. The reason for 
this discrepancy is not clear. As mentioned above, an issue with using the LDEB 
can be that mice spend variable amounts of time exploring the light zone, and have 
been habituated to the dark zone so tend not to explore it during the test period. In 
the study by Yan et al. (2010), the activity was presented as ‘activity in the light per 
unit of time’. Therefore, it is possible that d-amphetamine affected the time animals 
spent in the light zone rather than their total activity, and that there was no 
difference in total activity between vehicle and d-amphetamine-injected NK1R-/- 
mice, as in this study. Either way, a lack of behavioural response to d-amphetamine 
fits with the finding that there is a lack of DA response to d-amphetamine in the 
pre-frontal cortex and striatum of NK1R-/- mice (Yan et al., 2010). Also, NK1R-/- 
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mice show no conditioned place preference to d-amphetamine, indicating that the 
rewarding properties of d-amphetamine are absent in NK1R-/- mice (Murtra et al., 
2000b). 
5.5 Conclusions 
A lack of functional NK1R causes hyperactivity in mice. Due to differential stress 
responses in wildtype and NK1R-/- mice, it is important to identify testing 
conditions that minimise stress. When tested in the home cage with telemetry, 
hyperactivity is present in NK1R-/- mice whether they are bred from homozygous 
or heterozygous parents, confirming that this deficit is due to a lack of functional 
NK1R rather than an interaction between early environment and behaviour. The 
next chapter looked at whether other behavioural and molecular deficits identified 
in NK1R-/- mice from homozygous breeding pairs are also present in NK1R-/- 
mice from heterozygous matings.  
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6 Increase in impulsivity and decrease in striatal 
cholinergic function in NK1R-/- mice bred from 
homozygotes 
6.1 Introduction 
In the previous chapter, it was shown that NK1R-/- mice bred from homozygous 
and heterozygous matings are hyperactive. This deficit is therefore not dependent 
on differences in early environment, and is likely caused by a lack of functional 
NK1R. In order to confirm that this is also the case for the deficits in impulsivity, 
attention and perseveration, both colonies were compared in the 5-CSRTT. 
Furthermore, preliminary data have suggested that NK1R-/- mice bred from 
homozygotes have decreased choline acetyltransferase (ChAT)-positive cells in the 
striatum (Slone-Murphy, 2011). This chapter aimed to further characterise this 
reduction in cholinergic function, and determine whether it is also present in mice 
bred from heterozygote breeding pairs.  
6.1.1 Medium spiny neurons 
Over 95% of striatal neurons are medium spiny neurons (MSNs). MSNs are the 
striatal output projection neurons and are inhibitory, using GABA as their main 
neurotransmitter. MSN output can be divided into two different pathways: the 
direct pathway, projecting to the internal part of the globus pallidus and the 
substantia nigra pars reticular, and the indirect pathway, projecting to the external 
part of the globus pallidus and the subthalamic nucleus (Bolam et al., 2000). The 
direct pathway disinhibits the basal ganglia, thereby facilitating movement, while 
the indirect pathway plays an opposite role. The striatum is densely innervated by 
DA, and DA receptor expression in this region is the highest in the brain (Missale et 
al., 1998). D1 DA receptors are located on striatonigral MSNs in the direct pathway, 
while D2 DA receptors are located on striatopallidal MSNs in the indirect pathway 
(Gerfen, 1992). Therefore, DA activation of these receptors can release or suppress 
motor movements.  
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6.1.2 Cholinergic interneurons 
As well as expressing high levels of DA, the striatum is densely innervated by 
cholinergic interneurons, which are the only source of striatal acetylcholine. 
Despite only constituting 2% of striatal neurons, they have large, dense axonal 
arbors which, like dopaminergic arbors, are denser in the striatum than in any 
other brain region (Zhou et al., 2003). These interneurons are tonically active 
neurons (TANs), meaning that they fire spontaneously. Their firing can also be 
modulated by DA. D1 and D2 receptors are located on striatal cholinergic 
interneurons (Le Moine et al., 1991, 1990). Activation of D1 receptors facilitates 
acetylcholine release (Acquas and Di Chiara, 1999), while activation of D2 
receptors inhibits its release (Bertorelli and Consolo, 1990; DeBoer et al., 1996).  
Acetylcholine can also exert control over DA. Acetylcholine in the striatum acts on 
two different types of receptor: muscarinic acetylcholine receptors (mAChR) and 
nicotinic acetylcholine receptors (nAChR). MSNs express M1 and M4 mAChR 
subtypes (Ince et al., 1997; Levey et al., 1991), with M1 receptors mainly 
colocalised with D2-expressing MSNs and M4 mainly colocalised with D1-
expressing MSNs. This suggests that acetylcholine can modulate the direct and 
indirect pathways (Zhou et al., 2003). The other type of ACh receptor, nAChRs, are 
located on dopaminergic axon terminals, and their activation increases tonic 
release of DA, while reducing phasic release (Rice and Cragg, 2004). Furthermore, 
activation of nAChRs is modulated by mACh autoreceptors located on cholinergic 
interneurons. Activation of these autoreceptors reduces acetylcholine release, thus 
modifying nAChR activity (Threlfell et al., 2010). DA and acetylcholine therefore 
have a strong reciprocal relationship within the striatum, allowing great control 
over striatum-mediated behaviours. 
6.1.3 Cholinergic hypothesis of ADHD 
Much of the research into the pathophysiology of ADHD continues to focus on the 
dopaminergic hypothesis (Genro et al., 2010), which states that a deficit in DA 
within fronto-striatal circuits causes symptoms of ADHD (Levy, 1991). Indeed, the 
cortex and striatum are rich in DA, and these structures are thought to play an 
important part in the pathophysiology of ADHD. Also, psychostimulants acting on 
the DA system are the most prescribed treatments for ADHD, and the majority of 
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animal models of ADHD have some degree of DA dysfunction (Van der Kooij and 
Glennon, 2007). However, the evidence described above that DA and acetylcholine 
interact within the striatum suggests acetylcholine could also play an important 
role in ADHD.  
Cholinergic dysfunction has long been linked to deficits in learning and memory 
(Everitt and Robbins, 1997). For example, it is thought to underlie the cognitive 
deficits seen in Alzheimer’s disease. Indeed, a decrease in cholinergic markers 
positively correlates with the extent of cognitive damage (Perry et al., 1978). 
Rodent and human studies have also indicated that acetylcholine plays an 
important role in the control of attention (Klinkenberg et al., 2011). A link between 
ADHD and acetylcholine was first suggested due to the fact that smoking is highly 
comorbid with ADHD. As mentioned above, activation of nAChRs increases DA 
release, and this is normally regulated by cholinergic interneurons (Threlfell et al., 
2010) . The high incidence of smoking in patients with ADHD indicates that there 
may be a dysregulation of acetylcholine binding to nAChRs that patients are trying 
to self-medicate. In line with this, it has been shown that nicotine improves 
symptoms of ADHD in smokers and non-smokers (Levin et al., 1996), as do other 
nicotinic agonists (Wilens et al., 1999). Donepezil, an acetylcholinesterase 
inhibitor, also improves symptoms of ADHD (Wilens et al., 2000) and a link 
between choline transporter polymorphisms and ADHD has been found (English et 
al., 2009). This evidence suggests that cholinergic dysfunction may underlie the 
pathophysiology of ADHD. 
6.1.4 Role of acetylcholine in the 5-CSRTT 
IgG-saporin lesions to the nucleus basalis magnocellularis (a cholinergic structure 
in the basal forebrain) reduce acetylcholine efflux in the medial prefrontal cortex, 
and this reduction positively correlates with decreased accuracy in the 5-CSRTT 
(McGaughy et al., 2002). Another study found that cholinergic lesions to the  basal 
forebrain decrease response accuracy, while increasing premature and 
perseverative responses (Muir et al., 1994). Both mAChRs and nAChRs have been 
shown to modulate attentional functional in the 5-CSRTT. The muscarinic receptor 
antagonist scopolamine causes a decrease in accuracy in the 5-CSRTT in mice 
(Humby et al., 1999) and rats (Stolerman et al., 2000). Spontaneously Hypertensive 
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Rats (SHRs), one of the most widely studied models of ADHD, have a reduced 
number of nAChRs (Gattu et al., 1997a, 1997b; Terry et al., 2000), and show 
deficits in accuracy in the 5-CSRTT. These deficits are improved by increasing 
acetylcholine release, suggesting that disrupted cholinergic transmission underlies 
deficits in selective attention (De Bruin et al., 2003). Furthermore, nicotine 
improves accuracy in the 5-CSRTT in normal rats (Stolerman et al., 2000), and 
reverses a deficit in accuracy following lesions to the basal forebrain (Muir et al., 
1995).  
However, while nicotine improves attentional deficits, studies have shown that it 
worsens impulsivity (Blondel et al., 2000; Grottick and Higgins, 2000; Mirza and 
Stolerman, 1998). An increase in premature responses can be improved by the 
nicotinic antagonist mecamylamine, although attention is simultaneously 
worsened (Grottick and Higgins, 2000). This suggests that attention and 
impulsivity are differentially regulated by acetylcholine. In contrast, the mAChR 
antagonist scopolamine increases premature responses when attentional demands 
are high (Jones and Higgins, 1995). Furthermore, using a touch screen version of 
the 5-CSRTT, it has recently been shown that M1 receptor knockout mice have 
deficits in impulsivity and perseverative responses but no attentional problems 
(Bartko et al., 2011). This indicates an important role for muscarinic receptors in 
impulse control. 
6.1.5  Cholinergic interneurons and NK1R 
In the rat (Gerfen, 1991) and human brain (Aubry et al., 1994), all cholinergic 
interneurons express NK1R, and substance P binding to these NK1R triggers 
acetylcholine release (Anderson et al., 1994; Kemel et al., 2002). Therefore, 
cholinergic activity in the striatum of NK1R-/- mice warrants further investigation. 
One way of measuring acetylcholine activity is to label choline acetyltransferase 
(ChAT) positive cells. ChAT is only found in cholinergic neurons and is involved in 
the synthesis of acetylcholine. Preliminary data revealed that NK1R-/- mice bred 
from homozygotes have fewer ChAT-positive cells in the dorsal striatum than 
wildtype mice (Slone-Murphy, 2011). This suggests that NK1R-/- mice have 
reduced cholinergic function. However, because initial data were only collected 
from mice bred from homozygotes, it is not clear whether the loss of ChAT activity 
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is due to a lack of functional NK1R or to early environmental effects on 
development.  A lack of maternal care has been shown to induce apoptosis in 
rodents in other brain areas, such as the cerebral cortex and hippocampus, even if 
pups are only separated from their mother for 24h (Zhang et al., 2002). Although it 
is not currently known if NK1R-/- mice show reduced maternal care, it is possible 
that the care provided by parents with behavioural deficits would not be as 
effective, and cause the loss of ChAT-positive cells. Therefore, in this chapter, ChAT 
expression of mice from homozygous and heterozygous matings was measured. 
Also, it is not clear whether this loss of ChAT-positive cells increases with age. An 
age-related decline in cholinergic function has been found in patients with 
Alzheimer’s disease, and is thought to correlate with their cognitive symptoms 
(Bartus et al., 1982).  In order to determine whether the loss of ChAT-positive cells 
increases with age, 8-12 week and 9 month old mice were compared.  
6.1.6 Dorsal and ventral striatum 
The striatum has traditionally been divided into two main regions: the dorsal, 
comprising the caudate nucleus and the putamen and the ventral, comprising the 
nucleus accumbens and olfactory tubercle. The ventral striatum is involved in 
conditioned reinforcement to rewarding stimuli, while the dorsal striatum is 
involved in action-planning and habitual behaviour (Everitt and Robbins, 2005). 
However, a more global view of the striatum has also been adopted, suggesting 
that the striatum encodes and drives responses to salient events (Iversen and 
Iversen, 2007; Voorn et al., 2004). DA and acetylcholine within the striatum play an 
important role in these behaviours. Dopaminergic neurons fire at high frequency 
when encoding information about the prediction and receipt of reward-related and 
salient stimuli (Matsumoto and Hikosaka, 2009; Schultz, 2002). In contrast, 
cholinergic interneurons pause in response to salient stimuli (Aosaki et al., 1994; 
Morris et al., 2004). 
Behaviour in the 5-CSRTT is modulated by different regions of the striatum. The 
dorsal striatum plays an important role in 5-CSRTT performance, with lesions to 
this area inducing large deficits in performance (Rogers et al., 2001). However, the 
extent of the effects depends on the location of the lesion. It has been proposed 
that the dorsal striatum can be divided into two sub-regions: the medial area, 
Chapter 6 
 
121 
 
which is involved in goal-directed behaviour (Yin et al., 2005), and the lateral area, 
which mediates habitual behaviours (Yin et al., 2004). Dorsolateral lesions greatly 
impaired 5-CSRTT performance, with rats failing to respond to over 90% of the 
visual stimuli. Because these lesions were made post-training, and there was no 
disruption of locomotor or consummatory behaviour, it has been proposed that 
performance deficits were due to a disruption of stimulus-response habits 
(Robbins, 2002; Rogers et al., 2001). In contrast, rats were able to perform the task 
after dorsomedial lesions, although they exhibited deficits in accuracy, premature 
responding, perseveration and a slowing of response latencies (Rogers et al., 2001). 
Likewise, sub-regions in the ventral striatum are differentially involved in 5-CSRTT 
performance: while DA antagonism in the shell of the nucleus accumbens increases 
premature responses, these are decreased by DA antagonism in the core region 
(Besson et al., 2010). 
6.1.7 Aims 
The aim of this chapter was to determine whether there was a decrease in ChAT 
expression in NK1R-/- mice bred from homozygous and heterozygous breeding 
pairs. It also aimed to see whether 5-CSRTT deficits are present to the same extent 
in NK1R-/- mice bred from both colonies, and whether a decrease in ChAT 
expression is greater in these mice, due to their older age. The 5-CSRTT data 
should be regarded as preliminary because of the small group sizes. However this 
research is continuing and in due course the present results will be included as 
part of a larger study (Grimme, Dudley, Pillidge, Hunt and Stanford, research in 
progress). 
Initial worked confirmed that cholinergic interneurons express NK1R in the mouse 
striatum. Sub-regions of the dorsal and ventral striatum were analysed separately 
due to their different involvement in 5-CSRTT performance (Robbins, 2002). In 
order to control for the possibility that a decrease in ChAT expression was a 
consequence of general cell loss, the brains were also stained with parvalbumin 
because parvalbumin-positive cells in the striatum do not express NK1R (Kaneko 
et al., 1993). The areas of the dorsal striatal sections counted were also measured, 
to check whether cell loss was due to a smaller striatal area. Finally, overall 
expression of ChAT in the dorsal striatum was analysed with western blots. 
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6.2 Methods 
6.2.1 Mice 
As in the previous chapter, all mice were derived from the same background strain 
(129/Sv x C57BL/6 crossed with an MF1 strain), but half came from homozygous 
matings and the other half from heterozygous matings (see figure Figure 5.1). Full 
details of breeding and housing are described in section 2.1.  
6.2.2 Genotyping 
All mice bred from heterozygous matings were ear-punched and genotyped at 3 
weeks of age, as described in section 2.2. The genotypes of the mice in homozygous 
litters were also checked, although this was only done in some offspring to ensure 
there had been no mix-up in the housing facility (which was unlikely due to the 
segregation of the coat colours in each genotype). 
6.2.3 5-CSRTT 
The apparatus and full training regime are described in detail in section 2.4.1. 6 
wildtype and 6 NK1R-/- mice from homozygous and heterozygous breeding pairs 
were trained and then tested with a long and a variable inter-trial interval (LITI, 7s 
and VITI, 2, 5, 10 and 15s), once only. The order of these tests was randomized 
across groups and performed once weekly, on a Friday, if baseline performance 
was stable for 3 days prior to testing. 1 wildtype and 1 NK1R-/- mouse from 
heterozygous matings did not reach training criteria and were excluded from the 
experiment. 
6.2.4 Body weights 
In order to check whether any differences in 5-CSRTT performance between the 
two colonies could be due to a difference in body weight, the weights of a separate 
group of 6-10 week old wildtype and NK1R-/- mice from homozygous and 
heterozygous breeding pairs were compared (n=6). 
6.2.5 Immunohistochemistry 
In order to confirm co-localisation of ChAT and NK1R, a double fluorescent stain 
was carried out in a wildtype mouse. The dorsal striata of 5 wildtype and 5 
NK1R-/- mice aged 8-12 weeks from homozygote breeding pairs were stained with 
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ChAT and parvalbumin in order to replicate the previous finding that there is a 
decrease in ChAT in the dorsal striatum of NK1R-/- mice (Slone-Murphy, 2011). 
Next, the dorsal striata of 5 wildtype and 5 NK1R-/- from heterozygote breeding 
pairs aged 8-12 weeks were stained with ChAT and parvalbumin. After completing 
the LITI and VITI, as described in section 6.2.3, all mice were used in an 
experiment looking at the effects of guanfacine on performance of wildtype and 
NK1R-/- mice in the 5-CSRTT. They had therefore all received 3 i.p. injections of 
guanfacine (0.1, 0.3 and 1 mg/kg), as well as a vehicle injection of 0.9% saline.  On 
completion of this experiment, when they were 9 months old, all mice were killed 
and their brains were stained for ChAT and parvalbumin. 
Full details of the immunohistochemistry protocol are given in section 2.5. This is 
briefly summarised below. 
Tissue preparation 
Mice were killed by transcardial perfusion (see section 2.3.1). Brain sections were 
cut coronally at 40μm and every third section was stained (120 μm apart). This 
maximised the number of sections available for counting, while ensuring that 
cholinergic interneurons were not double-counted.  
3,3'-Diaminobenzidine (DAB) immunohistochemistry 
Sections were placed in a blocking solution for 1h with hydrogen peroxide to 
eliminate any endogenous peroxidase activity. They were then incubated 
overnight at room temperature with the primary antibody (Table 6.1). The next 
day, sections were washed in 0.1M PB and placed in the secondary antibody for 2h 
(Table 6.1), before being washed again. In order to improve detection, Avidin-
Biotin Complex (ABC, Vectastain kit, Vector labs) was made and added to the 
sections for 1h. Finally, sections were washed again, staining was visualised and 
sections were mounted.  
Fluorescent immunohistochemistry 
Sections were placed in a blocking solution for 1h and incubated in the primary 
antibody (Table 6.1) for 3 nights at 4 degrees. Following this, sections were 
incubated for 90 minutes in the secondary antibody (Table 6.1). Then, sections 
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were incubated with the ABC solution (Vectastain kit, Vector labs) for 30 minutes. 
Biotinylated tyramide solution (PerkinElmer, MA, USA) was added to the sections 
for 7 minutes, before being placed in the dark in FITC-conjugated avidin (Vector, 
Burlingame, USA) for 2 hours. Sections were washed in 0.1M PB between each 
step. For double-labelled fluorescence, sections were subsequently placed in the 
second primary antibody (Table 6.2) overnight at room temperature then 
incubated in the secondary antibody for 2 hours (Table 6.2). Finally, sections were 
washed and mounted.  
6.2.6 Cell counting 
Sections were counted on a Nikon Eclipse E800 microscope. Dorsal striatal 
sections were taken between 0.4 and 0.1 mm rostral of bregma, and nucleus 
accumbens sections were taken between 1.5 and 1.2 mm rostral of bregma. For 
dorsal counts, the contour of each striatal area was drawn with a camera lucida, 
and the dorsal striatum was divided into 4 areas (ventrolateral; ventromedial; 
dorsolateral; dorsomedial). This was done by drawing 2 lines roughly parallel to 
the tops and sides of each striatal drawing (Figure 6.1A). For nucleus accumbens 
counts, the contour was also drawn with a camera lucida, and subsequently the 
core and shell were outlined with the help of a mouse brain atlas (Franklin and 
Paxinos, 1997) (Figure 6.1B). At least 2 sections were counted per animal, 
bilaterally, meaning that there were at least 4 counts. These counts were averaged 
for each animal, and the means were used for statistical analysis. 
6.2.7 Area measurements 
In order to compare the striatal areas of wildtype and NK1R-/- mice from both 
colonies, a picture of each counted section was taken with a Nikon E4500 camera 
attached to a Nikon Eclipse E800 microscope. Using ImageJ, a scale bar was set and 
the circumference of each striatum was drawn, from which an area could be 
automatically calculated. 
6.2.8 Western blots 
In order to measure overall ChAT expression in the dorsal striatum, western blots 
were performed on tissue from 8-12 week old wildtype and NK1R-/- mice from 
homozygous and heterozygous matings (n=5). Tissue preparation, protein 
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extraction and immunoblotting were carried out as described in section 2.6. Data 
were normalised with GAPDH (Santa Cruz, USA). Details of ChAT and GAPDH 
antibodies are provided in Table 6.3. The molecular weight of ChAT was 70/74 
kDA and for GAPDH it was 37 kDA. 
6.2.9 Statistical analysis 
Full details of statistical analysis are given in section 2.7. 5-CSRTT data for the 
number of trials to reach training baseline, the LITI and the VITI were analysed 
separately, with a 2-way between-subjects ANOVA. The between subjects factors 
were ‘genotype’ and ‘colony’. The behaviours scored were identical to those in 
chapters 3 and 4 and are described in full in section 2.4.1.3. In addition, the 
training performance of wildtype and NK1R-/- mice was compared with a 2-way 
repeated measures ANOVA, with ‘stage’ as the within-subjects factor and ‘group’ 
(wildtype homozygous, NK1R-/- homozygous, wildtype heterozygous, NK1R-/- 
heterozygous) as the between-subjects variable. The VITI data from each time bin 
(2s, 5s, 10s, 15s) was also analysed separately. However, the pattern of results did 
not differ from the overall results, so the data are not presented. Body weight data 
was compared with a 2-way between subject ANOVA, with ‘genotype’ and ‘colony’ 
as the between subjects factors. Cell counts from each colony and age group were 
analysed with a 2-way within-subjects ANOVA, with ‘genotype’ as the between-
subjects factor and region (either ventromedial / ventrolateral / dorsomedial / 
dorsolateral or core / shell) as the within-subjects factor. A main effect or 
interaction between the factors lead to post-hoc one-way ANOVAs with LSD post-
hoc tests. Total striatal cell counts and area measurements were analysed with an 
independent-samples t-test, with ‘genotype’ as the between-subjects factor. 
Western blots were analysed separately for each colony, in order to normalise the 
NK1R-/- mouse data to their respective wildtype controls. A ratio of the band 
density of ChAT to GAPDH was calculated and expressed as a percentage of mean 
wildtype control. These percentages were analysed with an independent samples 
t-test. 
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Figure 6.1 Division of the striatum for counting. Representation of the subregions of the (A) dorsal and (B) 
ventral striatum that were quantified. DL: Dorsolateral; DM: Dorsomedial; VL: Ventrolateral; VM: 
Ventromedial. 
 
 
 
Table 6.1 Antibodies for single antigen immunohistochemistry. ChAT: Choline acetyltransferase; PV: 
Parvalbumin; NK1R: Neurokinin-1 receptor. Secondary antibodies were diluted 1:400. DAB: 3,3’-
Diaminobenzidine; FITC: fluorescein isothiocyanate. 
Antigen 
Primary Antibody Secondary Antibody 
Antibody Dilution Antibody Visualisation 
ChAT 
Goat α-ChAT 
(Millipore) 
1:100 
Biotinylated 
rabbit α-goat 
DAB 
PV 
Rabbit α-PV      
(Synaptic Systems) 
1:20 000 
Biotinylated 
goat α-rabbit 
DAB 
NK1R 
Rabbit α-NK1R 
(Millipore) 
1:10 000 
Biotinylated 
goat α-rabbit 
FITC 
 
Table 6.2 Antibodies for double antigen labeling. NK1R: Neurokinin-1; ChAT: Choline acetyltransferase; 
TSA: Tyramide Signal Amplification. The biotinylated secondary antibody was diluted 1:400 and the Alexa 
Fluor secondary antibody was diluted 1:500. 
Antigen 
TSA Direct 
Primary 
antibody 
Secondary 
antibody 
Primary 
antibody 
Secondary 
antibody 
NK1R + ChAT 
Rabbit α-
NK1R 1:10 
000 
(Millipore) 
Biotinylated 
Horse α-rabbit  
Goat α-ChAT 
1:100 
(Millipore) 
Alexa Fluor 
594       
Chicken α-
goat  
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Table 6.3 Antibodies for immunoblotting. ChAT: choline acetyltransferase; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. HRP: horseradish peroxidase. 
Antigen 
Primary Antibody Secondary Antibody 
Antibody Dilution Antibody Dilution 
ChAT 
Goat α-ChAT 
(Millipore) 
1:500 
HRP-
conjgated 
rabbit α-goat  
1:1 000 
GAPDH 
Mouse α-GAPDH 
(Santa Cruz) 
1:1 000 
HRP-
conjugated 
goat α-mouse 
1:1 000 
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6.3 Results 
6.3.1 5-CSRTT 
6.3.1.1 Number of trials to reach baseline 
There was no genotype difference (F(1,18) = 0.978, P=0.336), no colony difference 
(F(1,18) = 1.104, P=0.307) and no interaction (F(1,18) = 1.344, P=0.262). In the 
homozygous colony, wildtype mice took an average of 53 trials and NK1R-/- mice 
took an average of 37.8 trials to complete training. In the heterozygous colony, 
wildtype mice took an average of 37.4 trials and NK1R-/- mice took an average of 
38.6 trials (Figure 6.2). As training was carried out 5 days a week, the mice were 
between 3-5 months when they were first tested in the 5-CSRTT. 
 
Figure 6.2 Total number of trials to reach baseline in the 5-CSRTT in wildtype (WT) and NK1R-/- mice 
from homozygous and heterozygous breeding pairs. 
6.3.1.2 Training 
There was a main effect of group for perseverative responses (F(3,17) = 5.50, 
P<0.01). There were differences in stages 1 and 3, as summarised in (Table 6.4). 
There were no other differences in training performance. 
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Table 6.4 Differences in perseverative responses between wildtype and NK1R-/- mice from 
homozygous and heterozygous breeding pairs during 5-CSRTT training. F values represent the One-way 
ANOVA for the corresponding stage. P values represent significance in post-hoc LSD tests. WT: wildtype; hom: 
offspring from homozygous parents; het: offspring from heterozygous parents. 
Stage 1 
F(3,20) = 4.09, P<0.05 
NK1R-/-(hom)>WT(hom), P<0.05 
NK1R-/-(het)>WT(het), P<0.05 
Stage 3 
F(3,20) = 1.17, P<0.05 
NK1R-/-(hom)>WT(hom), P<0.05 
 
6.3.1.3 LITI 
There was a main effect of colony for the latency to correct response (F(1,17) = 
5.52, P<0.05). Overall, mice bred from heterozygotes were quicker to respond than 
mice bred from homozygotes (F(1,19) = 6.01, P<0.05) (Figure 6.3). There were no 
other differences between genotype or colony (Table 6.5). 
Table 6.5 Statistical values for the behaviours that did not differ between genotype or colony for 
wildtype and NK1R-/- mice tested in the 5-CSRTT with a LITI. 
 Effect of genotype Effect of colony Interaction 
%Accuracy 
F(1,17) = 0.02, 
P=0.90 
F(1,17) = 0.61, 
P=0.45 
F(1,17) = 1.53, 
P=0.23 
Latency to collect 
the reward 
F(1,17) = 0.13, 
P=0.72 
F(1,17) = 0.33, 
P=0.58 
F(1,17) = 1.09, 
P=0.31 
%Omissions 
F(1,17) = 0.01, 
P=0.94 
F(1,17) = 1.22, 
P=0.28 
F(1,17) = 0.71, 
P=0.41 
Perseverative 
responses 
F(1,17) = 0.71, 
P=0.41 
F(1,17) = 0.05, 
P=0.83 
F(1,17) = 0.39, 
P=0.54 
%Premature 
responses 
F(1,17) = 0.01, 
P=0.93 
F(1,17) = 2.53, 
P=0.13 
F(1,17) = 1.64, 
P=0.22 
Total number of 
trials 
F(1,17) = 0.01, 
P=0.95 
F(1,17) = 1.73, 
P=0.21 
F(1,17) = 0.01, 
P=0.95 
 
6.3.1.4 VITI 
%Premature responses 
There was a main interaction between genotype and colony (F(1,18) = 22.81, 
P<0.001). Post-hoc LSD tests revealed that NK1R-/- mice bred from homozygotes 
were significantly more impulsive than wildtype mice (P=0.001). In contrast, 
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NK1R-/- mice from heterozygotes were significantly less impulsive than wildtype 
mice (P=0.01). Finally, wildtype mice from homozygotes were significantly less 
impulsive than wildtypes from heterozygotes (P<0.001). The difference between 
NK1R-/- from each colony just missed criterion for significance (P=0.051) (Figure 
6.4A). 
Perseverative responding 
There was a main effect of genotype (F(1,18) = 4.72, P<0.05), but no effect of 
colony or interaction (Figure 6.4C). Therefore, the 2 colonies were merged. 
NK1R-/- mice from both colonies made consistently more perseverative responses 
than wildtype mice (F(1,20) = 4.90, P<0.05) (Figure 6.4D). 
%Accuracy 
There was an interaction between genotype and colony F(1,18) = 5.06, P<0.05. 
However, post-hoc analyses highlighted no further differences (Figure 6.4B).  
Latency to correct response, latency to collect the reward, %Omissions and 
total number of trials 
There were no statistical differences for any of these behaviours (Table 6.6) 
Table 6.6 Statistical values for the behaviours that did not differ between genotype or colony for 
wildtype and NK1R-/- mice tested in the 5-CSRTT with a VITI. 
 Effect of genotype Effect of colony Interaction 
Latency to 
correct response 
F(1,18) = 0.59, 
P=0.45 
F(1,18) = 0.42, 
P=0.52 
F(1,18) = 0.15, 
P=0.70 
Latency to collect 
the reward 
F(1,18) = 2.07, 
P=0.17 
F(1,18) = 2.44, 
P=0.14 
F(1,18) = 0.24, 
P=0.63 
%Omissions 
F(1,18) = 0.22, 
P=0.12 
F(1,18) = 0.77, 
P=0.39 
F(1,18) = 0.15, 
P=0.70 
Total number of 
trials 
F(1,18) = 1.98, 
P=0.18 
F(1,18) = 0.001, 
P=0.98 
F(1,18) = 0.001, 
P=0.98 
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Figure 6.3 Latency to correct response of wildtype (WT) and NK1R-/- mice tested in the 5-CSRTT with a 
LITI (n=5-6). Overall, mice bred from homozygotes were slower to make a response than mice bred from 
heterozygotes. *P<0.05 
 
 
Figure 6.4 Behaviour of wildtype (WT) and NK1R-/- mice tested in the 5-CSRTT with a VITI. (A) 
%Premature responses, (B) %Accuracy, (C) Perseverative responses of wildtype and NK1R-/- mice from 
homozygous and heterozygous matings in the VITI. (D) Perseverative responses of wildtype and NK1R-/- mice 
regardless of colony. n=5-6 per group. *P<0.05; **P<0.01; ***P<0.001. 
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6.3.2 Body weights 
In mice from homozygous breeding pairs, wildtype mice weighed 35.6±1.5g and 
NK1R-/- mice weighed 30.5±0.7g. In mice from heterozygous breeding pairs, 
wildtype mice weighed 34.1±2.8g and NK1R-/- mice weighed 33.8±1.9g. Although 
NK1R-/- mice from homozygous breeding pairs weighed less than the other groups 
of mice, there were no overall significant main effects (Effect of genotype: 
F(1,18)=2.33, P=0.14; Effect of colony: F(1,18) = 0.28, P=0.60; Interaction: F(1,18) 
= 1.87, P=0.19) (Figure 6.5). 
 
Figure 6.5 Body weights of 6-10 week old wildtype (WT) and NK1R-/- mice from homozygous and 
heterozygous breeding pairs (n=6). 
6.3.3 Immunohistochemistry 
An immunohistochemical stain of wildtype and NK1R-/- mice from both colonies 
confirmed the loss of NK1R in NK1R-/- mice (Figure 6.6). A double fluorescent 
stain in the striatum of a wildtype mouse confirmed the co-localisation of ChAT 
and NK1R (Figure 6.7). 
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Figure 6.6 NK1R immunoreactivity in wildtype and NK1R-/- mice. Fluorescent staining of NK1R in 
wildtype (A) and NK1R-/- (B) mice bred from homozygotes and wildtype (C) and NK1R-/- (D) mice bred from 
heterozygotes. Arrows indicate NK1R-positive cells. 
 
 
Figure 6.7 Co-localisation of ChAT and NK1R. Fluorescent staining of NK1R and ChAT in the dorsal striatum 
of a wildtype mouse. Arrows indicate examples of NK1R and ChAT positive cells. 
Wildtype NK1R-/- 
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Figure 6.8 ChAT immunoreactivity in 8-12 week old wildtype (WT) and NK1R-/- mice. Representative 
sections of the dorsal and ventral striatum of wildtype and NK1R-/- mice bred from homozygotes (WT Hom; 
NK1R-/- Hom) and from heterozygotes (WT Het; NK1R-/- Het). Arrows indicate examples of ChAT-positive 
cells that were labelled with 3,3’-Diaminobenzidine. 
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Figure 6.9 ChAT immunoreactivity in 9 month old wildtype (WT) and NK1R-/- mice. Representative 
sections of the dorsal and ventral striatum of wildtype and NK1R-/- mice bred from homozygotes (WT Hom; 
NK1R-/- Hom) and from heterozygotes (WT Het; NK1R-/- Het). Arrows indicate examples of ChAT-positive 
cells that were labelled with 3,3’-Diaminobenzidine. 
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6.3.4 ChAT immunohistochemistry 
Overall differences in cell count between striatal sub-regions that were 
independent of genotype are summarised in Table 6.7. The mean cell count for 
each group is shown for 8-12 week old mice (Table 6.8) and 9 month old mice 
(Table 6.9).  
Table 6.7 Significant differences in the number of ChAT positive cells in each striatal sub-region of mice 
from homozygous and heterozygous matings, regardless of genotype (n=10). DStr: dorsal striatum; VStr: 
ventral striatum; DM: dorsomedial; VM: ventromedial; DL: dorsolateral; VL: ventrolateral. 
 Homozygous Heterozygous 
 DStr VStr DStr VStr 
8-12 
weeks 
DM>VM; DM>VL 
DL>VM 
Shell>Core 
DM>VM 
DL>VM 
Shell>Core 
 
9 months DM>VM; DM>VL 
DL>VM 
Shell>Core 
DM>VM; DM>VL 
DL>VM; DL>VM 
Shell>Core 
 
ChAT expression in the dorsal striatum of 8-12 week old wildtype and NK1R-/-
mice (Figure 6.8) 
The difference in total number of ChAT-positive cells just missed criterion for 
significance (P=0.059) (Figure 6.10A). The 2-way ANOVA showed a main effect of 
area (F(3,24) = 17.28, P<0.001). Further analysis within each area revealed that 
NK1R-/- mice had significantly fewer ChAT-positive cells in the dorsomedial 
striatum compared to NK1R-/- mice (F(1,8) = 7.14, P<0.05). The dorsolateral 
striatum just missed criterion for significance (P=0.066) (Figure 6.12A). 
In wildtype and NK1R-/- mice from heterozygous matings there was no overall 
difference in total number of ChAT-positive cells (Figure 6.10B). The 2-way ANOVA 
revealed a main effect of area (F(3,24) = 6.19, P<0.01). However, there were no 
differences between the two genotypes (Figure 6.12B).  
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ChAT expression in the ventral striatum of 8-12 week old wildtype and NK1R-/- 
mice (Figure 6.8) 
There was no difference in total ChAT-expression in the nucleus accumbens 
between wildtype and NK1R-/- mice from the homozygous or heterozygous 
colonies (Figure 6.10C, D). The 2-way ANOVA revealed a main effect of area for the 
homozygous (F(1,8) = 88.69, P<0.001) and the heterozygous colonies (F(1,7) = 
187.82, P<0.001) However, there were no differences between the two genotypes 
(Figure 6.12C, D). 
ChAT expression in the dorsal striatum of 9 month old wildtype and NK1R-/- mice 
(Figure 6.9) 
There were significantly fewer ChAT-positive cells in NK1R-/- mice than wildtype 
mice bred from homozygotes (t(8) = 3.22, P<0.05) (Figure 6.11A). The 2-way 
ANOVA revealed a main effect of area (F(1.6,12.4) = 14.41, P=0.001) and genotype 
(F(1,8) = 10.34, P<0.05). Further analysis within each area revealed that there 
were significantly fewer ChAT-positive cells in NK1R-/- mice in the ventrolateral 
(F(1,8) = 13.95, P<0.01) and dorsolateral (F(1,8) = 5.34, P=0.050) striatum 
compared to wildtype mice. Although ChAT-expression was lower in NK1R-/- mice 
in the dorsomedial striatum, this did not reach significance (P=0.093) (Figure 
6.13A). 
In the heterozygous colony there was no overall difference in total number of 
ChAT-positive cells (Figure 6.11B). The 2-way ANOVA showed a main effect of area 
(F(3,27) = 33.83, P<0.001). However, there were no genotype differences (Figure 
6.13B). 
ChAT expression in the ventral striatum of 9 month old wildtype and NK1R-/- mice 
(Figure 6.9) 
Overall there was greater expression of ChAT in wildtype than NK1R-/- mice in the 
homozygous colony (t(8) = 2.83, P<0.05) (Figure 6.11C). In the 2-way ANOVA 
there was a main effect of area (F(1,8) = 134.39, P<0.001) and a main effect of 
genotype (F(1,8) = 7.99, P<0.05). Analysis of individual areas revealed a significant 
decrease in ChAT-positive cells in NK1R-/- mice in the core (F(1,8) = 12.03, 
P<0.01) and in the shell (F(1,8) = 5.37, P<0.05) (Figure 6.13C). 
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There was no overall difference in the total number of ChAT-positive cells in the 
heterozygous breeding colony (Figure 6.11D). There was a main effect of area in 
the 2-way ANOVA (F(1,7) = 136.9, P<0.001), but there were no genotype 
differences (Figure 6.13D). 
 
Table 6.8 Number of ChAT-positive cells in 8-12 week old wildtype and NK1R-/- mice from 
homozygous and heterozygous matings (n=5). VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: 
Dorsolateral. Data indicate mean ± standard error. These data are also represented in Figure 6.10. 
          Colony 
  Homozygous Heterozygous 
Count Genotype VM VL DM DL VM VL DM DL 
ChAT, Dorsal  
Wildtype 30.95 
±3.59 
34.48 
±6.34 
55.58 
±4.07 
47.83 
±7.39 
30.20 
±5.23 
35.75 
±2.84 
42.95 
±7.50 
43.90 
±4.96 
NK1R-/- 24.19 
±1.96 
29.10 
±1.50 
37.92 
±5.20 
31.96 
±1.02 
31.07 
±5.28 
39.78 
±2.05 
39.17 
±7.74 
42.72 
±4.64 
  Core Shell Core Shell 
ChAT, Ventral  
Wildtype 19.60 ±1.91 63.20 ±5.75 17.13 ±0.43  68.75 ±5.55 
NK1R-/- 17.80 ±3.31 65.86 ±2.64 20.54 ±0.60 65.86 ±2.64 
 
 
Table 6.9 Number of ChAT-positive cells in 9 month old wildtype and NK1R-/- mice from homozygous 
and heterozygous matings (n=5). VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: Dorsolateral. 
n=5 per group. Data indicate mean ± standard error. These data are also represented in Figure 6.11. 
          Colony 
  Homozygous Heterozygous 
Count Genotype VM VL DM DL VM VL DM DL 
ChAT, Dorsal  
Wildtype 31.10 
±3.19  
39.80 
±3.01 
53.80 
±5.49 
49.50 
±6.57 
29.00 
±0.95 
35.25 
±2.58 
56.35 
±2.31 
46.45 
±5.01 
NK1R-/- 26.15 
±2.27 
26.80 
±1.75 
41.95 
±2.88 
33.95 
±1.44 
28.65 
±1.17 
32.30 
±2.18 
46.65 
±2.45 
42.85 
±1.52 
  Core Shell Core Shell 
ChAT, Ventral  
Wildtype 19.60 ±1.54 69.75 ±6.59 11.63 ±3.25 62.63 ±8.27 
NK1R-/- 11.85 ±1.62 50.30 ±5.20 12.90 ±1.69 60.30 ±6.11 
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Figure 6.10 Total number of ChAT-positive cells in the striatum of 8-12 week old wildtype (WT) and 
NK1R-/- mice (n=5). Total counts in the dorsal and ventral striatum of (A) and (C) homozygous matings, and 
(B) and (D) heterozygous matings.  
 
Figure 6.11 Total number of ChAT-positive cells in the striatum of 9 month old wildtype and NK1R-/- 
mice (n=5). Total counts in the dorsal and ventral striatum of (A) and (C) homozygous matings, and (B) and 
(D) heterozygous matings. *P<0.05. 
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Figure 6.12 Number of ChAT-positive cells in the striatum of 8-12 week old wildtype (WT) and NK1R-/- 
mice (n=5). Total counts in the dorsal striatum of (A) mice bred from homzygotes and (B) mice bred from 
heterozygotes, and total counts in the ventral striatum of (C) mice bred from homozygotes and (D) mice bred 
from heterozygotes. VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: Dorsolateral. *P<0.05. 
 
Figure 6.13 Number of ChAT-positive cells in the striatum of 9 month old wildtype (WT) and NK1R-/- 
mice (n=5). Total counts in the dorsal striatum of (A) mice bred from homzygotes and (B) mice bred from 
heterozygotes, and total counts in the ventral striatum of (C) mice bred from homozygotes and (D) mice bred 
from heterozygotes. VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: Dorsolateral. *P<0.05; 
**P<0.01. 
Homozygous matings
N
u
m
b
er
 o
f 
C
h
A
T
-p
o
si
ti
ve
 c
el
ls
VM V
L
DM D
L
0
20
40
60
80
*
P = 0.066
Heterozygous matings
N
u
m
b
er
 o
f 
C
h
A
T
-p
o
si
ti
ve
 c
el
ls
VM V
L
DM D
L
0
20
40
60
80
N
u
m
b
er
 o
f 
C
h
A
T
-p
o
si
ti
ve
 c
el
ls
Co
re
Sh
el
l
0
20
40
60
80
N
u
m
b
er
 o
f 
C
h
A
T
-p
o
si
ti
ve
 c
el
ls
Co
re
Sh
el
l
0
20
40
60
80
WT
NK1R-/-
A B
C D
Homozygous matings
N
u
m
b
e
r 
o
f 
C
h
A
T
-p
o
s
it
iv
e
 c
e
lls
VM V
L
D
M D
L
0
20
40
60
80
**
*
N
u
m
b
e
r 
o
f 
C
h
A
T
-p
o
s
it
iv
e
 c
e
lls
C
or
e
Sh
el
l
0
20
40
60
80
**
*
Heterozygous matings
N
u
m
b
e
r 
o
f 
C
h
A
T
-p
o
s
it
iv
e
 c
e
lls
VM V
L
D
M D
L
0
20
40
60
80
N
u
m
b
e
r 
o
f 
C
h
A
T
-p
o
s
it
iv
e
 c
e
lls
C
or
e
Sh
el
l
0
20
40
60
80
WT
NK1R-/-
A B
C D
Chapter 6 
 
141 
 
6.3.5 Parvalbumin immunohistochemistry 
Mean cell counts for 8-12 week old mice and 9 month old mice are summarised in 
Table 6.10 and Table 6.11, respectively. An example of parvalbumin-positive cells 
is shown in Figure 6.14. There were no genotype differences in either colony at 
either age.  
6.3.6 Area measurements 
In both colonies the area of the striatum was bigger in younger mice (homozygous 
matings: X2 = 6.64, P=0.01; Z = 2.58, P<0.01; heterozygous matings: F(1,17) = 
39.82, P<0.001; t(18) = 6.46, P<0.001). There were no genotype differences 
(Figure 6.15). 
 
Figure 6.14 Parvalbumin immunoreactivity in a wildtype mouse. Representative sections of the dorsal 
and ventral striatum of a wildtype mouse bred from homozygotes. Arrows indicate examples of Parvalbumin-
positive cells that were labelled with 3,3’-Diaminobenzidine. 
 
Table 6.10 Number of Parvalbumin-positive cells in 8-12 week old wildtype and NK1R-/- mice from 
homozygous and heterozygous matings (n=5). VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: 
Dorsolateral. Data indicate mean ± standard error. 
          Colony 
  Homozygous Heterozygous 
Count Genotype VM VL DM DL VM VL DM DL 
Parv, Dorsal  
Wildtype 10.5 
±0.14 
34.67 
±1.24 
36.75 
±6.13 
46.33 
±9.37 
19.50 
±3.02 
29.19 
±2.67 
52.13 
±7.46 
39.13 
±1.88 
NK1R-/- 13.42 
±3.58 
31.75 
±4.13 
36.75 
±5.77 
38.33 
±5.66 
26.13 
±3.18 
32.50 
±3.96 
56.69 
±16.57 
43.56 
±9.30 
  Core Shell Core Shell 
Parv, Ventral  
Wildtype 3.33 ±0.73 15.83 ±2.67 4.92 ±0.36 35.42 ±3.43 
NK1R-/- 2.5 ±0.58 15.67 ±1.67 8.67 ±1.88 44.25 ±4.69 
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Table 6.11 Number of parvalbumin-positive cells in 9 month old wildtype and NK1R-/- mice from 
homozygous and heterozygous matings (n=5). VM: Ventromedial; VL: Ventrolateral; DM: Dorsomedial; DL: 
Dorsolateral. Data indicate mean ± standard error. 
          Colony 
  Homozygous Heterozygous 
Count Genotype VM VL DM DL VM VL DM DL 
Parv, Dorsal  
Wildtype 25.23 
±3.90 
30.54 
±5.15 
46.92 
±3.94 
34.39 
±1.52 
19.81 
±1.55 
23.06 
±2.38 
38.75 
±2.36 
27.25 
±0.44 
NK1R-/- 31.00 
±1.45 
34.50 
±1.99 
43.94 
±1.77 
32.56 
±3.54 
21.92 
±3.32 
21.69 
±0.43 
39.48 
±4.83 
26.71 
±3.61 
  Core Shell Core Shell 
Parv, Ventral  
Wildtype 5.90 ±1.12 24.90 ±3.83 4.40 ±1.37 23.10 ±4.12 
NK1R-/- 7.05 ±0.78 27.48 ±2.65 3.10 ±1.03 24.60 ±3.25 
 
 
Figure 6.15 Striatal areas of wildtype (WT) and NK1R-/- mice from homozygous and heterozygous 
matings (n=5). Area of the dorsal striatum in 8-12 week (young) and 9 month (old) mice. **P<0.01; 
***P<0.001. 
6.3.7 ChAT western blots 
The mean ChAT expression appeared to be reduced in NK1R-/- mice from 
homozygous matings compared to wildtype mice. However, due to the large 
variance there was no significant difference (P=0.42). There was also no genotype 
difference in the mice from heterozygous matings (Figure 6.16). 
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Figure 6.16 ChAT expression in the dorsal striatum of 8-12 week old wildtype (WT) and NK1R-/- mice 
(n=5). The density of each band was normalized to GAPDH and the ratios were expressed as a percentage of 
control. (A) Mice from homozygous matings and (B) mice from heterozygous matings. 
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6.4 Discussion 
NK1R-/- mice bred from homozygotes have a reduction in ChAT-positive cells 
within the striatum. This deficit is not present in NK1R-/- mice bred from 
heterozygous matings. Because NK1R-/- mice from both colonies are bred on the 
same background strain, this suggests that there could be an important effect of 
early environment on cholinergic cell development. Alternatively, other genetic 
mutations could have occurred in NK1R-/- mice bred homozygously that are 
passed down through generations and cause the loss of ChAT-positive cells. 
Furthermore, the deficits in impulsivity seen in NK1R-/- mice from homozygous 
litters were not present in those bred heterozygously.  
6.4.1 Differences in impulsivity in the 5-CSRTT 
As seen previously (Yan et al., 2011), NK1R-/- mice bred from homozygous parents 
are significantly more impulsive than their wildtype counterparts. In contrast, 
NK1R-/- mice bred from heterozygote parents are not impulsive, and are even 
significantly less impulsive than their wildtype littermate controls. This difference 
was not caused by a difference in body weight between the two colonies. Although 
premature responding in mice tested in the 5-CSRTT tends to be low, especially 
compared to rats (Humby et al., 1999), other studies have found high premature 
responses in wildtype mice when they are first tested with a LITI (Peña-Oliver et al., 
2012). In the present experiment it is surprising that there is a large difference in 
premature responses in the VITI between the wildtype mice from each colony 
since no differences were seen during training. However, it is possible that the task 
demands during training were not great enough to pull out differences. Regardless, 
the disparity in the behaviour of wildtype mice from different breeding methods 
highlights how the interpretation of data can differ greatly depending on the 
control animals used.  
The difference in impulsive responding between the two colonies suggests that the 
behavioural deficits seen previously in NK1R-/- mice tested in the 5-CSRTT are not 
only caused by a lack of functional NK1R. As discussed in chapter 5, random 
mutations can occur in mice that are passed down to future generations (Crusio et 
al., 2009). If wildtype and NK1R-/- mice are bred separately, their genetic 
background could gradually segregate. Crossing wildtype and NK1R-/- mice and 
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creating heterozygous mating pairs prevents this drift, and increases the likelihood 
that differences between the genotypes are linked to a lack of functional NK1R. 
The behavioural differences seen between the two colonies could also arise from a 
different early environment. Early life maternal deprivation can induce lifelong 
behavioural deficits, including deficits in attentional set-shifting (Lovic and 
Fleming, 2004) and motor impulsivity tested on a DRL schedule (differential 
reinforcement of low response rate, Lovic et al., 2011). It is therefore possible that 
the deficits seen in the 5-CSRTT in NK1R-/- mice bred from homozygotes is a 
consequence of poor maternal care from NK1R-/- mothers. However, as discussed 
below, comparison of NK1R-/- mice from both colonies revealed differences in 
ChAT-positive cells in the striatum, suggesting that the differences seen in the 
5-CSRTT may be linked to an interaction between early environment and brain 
development. 
6.4.2 Cholinergic deficit in the striatum of NK1R-/- mice bred from 
homozygotes  
In this chapter, a deficit in ChAT-positive cells was identified in the striatum of 
homozygously-bred NK1R-/- mice. It was also shown that in the mouse striatum, 
NK1R are expressed on cholinergic interneurons, as has been reported in the rat 
(Gerfen, 1991). The deficit in ChAT expression was not due to a general cell loss in 
the striatum because there was no difference in parvalbumin-positive cells. The 
striatum was smaller in older mice from both colonies compared to young mice, 
and a reduction in striatal area has previously been found in aging humans 
(Gunning-Dixon et al., 1998). However, the cell loss was not due to a reduction in 
the area of the striatum, as this did not differ between wildtype and NK1R-/- mice. 
As well as being located on cholinergic interneurons in the striatum, NK1R are 
expressed on a subtype of interneurons expressing somatostatin (SS), 
neuropeptide Y (NPY) and nitric oxide synthase (NOS) (Kaneko et al., 1993). It is 
possible that SS, NPY and NOS expression would also be reduced in NK1R-/- mice. 
However, preliminary data found no decrease in NPY expression in the striatum of 
young NK1R-/- mice bred from homozygotes (D’angelo and Weir, unpublished 
data). 
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The loss of ChAT-positive cells within the dorsal striatum was present to the same 
extent in 8-12 week old and 9 month old NK1R-/- mice, suggesting there is no 
further cell death throughout the animals’ lives. However, this does not confirm 
that there was never any cell death, as it could have occurred at a younger age. In 
order to confirm this, cell death needs to be checked at many different time points. 
This could be done with an immunohistochemical stain for caspase-3, a protein 
that plays an essential role in cell apoptosis (Porter and Jänicke, 1999). However, 
identifying the exact time point when this would occur in NK1R-/- mice is difficult. 
Another possibility is that the cholinergic interneurons within the striatum of 
NK1R-/- mice have shrunk. This has previously been reported in a patient with 
Alzheimer’s disease (Pearson et al., 1983), and in rats with lesions to the basal 
nucleus of Meynart (Sofroniew et al., 1983). Regardless of whether ChAT-positive 
cells have died or shrunk, it may be possible to restore ChAT function by 
administering nerve growth factor (NGF, Mobley et al., 1985). Indeed, patients 
with Alzheimer’s disease, that have a loss of cholinergic cells and ChAT activity, 
also have reduced NGF expression (Mufson et al., 2008). Similarly, ChAT function 
could be restored with brain-derived neurotrophic factor (BDNF), as it has been 
shown that BDNF is vital for the survival of striatal cholinergic neurons in mice 
(Ward and Hagg, 2000). Since ChAT is involved in the synthesis of acetylcholine, it 
is also possible that the cholinergic interneurons of NK1R-/- mice are synthesising 
lower levels of ChAT. Western blots were performed to see whether this is the 
case. However, despite a tendency for there to be a reduced amount of ChAT 
protein in NK1R-/- mice, this did not reach significance due to the large variance 
between samples.  
Whereas there was no decrease in ChAT expression within the ventral striatum of 
young NK1R-/- mice, there were significantly fewer ChAT-positive cells in the 
ventral striatum of 9 month old NK1R-/- mice. This suggests that there is a gradual 
decrease in ChAT function in the ventral striatum throughout the animals’ lives, 
whereas this is present from an early age in the dorsal striatum. Previously, a loss 
of cholinergic cells in the striatum has been shown to increase with age (Altavista 
et al., 1988). Interestingly, the extent of this loss positively correlates with the 
extent of spatial learning deficits in the Morris water maze (Fischer et al., 1989). 
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This fits with the present finding that NK1R-/- mice bred from homozygotes show 
behavioural deficits in the 5-CSRTT and have a decrease in ChAT-positive cells in 
both the dorsal and ventral striatum. It is important to note that the mice were 
between 3 and 5 months old when they were tested in the 5-CSRTT in this chapter, 
and as they were subsequently used in another experiment, they were 9 months 
old when they were perfused. It would be interesting to see whether there is a 
decrease in cholinergic activity in the ventral striatum of NK1R-/- mice at 3-5 
months. In addition, the drug treatment experienced by the mice prior to perfusion 
may have affected cholinergic transmission. However, guanfacine is an alpha-
receptor agonist that inhibits NA, not acetylcholine, and levels of NA are very low 
in the dorsal striatum (Glowinski and Iversen, 1966). Also, mice only received 3 
acute injections of guanfacine, making it unlikely that this caused a long-term 
deficit in cholinergic transmission. Furthermore, this loss was specific to NK1R-/- 
mice bred from homozygotes. If the treatment was causing a depletion of 
cholinergic activity, it would be present in both colonies. Regardless, in order to 
control for the effects of the 5-CSRTT, cell counts in 9 month old naïve mice are 
needed.  
As well as a lack of difference in cholinergic activity in the ventral striatum of 
littermate pairs, there was no loss of ChAT-positive cells in the dorsal striatum of 
NK1R-/- mice from heterozygote parents. This suggests that a deficit in cholinergic 
transmission is not a direct consequence of non-functional NK1R, but could instead 
be linked to the early environment. If NK1R-/- mothers are providing poor 
maternal care, this could induce apoptosis in their offspring (Zhang et al., 2002). As 
yet, no studies have looked at whether maternal care is altered in NK1R-/- 
mothers. However, NK1R-/- mice have a blunted response to anxiogenic stimuli 
(De Felipe et al., 1998; Rupniak et al., 2000; Santarelli et al., 2001) and mice treated 
with an anxiolytic show reduced maternal care (D’Amato et al., 1998). Also, high-
responding rats, that show reduced anxiety, exhibit a reduction in maternal care 
(Clinton et al., 2010, 2007). Further studies are required to look at maternal 
behaviours in NK1R-/- mice. It would also be interesting to look at how cross-
fostering NK1R-/- pups to wildtype mothers, and vice-versa, affects cholinergic 
development. Alternatively, the loss of cholinergic transmission could be caused by 
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a mutation that has occurred in the NK1R-/- mouse colony and passed down 
through generations (Crusio et al., 2009).  
6.4.3 Striatal sub-region 
In young NK1R-/- mice, the deficit in ChAT expression was found in the 
dorsomedial striatum, whilst in older mice the deficit was found in the dorsolateral 
and ventrolateral striatum. The dorsomedial striatum is involved in goal-directed 
behaviours, and as actions become habitual, they rely on dorsolateral mechanisms 
(Belin et al., 2009; Everitt and Robbins, 2005). When the mice are tested with a 
VITI or LITI in the 5-CSRTT, they have been trained on the task for several months, 
and it is therefore likely that in wildtype mice the actions have become habitual. It 
is therefore not surprising that behavioural deficits in NK1R-/- mice correlate with 
cell loss in the dorsolateral region of the striatum, because this could cause a 
disruption of habit learning. However, in old NK1R-/- mice there tended to be 
fewer ChAT-positive cells in the dorsomedial striatum, and overall counts in the 
dorsal striatum were significantly reduced. Therefore, a general reduction in 
ChAT-positive cells in the dorsal striatum regardless of sub-region may underlie 
deficits in the 5-CSRTT.   
6.4.4 Cholinergic deficits and the 5-CSRTT 
A loss of ChAT-positive cells was found in the ventral and dorsal striatum of 
NK1R-/- mice bred from homozygotes. These mice showed increased impulsivity 
in the 5-CSRTT. Cholinergic transmission has previously been linked to attention in 
the 5-CSRTT, with lesions to the basal forebrain and systemic cholinergic agents 
affecting accuracy (for review see (Robbins, 2002). However, basal forebrain 
lesions affect cholinergic transmission within the cortex, and as yet the effects of 
selective cholinergic lesions to the striatum have not been studied in the 5-CSRTT. 
Cholinergic interneurons in the dorsal and ventral striatum are innervated by the 
thalamus, not the cortex (Lapper and Bolam, 1992; Meredith and Wouterlood, 
1990). As discussed in chapter 4, basal ganglia loops projecting through structures 
including the striatum and the thalamus are involved in motor inhibition, and thus 
could play an important role in impulsivity. Indeed, an increase in premature 
responding following d-amphetamine is thought to be mediated by the nucleus 
accumbens (Cole and Robbins, 1989), and lesions to the core of the nucleus 
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accumbens increase premature responding and perseverative responding without 
affecting accuracy (Christakou et al., 2004).  Futhermore, ablation of cholinergic 
interneurons in the ventral striatum increases conditioning to cocaine (Hikida et 
al., 2001), indicating increased impulsivity. In light of the results in the current 
chapter, it would be interesting to look at the effects of selective dorsal and ventral 
striatal cholinergic lesions on 5-CSRTT performance. 
6.4.5 Other behaviours in the 5-CSRTT 
Perseverative responding was increased in NK1R-/- mice in the VITI regardless of 
colony. This increase was also seen in stages 1 and 3 of training, suggesting that 
NK1R-/- mice learn to inhibit this behaviour during training and it only re-emerges 
when task demands were high. Overall, this agrees with previous evidence that 
perseverative responding in the 5-CSRTT is linked to a lack of functional NK1R 
(Dudley et al., 2013; Yan et al., 2011). It also suggests that perseverative responding 
is independent of alterations in the striatal cholinergic system. There was a slight 
increase in the latency to make a correct response in mice bred from homozygotes 
when they were tested in the LITI. However, this was not affected by genotype. 
There was a main interaction between genotype and colony for %accuracy in the 
VITI. However, further post-hoc tests did not reach significance. Due to the number 
of 5-CSRTT boxes, it was only possible to test six wildtype mice and six NK1R-/- 
mice from each colony. Also, one wildtype and one NK1R-/- mouse bred from 
heterozygous matings did not complete training. In order to see whether any 
further differences in attention can be identified, this experiment needs to be 
repeated. These experiments are in progress and the present data will be 
combined with 5-CSRTT data from another cohort of mice derived from 
homozygous and heterozygous matings (A. Grimme, work in progress). However, 
significant differences in impulsivity and perseverative responses were identified 
here, suggesting that these deficits are more robust.     
6.4.6 Conclusions 
NK1R-/- mice bred from homozygote matings show a deficit in impulsivity in the 
5-CSRTT and a loss of ChAT-positive cells in the dorsal and ventral striatum. In 
contrast, these deficits are not present in NK1R-/- mice bred from heterozygote 
matings. Although the behavioural results are preliminary they do suggest a 
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relationship between cholinergic activity in the striatum and impulsivity. The 
results also highlight an important interaction between early environment, brain 
development and behaviour. 
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7 General discussion 
ADHD affects between 5.9 and 7.1% of the population worldwide (Willcutt, 2012), 
yet the aetiology remains poorly understood. There are also concerns over the 
safety and efficacy of the use of psychostimulants such as d-amphetamine and 
methylphenidate for the treatment of ADHD. Animal models play a crucial role in 
our understanding and treatment of human disorders. Although various animal 
models of ADHD have been proposed, none completely satisfies all the criteria 
(face, construct and predictive validity) for a good animal model. The validation of 
animal models of neuropsychiatric disorders is complicated due to the fact that the 
symptoms presented tend to be human-specific. Also, the diagnosis of the vast 
majority of these disorders is based on the patient’s description of symptoms, 
rather than an objective diagnostic test (Nestler and Hyman, 2010). Therefore 
species-specific tests have been developed that aim to mimic individual aspects of 
the disorder.  
Locomotor activity paradigms are commonly used to test for ADHD in rodents. 
These can be used in conjunction with the current treatments for ADHD, to 
determine whether they alleviate hyperactivity. However, hyperactivity alone does 
not define ADHD, and it is also seen in animal models of other disorders, including 
models of autism (Dichter et al., 2012) and addiction (Fernando and Robbins, 
2011). It is therefore important to test other symptoms of the disorder. The 5-
CSRTT measures sustained visual attention and motoric impulsivity. It also 
provides a measure of perseveration, which is commonly seen in patients with 
ADHD, although it is not a diagnostic criterion. The 5-CSRTT was developed from 
the human CPT test, which patients with ADHD perform poorly on. Therefore, 
deficits in this paradigm in rodents may provide important insights into the 
deficits seen in humans.  
The NK1R-/- mouse has recently been proposed as a new animal model of ADHD. 
It is hyperactive and this is reduced by the psychostimulants d-amphetamine and 
methylphenidate. It also has abnormal DA, 5-HT and NA transmission within 
fronto-striatal circuits and polymorphisms of the human equivalent of the NK1R 
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gene (TACR1) have been found in patients with ADHD (Yan et al., 2010) . Finally, 
NK1R-/- mice have deficits in attention, impulsivity and perseverative responding 
in the 5-CSRTT (Yan et al., 2011). The work in this thesis aimed to further validate 
the NK1R-/- mouse model of ADHD. Due to the emerging evidence that a deficit in 
cholinergic transmission may underlie ADHD, the striatal cholinergic 
neuroanatomy of the NK1R-/- mouse was also investigated. 
7.1 Summary of findings 
7.1.1 Effects of d-amphetamine on performance of NK1R-/- mice in the 
5-CSRTT 
D-amphetamine is one of the most widely prescribed treatments for ADHD and it 
alleviates the hyperactivity seen in NK1R-/- mice tested in the LDEB (Yan et al., 
2010). To further validate the NK1R-/- mouse model of ADHD, the effects of 
d-amphetamine on attention, impulsivity and perseveration were tested in the 5-
CSRTT (Yan et al., 2011). NK1R-/- mice were more inattentive than wildtype mice, 
as measured by an increase in %omissions and a decrease in %accuracy. This 
difference was abolished by d-amphetamine. However, %accuracy was not 
improved in NK1R-/- mice by d-amphetamine, but instead was decreased in 
wildtype mice. Furthermore, a significant improvement in %omissions in NK1R-/- 
mice was only seen when task demands were high (when the ITI was increased to 
15s on a random schedule). D-amphetamine also prevented a vehicle-induced 
increase in perseveration in NK1R-/- mice. D-amphetamine failed to reduce 
%premature responses in NK1R-/- mice. However, a therapeutic effect of 
d-amphetamine on impulsivity may not have been detectable because NK1R-/- no 
longer showed an increase in %premature responses on repetition of the test. This 
suggests that the mice adapt quickly to the task parameters and a deficit in 
impulsivity may reappear if task demands are heightened by increasing the ITI. 
These results suggest that d-amphetamine has some therapeutic effect on attention 
and perseverative responding in NK1R-/- mice. However, the effects varied 
depending on the test parameters used. It could be that there was no robust 
therapeutic effect of d-amphetamine because a lack of functional NK1R prevents 
the normal response to d-amphetamine. Indeed, although patients with ADHD may 
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have polymorphisms of the NK1R gene, the receptor will still maintain a certain 
level of functionality. A lack of normal response to d-amphetamine is supported by 
a microdialysis study showing that wildtype mice injected with an NK1R 
antagonist  and NK1R-/- mice do not show an increase in striatal extracellular DA 
following administration of d-amphetamine (Yan et al., 2010).   
7.1.2 Identifying new treatments for ADHD 
In chapter 4, nifedipine was tested in the 5-CSRTT as a potential alternative 
treatment for ADHD. A study has shown that the L-type calcium channel blocker 
nifedipine can alleviate ADHD-like symptoms in children with renal hypertension 
(Krause et al., 2009). Other studies have shown that NK1R antagonists have L-type 
calcium channel blocking effects (Guard et al., 1993; Rupniak et al., 1993, 2003). 
These findings suggest an interaction between NK1R and L-type calcium channels.  
Nifedipine had similar effects on the performance of wildtype and NK1R-/- mice in 
the 5-CSRTT. It reduced %premature responses, increased %omissions and 
increased the latencies to respond and collect the reward. In the striatum, L-type 
calcium channel currents are suppressed by the activation of DA D2 receptors 
(Hernandez-Lopez et al., 2000) and M1 muscarinic receptors (Wang et al., 2006) 
located on MSNs. This reduces overall network excitability. D2-expressing MSNs 
are part of the indirect pathway, which is involved in action inhibition. Therefore, 
direct blockade of L-type calcium channels would theoretically increase network 
inhibition and reduce impulsivity. An increase in network inhibition would also 
inhibit the direct pathway, preventing new actions from being initiated and 
increasing %omissions.  
Although similar effects were seen in both genotypes, a higher dose was required 
to see the decrease in %premature responses and increase in %omissions in 
NK1R-/- mice. Substance P binding to NK1R located on cholinergic interneurons in 
the striatum stimulates acetylcholine release which binds to M1 receptors located 
on MSNs. As mentioned above, this reduces L-type calcium channel opening (Wang 
et al., 2006). Therefore, in the absence of NK1R, it is possible that there is overall 
less network inhibition due to a reduction in acetylcholine release, and 
subsequently a higher dose of nifedipine is required to see the inhibitory effects. 
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As seen in the first 5-CSRTT experiment, an increase in impulsivity in NK1R-/- 
mice was not seen on repetition of the test and, in contrast to the first experiment, 
deficits in attention were no longer present. Therefore, it was not possible to 
determine whether nifedipine has a therapeutic effect on these deficits in NK1R-/- 
mice. Overall this experiment highlighted an interaction between NK1R and L-type 
calcium channels, and suggested that blockade of these channels may be beneficial 
in impulse control disorders. However, the lack of therapeutic effect on 
perseverative responding, the increased inattention in both genotypes and the 
non-specific increases in latencies to perform the task suggest that nifedipine may 
not be useful for the treatment of ADHD. 
Behavioural screens are commonly used to identify new drug targets. Ideally, these 
tests are quick to run, so that a range of drugs can be rapidly screened. Because it 
takes many months to train and test rodents in the 5-CSRTT, locomotor activity 
paradigms are more suitable drug screens. However, these paradigms are often 
confounded by stress, and NK1R-/- mice have altered stress responses (De Felipe 
et al., 1998; McCutcheon et al., 2008; Rupniak et al., 2000; Santarelli et al., 2001). 
Also, previous work measuring the activity of NK1R-/- mice used a LDEB 
paradigm. This was initially developed as a screen for anxiolytic drugs (Crawley, 
1985, 1981), and is therefore susceptible to stress. Moreover, animals were tested 
in the light phase when they are least active. Possibly due to these confounds, the 
hyperactivity of NK1R-/- mice was highly variable, and not significantly different 
from wildtype mice. The work in chapter 5 aimed to identify conditions under 
which hyperactivity in NK1R-/- mice was robust. This was achieved by measuring 
their activity in the home cage during the dark phase with telemetry. Telemetry is 
therefore a good screen for hyperactivity in NK1R-/- mice, and may help identify 
new treatments for ADHD. 
7.1.3 Behavioural and molecular comparison of mice from homozygote and 
heterozygote matings 
The mice tested in the 5-CSRTT in chapters 3 and 4 had been bred from 
homozygotes for many generations. The deficits seen in NK1R-/- mice tend to be 
attributed to a lack of functional NK1R. However, the deficits could be caused by 
other de novo genetic mutations occurring independently in the wildtype and 
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NK1R-/- colonies that are passed down to future generations (Crusio et al., 2009). 
Also, maternal care could be different in mothers lacking functional NK1R, and 
early environment can have long-term effect on animals’ phenotypes (Crusio, 
2004). In order to overcome these limitations, mice were also bred from 
heterozygous matings. They were then tested with telemetry and compared in the 
5-CSRTT with mice bred from homozygotes. NK1R-/- mice from heterozygous 
matings continued to show hyperactivity although this was less pronounced than 
in NK1R-/- mice from homozygous matings. This suggests that a lack of functional 
NK1R is linked to hyperactivity, but that something else is exacerbating this deficit 
in mice from homozygous matings. As discussed below, this could be due to a loss 
of striatal cholinergic function. NK1R-/- mice from both colonies also showed an 
increase in perseverative responses. However, the deficit in impulsivity was only 
present in NK1R-/- mice from homozygote breeding pairs. No deficits in attention 
were present in either colony. 
Further work looked at whether d-amphetamine could reduce the hyperactivity of 
NK1R-/- mice bred from heterozygotes, and whether the NK1R antagonist RP 
67580 induced hyperactivity in their wildtype counterparts. In line with the lack of 
clear therapeutic effect of d-amphetamine in the 5-CSRTT, d-amphetamine failed to 
reduce the hyperactivity of NK1R-/- mice, but increased activity in wildtype mice, 
thereby abolishing the genotype difference. There was no clear effect of RP 67580 
on activity, although group sizes were small so this experiment needs to be 
replicated. 
Increasing evidence suggests that abnormalities in cholinergic transmission may 
be involved in the pathophysiology of ADHD. Studies have shown that 
acetylcholine receptor agonists, such as nicotine and the acetylcholinesterase 
inhibitor donezepil can improve symptoms of ADHD (Levin et al., 1996; Wilens et 
al., 2000). Also, all cholinergic interneurons in the striatum express NK1R (Aubry 
et al., 1994; Gerfen, 1991). Therefore, chapter 6 compared the number of ChAT-
positive striatal cells in 8-12 week old wildtype and NK1R-/- mice from each 
colony, as well as in 9 month old mice that had completed the 5-CSRTT experiment. 
The results showed that in NK1R-/- mice bred from homozygote matings there 
was a loss of ChAT-positive cells in the dorsal and ventral striatum, although in the 
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latter region this was only seen in 9 month old mice. These experiments also 
revealed a decrease in overall striatal area in all mice as they age, regardless of 
genotype. 
7.2 The NK1R-/- mouse as a model of ADHD 
Extending previous findings, NK1R-/- mice are hyperactive, and this is the case 
whether they are bred from homozygous or heterozygous parents. However, 
previous studies found hyperactivity after a vehicle injection. When NK1R-/- mice 
were uninjected, hyperactivity was only consistently identified when they were 
tested in their home cage, with telemetry. It has previously been reported that 
hyperactivity in animal models of ADHD should be observed in a familiar 
environment, as this is when symptoms of ADHD are observed in patients (Russell 
et al., 2005). The findings presented here suggest that the hyperactivity of NK1R-/- 
mice measured with telemetry could mimic the hyperactivity observed in patients 
with ADHD. On the other hand, the lack of effect of d-amphetamine on the 
hyperactivity of NK1R-/- mice tested with telemetry could be an issue for the 
predictive validity of the model.  
The deficits in attention previously observed in NK1R-/- mice tested in the 
5-CSRTT (Yan et al., 2011) were only present in the first experiment in this thesis. 
It is not clear why these deficits disappeared, but perhaps increasing the difficulty 
of the task will reinstate attentional deficits. Another possibility is that the NK1R-/- 
mouse is a model of the Predominantly Hyperactive/Impulsive clinical subtype of 
ADHD. However, impulsivity was only present in mice from homozygote matings. 
Also, in all the 5-CSRTT experiments presented in this thesis, impulsivity was only 
evident when animals were first tested post-training. Reinstatement of impulsivity 
may depend on increasing the task difficulty. Alternatively, testing mice in the dark 
phase may increase impulsivity. Indeed, testing in the dark phase revealed greater 
hyperactivity in NK1R-/- mice, and this could also be the case for impulsivity. 
However, NK1R-/- mice have yet to be tested with paradigms that measure more 
cognitive forms of impulsivity, such as delay discounting. This is discussed in more 
detail in section 7.4.1. One deficit that was consistently seen in NK1R-/- mice from 
both colonies was an increase in perseverative responding. This is not a diagnostic 
symptom of ADHD, but is often found in patients (Lawrence et al., 2004). 
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In summary, the phenotype of the NK1R-/- mouse investigated in this thesis 
suggests that it could be used for investigating hyperactive and perseverative 
deficits. Furthermore, NK1R-/- mice from homozygote matings could provide 
insights into the mechanisms involved in impulsivity. However, further studies are 
needed to investigate impulsivity under different experimental parameters and in 
different paradigms. Additionally, the predictive validity of the NK1R-/- mouse 
model needs further confirmation. 
7.3 Cholinergic hypothesis of ADHD 
The dominant theory of ADHD suggests that it is caused by abnormal DA 
transmission within fronto-striatal circuits (Levy, 1991), and it has also been 
suggested that symptoms of ADHD are caused by a dysregulation of 
catecholamines (Pliszka et al., 1996). In line with this, the majority of animal 
models of ADHD show some degree of DA dysfunction (Van der Kooij and Glennon, 
2007) and psychostimulants, which are used to treat ADHD, increase DA 
transmission.  However, the mechanism of action of psychostimulants remains 
poorly understood and the beneficial effects of d-amphetamine on hyperactivity, 
impulsivity and attention are found in healthy children as well as children with 
ADHD (Zahn et al., 1980). Also, imaging studies of patients with ADHD disagree on 
whether there is an increase, a decrease or no change in expression of the DA 
transporter in the striatum (Hesse et al., 2009; Krause et al., 2000; van Dyck et al., 
2002). 
The reduction in ChAT-positive cells in the striatum of NK1R-/- mice supports 
increasing evidence that a deficit in cholinergic function underlies the symptoms of 
ADHD (discussed in section 7.1.3). More specifically, because the loss was specific 
to NK1R-/- mice bred from homozygous breeding pairs, the cholinergic deficit is 
likely to underlie behavioural deficits that are not present in NK1R-/- mice bred 
from heterozygous breeding pairs. When directly compared in the 5-CSRTT, only 
NK1R-/- mice from homozygotes were impulsive. Therefore, a new mechanism 
underlying impulsivity is proposed, caused by disruption of normal cholinergic 
function in the dorsal and ventral striatum. This fits with a recent study showing 
that mice lacking muscarinic M1 receptors have deficits in impulsivity in the 
5-CSRTT without showing attentional deficits (Bartko et al., 2011). In addition, M1 
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receptor knockout mice are hyperactive (Miyakawa et al., 2001), so the increased 
hyperactivity seen in NK1R-/- mice bred from homozygous matings could also be 
due to a decrease in cholinergic function. 
The striatum is densely innervated by DA neurons and cholinergic interneurons 
that exert control over each other. As discussed in chapter 6, dopaminergic 
neurons fire at high frequency when encoding information about the prediction 
and receipt of reward-related and salient stimuli (Matsumoto and Hikosaka, 2009; 
Schultz, 2002). In contrast, cholinergic interneurons pause in response to salient 
stimuli (Aosaki et al., 1994; Morris et al., 2004), and this pause is mediated by 
activation of mACh autoreceptors located on cholinergic interneurons. A pause in 
firing reduces acetylcholine binding to nAChRs located on DA neurons. This 
increases the phasic, high frequency firing rate of DA neurons (Rice and Cragg, 
2004). Striatal DA and acetylcholine therefore interact in the striatum to signal 
events of high saliency (Threlfell and Cragg, 2011). 
Cholinergic interneurons alter their firing pattern during learned and rewarded 
motor tasks (Graybiel et al., 1994; Kitabatake et al., 2003). GABAergic projections 
from the ventral tegmental area to the nucleus accumbens cause a pause in 
cholinergic interneuron firing to signal events of motivational significance, and 
reinforce stimulus-outcome associations (Brown et al., 2012). In addition, 
cholinergic interneurons modulate the activity of MSNs in the direct and indirect 
pathways through the activation of mAChRs (Zhou et al., 2003). Thalamic input to 
these interneurons causes a burst of acetylcholine release in response to salient 
stimuli which enhances the activation of the indirect pathway. More specifically, 
the thalamic-mediated increase in acetylcholine release transiently activates 
presynaptic M2 receptors located on corticostriatal glutamatergic terminals. This 
inhibits the activation of direct and indirect MSNs. Subsequently, acetylcholine has 
a slower, long-lasting facilitatory effect on M1 receptors located on indirect 
pathway MSNs. The pause in cholinergic interneuron firing ensures there is no 
concomitant corticostriatal suppression of the indirect pathway. Activation of the 
indirect pathway inhibits locomotor activity (Miyakawa et al., 2001) and 
suppresses actions, thus allowing attention to be redirected (Ding et al., 2010; 
Thorn and Graybiel, 2010). Therefore, a reduction in cholinergic function would 
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theoretically increase impulsivity and hyperactivity due to hypoactive indirect 
pathway MSNs. This is illustrated in Figure 7.1. Furthermore, the activation of 
nAChRs through nicotine injection or smoking increases impulsive behaviour 
(Ohmura et al., 2012). Interestingly, nAChRs are upregulated following striatal 
cholinergic interneuron ablation (Kitabatake et al., 2003). Therefore, the 
impulsivity seen in NK1R-/- mice with a reduction in ChAT-positive cells could 
result from an upregulation of nAChRs. This requires further investigation. 
7.4 Future directions 
In this thesis, work was done to validate the NK1R-/- mouse model of ADHD. The 
findings presented here can help guide future clinical studies. However, further 
work with NK1R-/- mice is required to establish the nature and extent of the 
deficits, both behaviourally and molecularly. These are discussed below. 
7.4.1 Behavioural studies with NK1R-/- mice 
NK1R-/- mice bred from homozygote breeding pairs are impulsive when first 
tested in the 5-CSRTT. Impulsivity is not a unitary construct, and different 
behavioural paradigms are thought to represent different facets of impulsivity, 
relying on different biological mechanisms (Evenden, 1999). In the 5-CSRTT, 
impulsivity is measured by premature responses. This represents the animal’s 
failure to withhold an action, which is a type of ‘motoric’ impulsivity (Winstanley 
et al., 2006). Other behavioural paradigms that measure this type of impulsivity 
exist, such as the go/no-go task (Harrison et al., 1999), and the stop-signal 
reaction-time task (Eagle and Robbins, 2003). In these tasks, rodents have to nose-
poke in response to certain stimuli. However, on some trials other cues are 
presented indicating that the animal must not respond. These tests were 
specifically designed to test the ability to quickly inhibit a pre-programmed action. 
These tests are yet to be published in mice, but it would be interesting to test 
NK1R-/- mice in these paradigms to see whether they are impulsive and whether 
the impulsivity is more robust than when measured in the 5-CSRTT. 
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Figure 7.1 Illustration of the thalamic facilitation of the indirect pathway. A burst of thalamic activity in 
response to a salient stimulus triggers a burst of acetylcholine release. This activates postsynaptic M1 
receptors on D2 MSNs, facilitating the ‘no go’ pathway, while also suppressing cortical input through the 
activation of presynaptic M2 receptors. MSN: medium spiny neuron. DA: dopamine. 
Another type of impulsivity is choice impulsivity (Winstanley et al., 2006). This 
represents the avoidance of delay and can be measured with a delay discounting 
task. This task measures the ability to wait and receive a large reward rather than 
taking a smaller, more immediate one. When patients with ADHD are tested in this 
task, they prefer to avoid delay and take the smaller, more immediate reward 
(Schweitzer and Sulzer-Azaroff, 1995) and poor performance in delay discounting 
correlates with symptoms of ADHD (Solanto et al., 2001). It would therefore be 
interesting to test NK1R-/- mice in this paradigm. 
Perseverative responses were higher in NK1R-/- mice in all 5-CSRTT experiments. 
This was true regardless of breeding method, suggesting that it is linked to a deficit 
in NK1R function. Although it has been described as a measure of compulsivity, it is 
not clear what perseverative responding in the 5-CSRTT represents. Recent work in 
our lab has looked at species –typical behavioural tests that measure perseverative 
digging (Weir, 2012), but results from NK1R-/- mice are contradictory and the 
cause of perseveration remains unknown. When mice are first habituated to the 
5-CSRTT apparatus, milk is placed in the stimulus holes to encourage nose poking. 
It is possible that NK1R-/- mice fail to extinguish this stimulus/reward association. 
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This could be further tested using reversal learning paradigms such as the T-maze 
or attentional set shifting. In these tasks, animals learn that a reward is found in a 
certain location, and this location is then changed. The inability of an animal to 
learn the new reward location is a measure of perseverative behaviour (Izquierdo 
and Belcher, 2012).  
7.4.2 Molecular studies  
There were fewer ChAT-positive cells in the striatum of NK1R-/- mice compared to 
their wildtype counterparts. ChAT is an enzyme involved in the synthesis of 
acetylcholine. There are various ways in which this reduction needs to be further 
studied. Microdialysis in the striatum of NK1R-/- mice can determine whether 
there is reduced acetylcholine efflux compared to wildtype mice. As yet, it is not 
known whether there are fewer cholinergic cells in the striata of NK1R-/- mice, or 
whether they are simply reduced in size. This can be determined with more 
precise counting techniques. Another possibility is that cholinergic cells are 
synthesising lower levels of ChAT in NK1R-/- mice, meaning that some cells failed 
to be detected with the immunohistochemical technique used here. Western blots 
suggested that there was overall less ChAT protein in young NK1R-/- mice bred 
from homozygote matings. However, due to the high variability within each 
sample, no significant differences were identified. This could be due to the fact that 
striatal sub-regions were not analysed separately. However, this study should also 
be repeated with a larger number of samples. 
If it turns out there is a reduction in the number of cholinergic interneurons, it 
remains to be determined when this loss happens. Cell death could occur during 
the first few weeks of the animals’ lives. Alternatively, disruption of the NK1R gene 
could prevent normal embryonic development or migration of striatal cholinergic 
interneurons. However, disruption of the NK1R gene alone does not cause the 
reduction in ChAT expression, because it was not found in NK1R-/- mice bred from 
heterozygotes. This suggests that there could be other genetic modifications in 
homozygous NK1R-/- breeders that are causing the reduced ChAT expression. 
Alternatively, early environment may prevent normal development of the striatal 
cholinergic system. This possibility can be investigated by fostering wildtype mice 
to NK1R-/- breeding pairs. 
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Finally, in young mice, the loss of cholinergic function was found in the dorsal 
striatum, but in 9 month old mice there was also a loss in the ventral striatum. This 
could indicate that there is on-going cell death in the striatum throughout the 
animals’ lives. However, the 9 month old mice were not treatment-naïve, having 
been trained and tested in the 5-CSRTT. Therefore, it would be interested to look at 
ChAT expression in the striatum of old, naïve mice. The dorsal striatum has been 
linked to motoric impulsivity, while the ventral striatum has been linked to reward 
impulsivity. The latter type of impulsivity is thought to mimic aspects of 
compulsive drug seeking in addicts. In this context an increase in impulsivity in 
NK1R-/- mice is surprising, because a previous study has found that NK1R 
antagonists can reduce alcohol craving in patients (George et al., 2008). This would 
suggest that NK1R antagonism reduces, rather than increases, impulsivity.  
However, the findings presented here help to reconcile this contradiction, 
suggesting that it is a loss of striatal cholinergic function, rather than disruption of 
the NK1R gene, that causes the increase in impulsivity. This should be further 
investigated by selectively lesioning striatal cholinergic cells in wildtype mice and 
testing them in the 5-CSRTT. It would also be interesting to test the effects of 
cholinergic agonists in NK1R-/- mice tested in the 5-CSRTT. 
7.4.3 Other neurokinin receptors 
Substance P preferentially binds to NK1R. However, disruption of the NK1R gene 
may not mean there is reduced substance P binding, since it also shows some 
binding affinity to NK2 and NK3 receptors (Maggi and Schwartz, 1997). It is 
possible that there has been an upregulation of these receptors to compensate for 
the loss of NK1R, although initial studies with NK1R-/- mice showed that there was 
no substance P binding in the brain (De Felipe et al., 1998). Furthermore, 
acetylcholine release from striatal cholinergic interneurons is modulated by all 
three tachykinin receptor subtypes (Preston et al., 2000). The role of other 
neurokinin receptors in ADHD remains to be investigated.  
7.4.4 Extending the findings to the clinic 
The aim of developing an animal model is to gain further understanding of a 
clinical disorder and to identify new ways of treating it. Imaging studies have 
aimed to identify biomarkers for ADHD in the brains of patients. So far, these 
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investigations have focused on the DA system. The findings presented here suggest 
that striatal cholinergic markers could identify patients with impulse control 
disorders. There are no radioligands for ChAT, so it cannot be measured in vivo 
(Bohnen and Frey, 2007). However, there are radioligands for other markers of 
cholinergic activity, including acetylcholinesterase, which hydrolyses 
acetylcholine, and vesicular acetylcholine, the acetylcholine transporter. Other 
radioligands can also image both nicotinic and muscarinic receptors (Bohnen and 
Frey, 2007). If binding studies reveal a loss of cholinergic function in patients with 
impulse control disorders, clinical studies should also investigate the effects of 
cholinergic agonists. 
The deficit in perseverative responding was consistently found in NK1R-/- mice 
regardless of breeding method, suggesting that it is due to a lack of NK1R function. 
It remains to be determined how a deficit in perseverative responding translates to 
the clinic, and further understanding of this deficit could lead to a new therapeutic 
effect of NK1R agonists. The finding that disruption of the NK1R gene results in 
hyperactivity also suggests that NK1R agonists could alleviate hyperactive 
symptoms in ADHD. 
7.5 Conclusions 
The work presented in this thesis further investigated the NK1R-/- mouse as a 
model of ADHD. Hyperactivity and perseveration appear to be linked to a loss of 
NK1R function, suggesting that NK1R agonists may be therapeutically beneficial 
for these symptoms. This work also suggests that impulsivity is not caused by a 
loss of NK1R function, but rather by reduced striatal cholinergic function. 
Therefore, abnormal striatal cholinergic activity could underlie impulse control 
disorders. There was no consistent deficit in attention. Overall, these results 
suggest that the NK1R-/- mouse can be used to study specific molecular and 
behavioural deficits in ADHD and related disorders. This will allow further 
elucidation of the different biological mechanisms underlying the symptoms of 
ADHD, as well as other comorbid disorders.  
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